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Abstract 
Fungi have been an inspiring source of diverse secondary metabolites, with a number of metabolites 
developed as pharmaceuticals and agrochemicals. Despite the past success, fungal biodiscovery has 
been challenged with the excessive rediscovery of known metabolites. This thesis is focused on 
investigating four selected strategies to explore fungal secondary metabolite potential to discover 
novel and bioactive metabolites. This includes, bioactivity-guided isolation, varying cultivation 
conditions, application of advance analytical techniques and microbial co-cultivation. A library of 
×185 microbes, including fungi (×132) and Streptomyces (×53), was constructed from a total of ×28 
samples collected from terrestrial and marine samples. High-throughput miniaturized 24-well 
microbioreactor culture approach was used to generate extracts from solid (agar) and liquid (broth 
shaken) cultures to prepare a crude extract library, which was subjected to chemical and bioactivity 
profiling using HPLC-DAD-MS and UHPLC-QTOF. Two innovative bioassays to discover bioactive 
metabolites in the extracts were employed; (i) The larval development assay (LDA), used to detect 
anti-parasitic metabolites against drug (monepantel) resistant sheep intestinal parasite Haemonchus 
contortus and (ii) GABA (β-aminobutyric acid) receptor inhibitory activity, to detect molecules that 
may have application as anti-anxiety drugs. Selected strains were subjected to a program of analytical 
miniaturized cultivation, supported by UHPLC-DAD-MS and UHPLC-QTOF profiling to explore 
the wider secondary metabolite potential of fungi. The metabolite production was visualised using 
the Global Natural Product Social (GNPS) molecular networking analysis. Based on the chemical 
and bioactivity profiling, a total of ×6 fungi were selected for further investigation, and the isolation 
and characterization of metabolites from these strains are discussed in this PhD thesis. 
Chapter 1 highlights the importance of understanding, and exploring silent fungal secondary 
metabolism. This chapter also reviews different strategies reported in the literature for the discovery 
of novel and bioactive metabolites from fungi, with main focus on (i) bioactivity guided isolation, (ii) 
varying cultivation condition, (iii) application of advance analytical techniques and (iv) microbial co-
cultivation. 
Chapter 2 focuses on investigating bioactivity-guided isolation as a prioritizing tool for microbial 
extracts to isolate biologically active metabolites. Anthelmintic metabolites identified from 
Penicillium sp. CMB-TS015 and Purpureocillium sp. CMB-F551 are discussed in this chapter. 
Chapter 3 discusses continued chemical and bioactivity investigation on Penicillium sp. CMB-TS015. 
Isolation, characterization and bioactivity profiling of three new fungal metabolites (+)-
spiroquinazoline B, (+)-fumiquinazoline J and the tetramic acid chaunolidine D, are described in this 
chapter.  
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 Chapter 4 illustrates the application of innovative 24-well microbioreactor plate miniaturised 
cultivation approach (MATRIX) and GNPS molecular networking analyses for discovering new 
cyclic peptides from tunicate–derived fungus Talaromyces sp. CMB-TU011. Isolation and 
characterization of novel cyclic peptide talarolides A–C are discussed.  
Chapter 5 describes the isolation and characterization of novel linear peptides talaropeptides A–D 
from Talaromyces sp. CMB-TU011. The chemical profiling revealed that CMB-TU011 suppressed 
the production of cyclic peptides, talarolides, in YES static broth medium in favour of novel linear 
peptides talaropeptides A–D. The talaropeptide mega non-ribosomal peptide synthetase (NRPS) is 
described, as second only in size to that for the fungus-derived immunosuppressant cyclosporine (an 
11-residue extensively N-methylated cyclic peptide).  
Chapter 6 discusses chemical and biological investigations of new 16-residues peptaibols, 
emeramides A–G, together with antiamoebin I, isolated from Emericellopsis spp. CMB-F057 and, 
CMB-F206, fungi isolated from sea mullet intestinal tissues. Here we demonstrated that UHPLC-
QTOF-MS and MS/MS analysis coupled with C3 Marfey’s analysis is a powerful tool in complete 
structure elucidation of peptides, with limited materials and overlapping NMR resonances. Structure-
activity relationship studies revealed that the number of D-Isovaline (D-Iva) presence in the structure 
is important for their cytotoxic and antibacterial activities. 
Chapter 7 investigates the application of co-cultivation of fungi and Streptomyces for isolating silent 
fungal metabolites. Co-cultivation of Fusarium sp. CMB-NF041 with co-existing antifungal amycin 
B producing Streptomyces sp. CMB-NB090 resulted in activating two silent antibacterial fungal 
metabolites, 8-O-methylbostrycoidin and bostrycoidin, which were only detected with single ion 
extraction (SIE) in the monoculture. Detailed analysis revealed that antifungal amycin B was not 
responsible for the activation of defensive fungal metabolites. Isolation, characterization and 
bioactivity profiling of three new amides, and known metabolites, 8-O-methylbostrycoidin, 
bostrycoidin and amycin B are discussed. 
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1. Chapter 1: Introduction  
Natural products have been a mainstay source of pharmaceuticals and agrochemicals discovery 
throughout history, due to the enormous structural and chemical diversity unsurpassed by synthetic 
libraries.1,2 Although pharma and agriculture industry favour alternate approaches based on synthetic 
chemicals and high-throughput screening, natural products continue to offer competitive advantages.3 
Several efforts at documenting and analysing drug launches in the last two decades have revealed that 
over 30% of small molecule drugs approved by the US Food and Drug Administration (FDA) were 
natural products or direct derivatives of natural products.4-6 As synthetic libraries continue to 
underperform and disappoint, drug lead compound discovery programs are currently returning to 
natural products discovery, which offer a wide range of pharmacophores spanning more diverse and 
biologically relevant chemical space.7  
1.1. Importance of microbial natural products 
Among the various sources that have been explored for natural products, microorganisms are 
considered as an inspiring source of exceptionally diverse secondary metabolites.8 Microbial natural 
products possess several intrinsic properties that have been acquired over millennia of evolution, 
refining these as selective modulators of many biological processes in living cells.9 This is perhaps 
not surprising given the competitive environment in which microorganisms thrive and interact. In 
microbial ecosystems, metabolites are used as signalling molecules to communicate with and across 
species, and as chemical defences to provide survival advantage.10-12 As a result, microbial NP-based 
drug discovery provides comparatively high-quality hits.13,14 Moreover, production of microbial 
metabolites by direct in situ fermentation, or by heterologous expression in alternative vectors, 
provide access to reliable and scalable supply, inclusive of analogues to support structure-activity 
relationship studies.15 Terrestrial as well as marine-derived prokaryotic archaea, bacteria, eukaryotic 
fungi and protists have been explored as sources of natural products.14  
1.2. Fungi as a source of natural products 
The first systematic study on fungal secondary metabolites was reported in 1922 by Harold Raistrick, 
who described over 200 fungal metabolites.16 However, the serendipitous detection of antibacterial 
activity of Penicillium notatum by Alexander Fleming (1929), and subsequent development of 
penicillin (1.1) as the first broad-spectrum antibiotic revolutionised the fungal natural product 
discovery.17 Since then, fungal biodiscovery has continued to offer structurally unique metabolites 
with a wide range of biological activities, including many that have been approved as first-in-class 
drugs (Figure 1.1). 
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Figure 1.1: Fungal metabolites developed as clinical drugs.  
By far, ascomycetes (e.g. Penicillium and Aspergillus species) have been the most prolific producers 
of fungal secondary metabolite, while the number of metabolites derived from basidiomycetes (e.g. 
mushrooms) have considerably increased over the years.18 Most documented fungal secondary 
metabolites are derived from either polyketide synthases (PKS), non-ribosomal peptide synthetases 
(NRPS) or a hybrid of PKS–NRPS. That said, fungi are also well-known for producing alkaloids and 
terpenes.17,19 The enormous ecological diversity of fungi contributes to these biosynthetically diverse 
secondary metabolites, as each adapts to environment challenges.20,21 There are ~120,000 recognised 
fungal species, inhabiting ecosystems as diverse as deep sea sediments to polar regions, and covering 
nearly all ecological niches.22 However, only a small portion of fungal diversity has been 
systematically studied for secondary metabolite production. Current estimations suggest that global 
fungal biome includes 1.5 million fungal strains.22 Given that this vast biosynthetic potential remains 
largely untapped, there is a reason to be optimistic about the future of fungal biodiscovery.  
N
S
H
N
O
O
R
OH
O
penicillin (1.1)
(antibacteril)
N
S
H
N
O
O
R2
OH
R1
O
cephalosporin (1.2)
(antibacterial)
O
O
O
O
O
O
N
H
N
N
H
N
N
H
N
N
N
H
N
N
O O
O
N
O
HO
O
O
O
O
HO O
H
lovastatin (1.3)
(antilipidemic)
NH
HN
O
O
OO N
O
O
NH
HO
H
N
N
OH
OH
OH
OH
HH
O
HO H
H
NH
O
HO
HO H
CO2H
HO
H
HO
H
H
O
O
fusidic acid (1.4)
(antibacterial)
echinocandin B (1.5)
(antifungal)
cyclosporin A (1.6)
(immunosuppressant)
Chapter 1: Introduction 
 
3 
 
1.3. The hidden biosynthetic treasure  
In spite of the historic success and future potentials, fungal biodiscovery have been challenged by (i) 
an excessive rediscovery of known metabolites and (ii) an underestimation of the capacity of fungal 
secondary metabolism.23 One of the reasons contributing to these challenges is the reliance of 
traditional approaches that only harness a fraction of the true biosynthetic potentials of fungi.24 
Impressive advances across the fields of microbial genomics and analytical techniques have revealed 
that microorganisms have far greater potential to produces unique secondary metabolites than 
previously imagined. A key reason for this is the observation that under standard laboratory 
conditions many fungal biosynthetic gene clusters (BGCs) remain silent/cryptic.25,26 
 A well-known example that demonstrates the hidden genetic capacity of the fungi is the discovery 
of over 50-putative secondary metabolites genes from the published Aspergillus nidulans genome.27 
This biosynthetic capacity has not been represented by the secondary metabolites isolated from this 
fungi, with the metabolites from only 5/27 NRPS gene clusters characterized so far.28 In general, it 
has been estimated that well-known secondary metabolite producers, such as Aspergillus spp., with 
a genome size of 28-40 Mb, typically harbour about 50 biosynthetic gene clusters (BGCs).29 Over the 
past decade, several studies have revealed that even well-studied model organisms like A. nidulans30 
and A. niger31 still carry a genetic capacity to produce novel chemical scaffolds. 
A recent analysis of microbial eDNA from a soil sample collected from New York city park revealed 
that microbes in the park bear the genetic capacity to produce clinically important secondary 
metabolites, which were originally isolated from all over the world.32 This report concluded that a 
systematic deep exploration of microbial secondary metabolites likely hold promise for discovering 
therapeutically relevant metabolites even from our backyard. These findings provide a glimpse into 
the untapped silent/cryptic biosynthetic potential of fungi, which were overlooked by traditional 
biodiscovery approaches. 
1.4. Regulation of fungal secondary metabolism 
Fungi produce diverse secondary metabolites in different stages of the life cycle, with sporulation 
being the most common.33 It has been found that fungal secondary metabolism is usually associated 
with cell differentiation or development, and in fact, fungi with complex morphological features tend 
to have relatively complex secondary metabolite profile.34 The genes that encode the biosynthetic 
enzymes (mainly PKS and NRPS for fungi) are organized in biosynthetic gene clusters, where genes 
for a broad range of secondary metabolites are located adjacent to one another.29  
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Intriguingly, fungal secondary metabolite gene clusters are controlled by a complex regulatory system 
composed of multiple proteins and complexes that are known to be responsive to various 
physiological and environmental cues, such as carbon and nitrogen sources, ambient temperature, 
light, pH, air composition, iron availability and biotic factors.35 Therefore, regulation of secondary 
metabolism can take place at several levels; pathway-specific regulation at the respective secondary 
metabolite pathway,30 global regulation via transcription factors that directly regulate all members of 
the gene cluster,36 or via chromatin-mediated regulation.37 
Advanced genetic engineering-based approaches, such as overexpressing transcription factors, 
chromatin modification, and promoter exchange (mainly targeting pathway-specific or the chromatin-
mediated regulation) have proved successful in discovering unique fungal metabolites.29 For 
example, overexpression of A. nidulans pathway-specific transcription factor gene apdR using an 
inducible promoter, resulted in activation of silent PKS-NRPS hybrid gene cluster that eventually led 
to the production of new cytotoxic aspyridones A (1.7) and B (1.8).38 Similarly, a 2010 study by 
Bergmann et al.30 demonstrated that overexpression of A. nidulans’s regulatory gene scpR, a 
transcription factor for a NRPS gene nipA and nipB, activated novel PKS-derived asperfuranone (1.9) 
in addition to the targeted silent NRPS products. Further, overexpression of silent aza gene cluster 
(PKS) in A. niger ATCC 1015 revealed the production of new azanigerones A–F (1.10–1.15).31 
 
In addition to the overexpression of pathway-specific genes, deletion of global regulatory gene, which 
create stress condition due to impaired regulation, can also be used to generate unprecedented fungal 
metabolites. Scherlach et al.39 (2011) revealed that deletion of N-acetyltransferase B gene (nnaB) in 
A. nidulans resulted in slow-growing mutant strain (DnnaB) producing novel red colour compounds 
pheofungin A–D (1.16–1.19). In another study, deletion of sumO gene that encodes a small ubiquitin-
like protein, which plays a role in regulation of transcription, caused a dramatic increase in the 
production of PKS-derived asperthecin (1.20).40 The expression of silent secondary metabolite gene 
clusters in heterologous host fungi has also been studied. A 2010 study by Sakai et al.41 reported that 
in addition to introducing the gene cluster of interest into the host fungi, overexpressing 
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transcriptional factors such as LaeA have successfully upregulated the production of biologically 
active fungal metabolites.41 
 
Despite recent advances in fungal genetic engineering, the numbers of new fungal metabolites 
reported from genetic engineering-based approaches fall well short of those isolated from bacteria 
using similar approaches. This is likely due to the complex regulatory network, and the higher cost 
associated with whole-genome sequencing in fungi compared to bacteria. Given that global 
regulatory network (Figure 1.2) provide an additional higher level to the modulation of fungal 
secondary metabolism, and this regulatory network is much more responsive to environmental 
stimuli, targeting the fungal global regulatory network could be a practical approach to explore the 
wider genetic capacity of fungi. 
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Figure 1.2: Global regulatory proteins those are responsive to environmental stimuli.29 
1.5. Strategies to explore fungal secondary metabolism 
During the past few decades, many attempts have been made to discover new bioactive secondary 
metabolites from fungi. This included, (i) bioassay-guided isolation with streamlined bioassays, (ii) 
exploiting fungi from underexplored habitat, (iii) de-replication with advanced analytical techniques, 
(iv) varying culture conditions, (v) microbial co-cultivation and (vi) activating silent gene clusters 
via chemical cues. In my PhD project, four selected strategies (Figure 1.3), were investigated with 
the primary aim for discovering new fungal metabolites. The following sections of this chapter 
provide a brief overview of the four strategies I studied during my PhD project. 
 
Figure 1.3: An illustration of the four selected strategies used in my PhD project to explore the wider ecological diversity 
and genetic capacity of fungi.  
Varying	culture	
condi0ons	
Co-cul0va0on	
Chemical	
proﬁling	
Bioac0vity	
proﬁling	
Strategy
Chapter 1: Introduction 
 
7 
 
1.5.1. Bioactivity-guided isolation 
Bioactivity profiling provides a valuable tool to probe metabolites in extracts that exhibit promising 
biological activity. This has been a prioritizing tool in microbial natural products research for decades, 
with cytotoxicity, anti-inflammatory, anti-oxidant and antibiotic assays being commonly used.42 
Many fungal metabolites that have inspired clinical drugs were discovered using the bioassay-
directed approaches. For instance, mevinolin (later described as lovastatin) was discovered as a part 
of the search program for inhibitors of HMG-CoA reductase.43  
Notwithstanding the past success, bioassay-guided isolation has several drawbacks. Complex 
matrices of unknown composition and concentration of active substances, can lead to false 
positive/negative results. This may be partially ameliorated by using pre-fractionated extracts that 
have chemically profiled with an HPLC-MS system, however, this requires a significant investment 
in time and resources. The other challenges include the excessive focus on easy-to-isolate fungal 
strains and the use of less discriminating cytotoxicity and/or antibacterial assays. 
Several approaches have been used to overcome these challenges. For example, the use of a microbial 
library targeting for the desired bioactivity had proved successful in discovering new antibiotics. A 
2001 study by Thaker et al.44 constructed a Streptomyces library consisting of strains resistant to 
known antibiotics, hypothesising that Streptomyces with a self-protective mechanism for known 
antibiotics may have the ability to produce more potent new metabolites. This study resulted in the 
isolation of a novel glycopeptide antibacterial compound, pekiskomycin (1.21), with an unusual 
peptide scaffold. Other approaches include, screening for activity against more diverse biological 
targets, with high selectivity and sensitivity. By employing a signal transduction enzyme  (MMP-3 
and caspase-1) inhibition assay, Stierle et al.45 isolated a potent anticancer metabolite, berkelic acid 
(1.22) with selective activity (GI50 91 nM) towards ovarian cancer cells OVCAR-3.  
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During my PhD, I employed two innovative biological assays to discover bioactive fungal 
metabolites; (i) The larval development assay (LDA), used to detect anti-parasitic activity against 
drug (monepantel) resistant sheep intestinal parasite Haemonchus contortus and (ii) GABAA receptor 
inhibitory activity, used to detect molecules that may have application as anti-anxiety drugs. 
1.5.1.1. Screening against Haemonchus contortus larval development   
Parasitic gastrointestinal nematodes are a major health problem in sheep, with anthelminthic 
(drenches) being the main control solution.46 However, as resistance compromises the value of 
existing anthelmintics, the social, economic and animal health impact of infections become more 
evident.47 Among the parasitic nematodes that are resistant to current anthelmintics, H. contortus 
(barber pole or wireworm) is considered as one of the major parasites of small ruminants in tropical 
and temperate farming areas.48 Increasing drug resistance in H. contortus has been reported in many 
Australian sheep farms,48 and thus, there is a need for novel and effective drugs to control this 
emerging problem. 
The H. contortus life cycle (Figure 1.4) begins with the adult female parasite in the abomasum or 
intestines producing thousands of eggs that are passed in the manure. Egg hatching and subsequent 
larval development to the third stage of the larva (L3) take place in the manure and surrounding soil. 
The L3 larvae enter into sheep via grazing, with the level of infection depending on the concentration 
of the L3 larvae in the soil.49  
 
Figure 1.4: The life cycle of Haemonchus contortus.   
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Several in vitro as well as in vivo assays have been developed to screen nematocidal anthelmintics; 
(i) faecal egg count reduction test (FECRT), (ii) egg hatch assay (EHA), (iii) larval paralysis, 
migration and motility tests and (iv) larval development assay (LDA).50 Among them, the LDA 
provides a cost-effective and reliable high-throughput screening tool, which can be used in laboratory 
conditions for the discovery of new anthelmintics. Therefore, the LDA was used during my PhD 
study to discover anthelmintic metabolites in the fungal extracts.  
Anthelmintics inspired by microbial secondary metabolites have revolutionised the animal health 
industry since the 1970s.51 After the discovery of avermectins (metabolites isolated from 
Streptomyces avermitilis), microbes received renewed attention in the search for new anthelmintic, 
including several potent anthelmintic metabolites from fungi. For example, a 1981 study by 
Yamazaki et al. reported a novel oxindole alkaloid, paraherquamide (1.23), from Penicillium 
paraherquei, with substantial anthelmintic activity against C. elegans. Later, several novel 
paraherquamide analogues with potent activity against ivermectin resistant H. contortus,52 were 
reported, and subsequently developed and commercialised as derquantel. A broad-spectrum 
anthelmintic cyclodepsipeptide, PF1022A (1.24), which has a novel mode of action against drug 
resistant nematode, was reported from a plant-derived fungus Mycelia sterilia.53 In another study, a 
novel 14-membered macrolide, clonostachydiol (1.25), was isolated from a marine algae-derived 
fungus Clonostachys cylindrospora showed in vivo activity against H. contortus.54 A 2001 study by 
Omura et al.55 reported that nafuredin (1.26), a novel anthelminthic metabolite isolated from 
Aspergillus niger, showed a potent activity with a novel mode of action, inhibition of complex I in 
helminth mitochondria.  
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It is well known that fungi, such as nematophagous fungi, have evolved with mechanisms to capture, 
kill and digest nematodes. These fungi produce specialised chemical and physical weapons to capture 
the pray. We hypothesised that fungi resident in nematode rich environments might have evolved 
with specialized communication tools and chemical weapons making these fungi a potential source 
for novel anthelmintic metabolites. 
1.5.1.2. Selective GABAA receptor modulators 
GABA (g-aminobutyric acid) is the major inhibitory neurotransmitter produced by GABAergic 
neurons in the mammalian brain. In vertebrates, GABA acts at inhibitory synapses in the brain by 
binding to specific transmembrane receptors. Between the two main GABA receptors (GABARs), 
ligand-gated ion channel type GABAARs hold significant targets for many neurological and 
behavioural disorders.56 GABAARs are pentameric in structure, and five subunits are arranged 
symmetrically around a central ion-conducting pore. These pentameric receptors are made up of a 
family of 19 different subunits (α1-6, β1-3, γ1-3, π, θ, ε, δ, and ρ1-3) of which distribution varies 
developmentally and regionally. The subunit composition provides different physiological and 
pharmacological properties and thus α5GABAAR is of particular interest due to its interesting 
pharmacological benefits.57 Modulation of α5GABAAR as either inhibitors or allosteric enhancers 
provide therapeutic targets for many disorders such as schizophrenia, age-related cognitive 
impairments, nootropics, down syndromes, stroke and amnestic.58  
A collaboration with Prof. Joe Lynch of The University of Queensland, Queensland Brain Institute 
(QBI), permitted screening of pure fungal metabolites against α5GABAAR. The most abundant form 
of GABAAR in mammalian brain, α5β3γ2-GABAARs, was the primary screening target, with 
particular interest in finding α5β3γ2-GABAARs inhibitors.  
1.5.2. Advance analytical tools for dereplication 
An efficient de-replication technique is of utmost importance to avoid reisolation of known 
metabolites. One of the first dereplication strategies was reported in 1978 as a methodology to avoid 
reisolation of known anticancer metabolites from microorganisms.59 The majority of the early 
dereplication approaches relied upon the comparison of features.60 However, the lack of publicly 
available natural product databases rich in spectroscopic data proved to be a key limitation.61 The 
advent of hyphenated technologies such as HPLC-DAD-MS techniques improved the reliability of 
dereplication.62 However, long acquisition time and low-resolution mass measurements appeared as 
the major limitations. In the meantime, impressive developments in the analytical techniques, 
including UHPLC, Q-TOF, high-resolution MS/MS and high-field 2D NMR, provided a new avenue 
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in dereplication.63 A number of public and commercial databases for dereplication of natural products 
have also been developed during the last decade, including DEREP-NP,60 Antibase 
(https://application.wiley-vch.de/stmdata/antibase.php), MarinLit (http://pubs.rsc.org/marinlit/ 
introduction), Pubchem (https://pubchem.ncbi.nlm.nih.gov), ZINC,64 NAPROC-13,65 NMRShiftDB 
(https://nmrshiftdb.nmr.uni-koeln.de), and GNPS.66 HRMS and MS/MS data coupled with statistical 
or computational analysis became comparatively popular among the natural product research 
community, because these techniques could be used as prioritizing tools. For example, LC/MS-
principal component analysis (PCA) has been used in prioritizing, and discovery of new metabolites 
from microbes.67 Part of my PhD research is focused at investigating the strength of recently 
developed GNPS molecular networking66 as an analytical tool to discover new fungal metabolites.  
1.5.2.1. GNPS 
Global Natural Product Social Molecular Network (GNPS) is a recently introduced open access 
database, which allows analysis of high-resolution tandem mass spectrometry (MS/MS) data and 
comparison of the data with a publicly available database.66 The intriguing capability of this analytical 
platform is the visualization of all the ions that were detected in a MS/MS analysis. Using MS/MS 
fragmentation data, as a definitive characteristic of a molecule, GNPS analyses the similarities of the 
MS/MS spectra, and molecules with similar MS/MS spectra are clustered together, based on the 
spectral similarities, to form a molecular network (Figure 1.5).68 In GNPS molecular networks, one 
consensus MS/MS spectrum is represented as a node, with dimension corresponding to the intensity 
of the parent ion. Computer-assisted modified “cosine score” defines the similarity between the 
spectra, and the thickness of the edges (lines) connecting two nodes represents the cosine score (value 
0–1). A series of interconnected nodes that represent structurally related molecules form molecular 
clusters or molecular families, and collectively these molecular families visualise all the metabolites 
detected and fragmented during the MS/MS analysis.69  
 
Figure 1.5: An Overview of the molecular networking.69 
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As the first publicly available molecular networking platform, which can be readily used for 
dereplication and discovery of new metabolites, GNPS received mounting interest in last few years. 
By applying the GNPS as a dereplication tool, a number of new microbial metabolites have been 
discovered. A series of new antibacterial amino-polyketides, vitroptocines (1.27), were reported from 
marine-derived Vibrio sp. using GNPS-based dereplication.70 Combining GNPS with genomic 
analysis for analysing secondary metabolites production in marine cyanobacteria Moorea sp. resulted 
in a new class of trichlorinated acyl-amides, columbamides (1.28).71 A 2015 study on secondary 
metabolite production of ×35 Salinspora strains by Liu et al. reported a new quinomycin-type 
depsipeptide retimycin A (1.29).72 MS/MS-based molecular networking analysis of Streptomyces 
roseosporus revealed that the strain produced at least four different non-ribosomal peptide synthetase-
derived molecular families with a number of new analogues, such as stenothricin D (1.30).73 
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1.5.3. Varying culture conditions to discover new fungal metabolites 
Culture conditions, including nutrient level (carbon and nitrogen sources and its ratio), aeration rate, 
pH, redox status and light intensity, have a great impact on microbial secondary metabolite 
production. It has been found that these factors can influence the transcriptional, translational and 
enzymatic levels of secondary metabolite biosynthesis.74 A subtle change in culture condition is 
powerful enough to activate or suppress a biosynthetic pathway.75 Therefore, varying culture 
condition is often used in “OSMAC” (one strain, many compounds) approach of which, single or 
multiple strains are investigated in detail to obtain new metabolites by activating silent biosynthetic 
gene clusters.76  
A 2007 study by Paranagama et al.77 showed that a very simple change in the culture medium, such 
as changing tap water to distilled water, resulted in the isolation of six new fungal metabolites 
cytosporones F–I (1.31–1.34), quadriseptin A (1.35), and 5′-hydroxymonocillin III (1.36).  
 
A 2002 study by Bode et al.78 reported more than 100 compounds belongs to over 25 structural classes 
from six different microbes by changing culture conditions. For example, changing the culture 
conditions (for example, shaking flasks, static liquid, different fermenters) of Aspergillus ochraceus 
DSM 7428 led to the isolation of 15 metabolites (1.37–1.52), which have five different biosynthetic 
origins.  
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In another study by Zhang et al.79 reported that plant-derived fungus Xylaria sp. suppressed the 
production of known cytochalasin-type metabolites to express new α-pyrone derivatives, xylapyrones 
A–F (1.53–1.58), when the culture medium change from solid to liquid shaking. Similarly, Fill et 
al.80 reported that supplementing the culture medium with CuSO4 completely suppressed the 
production of verruculogen in favour of the novel cyclodepsipeptide JBIR 113 (1.59), JBIR 114 
(1.60) and JBIR 115 (1.61).  
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Despite the promising outcomes in the discovery of new metabolites, changing culture conditions is 
laborious, particularly in handling quite large number of strains. Moreover, traditional solid or shake 
flask methods occupy a considerable lab space. To overcome this challenge, in the Capon lab we have 
adopted microtiter 96-well and 24-well plates for culturing fungi in multiple culture media and culture 
conditions.81 Today, the technology is a mature alternative to traditional agar plates and Erlenmeyer 
flask culturing, and offers a HTS alternative, optimal for academia laboratories.82  
1.5.4. Microbial co-cultivation 
In nature, microorganisms are often found in communities where they interact with each other by 
producing communication tools, mostly secondary metabolites.11 Among the different interactions 
involved, competition for limited nutrient and space often creates biotic stress in microbial 
communities. This biotic stress leads fungi to synthesise secondary metabolites and enzymes to 
enhance their own growth or to suppress the competitors. By culturing one or more microorganisms 
together, which is often referred as “co-cultivation”, it is possible to artificially mimic such biotic 
stress.83 Therefore, microbial co-cultivation has been an interesting approach to understand diverse 
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issues in microbiology. This includes, induction of pharmaceutically interesting secondary 
metabolites via activation of silent microbial metabolism.84  
Often, chemical investigations on microorganisms relies on laboratory monocultures, where single 
strain is cultured on artificial a culture medium to a very high density (as compared to original 
habitat). Due to the absence of particular biotic interactions that microbe experienced in the confined 
natural habitat, many secondary metabolite biosynthetic gene clusters tend to be silent/cryptic.84 
Therefore, challenging a given microbe with coexisting strains or a strain from a different habitat has 
been a successful strategy to discover novel and bioactive microbial secondary metabolites.85 
Co-cultivation of fungi with bacteria has been well studied for the induction of new secondary 
metabolites. For example, co-cultivation of mine drainage-derived Aspergillus fumigatus with co-
existing Sphingomonas bacterial strain led to the isolation of novel diketopiperazine disulfide, 
glionitrin A (1.62).86 In another study, co-cultivation of Aspergillus fumigatus with Streptomyces 
peucetius resulted in the isolation of new N-fromyl alkaloid fumiformamide (1.63).87  
 
A 2009 study by Schroeckh et al.88 reported that soil-dwelling Streptomyces rapamycinicus activated 
a silent polyketide synthase (PKS) gene clusters in the model fungus Auspergillus nidulans. This 
study demonstrated that an intimate physical interaction was required to induce biosynthesis of four 
new metabolites, orsellinic acid (1.64), lecanoric acid (1.65), and the cathepsin K inhibitors F-9775A 
(1.66) and F-9775B (1.67). Further investigation revealed that the bacterium activated the silent 
metabolites by histone modification through the action of the main histone acetyltransferase complex 
Saga/Ada.89 Interestingly, Kong et al. revealed that co-cultivation of the same Streptomyces with a 
pathogenic fungus Aspergillus fumigatus induced a cryptic fungal meroterpenoid pathway to produce 
novel fumicycline A (1.68) and B (1.69).90  
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A co-culture fermentation of co-existing fungi Penicillium fuscum and P. camembertii/clavigerum 
isolated from surface water collected from Berkeley Pit Lake resulted in the isolation of eight new 
16-membered-ring macrolides, berkeleylactones A−H (1.70–1.77), which were absent in axenic 
cultures.  
 
The important action to trigger theses microbial secondary metabolites is the interaction between the 
two test organisms, which could be mutualistic, neutralistic or competitive. These interactions can 
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occur either at distance or upon/after physical contact with each other.83 For active recognition of 
strains at distance requires release and recognition of diffusible chemical cues. There are several 
examples to prove that the underlying mechanism in microbial co-cultivation was unique, and 
detailed study provided valuable information that can be used for activating silent microbial 
secondary metabolism.89,91 Unfortunately, the molecular mechanism behind many co-cultivation 
studies are underexplored or, in many cases, untouched.  
1.6. Summary 
In the search of new drug leads, fungal natural products have been promising candidates, and a 
number of fungal natural product-derived compounds have been approved as drugs. Despite the 
decreased momentum in the discovery of novel bioactive metabolites, the vast ecological diversity 
and genetic capacity of fungi reveal an untapped hidden biosynthetic potential. Owing to the complex 
regulatory mechanism of fungal secondary metabolism, microbes do not express their full 
biosynthetic capacity under standard laboratory conditions, with many biosynthetic gene clusters 
remaining silent. The most challenging goals in the fungal biodiscovery are unravelling this hidden 
biosynthetic capacity, and identifying strategies to exploit the metabolic potential. Recent 
advancements in many related disciplinaries, such genomics, analytical techniques and culturing 
techniques, have opened up promising avenues to explore the fungal secondary metabolism. 
Therefore, coupling these new technologies with traditional biodiscovery approaches, such as 
bioactivity-guided isolation, varying culture conditions and co-cultivation, would allow researchers 
to discover the hidden potential of fungi. Further, detailed understanding of physiological and 
ecological conditions that drive the biosynthesis of fungal secondary metabolites are important to 
accelerate the exploitation of silent secondary metabolism in a more efficient and economical manner. 
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2. Chapter 2: Bioactivity-guided isolation of anthelmintic metabolites 
The focus of this chapter is to investigate the bioactivity-guided isolation as a prioritizing tool for 
microbial extracts to isolate biologically active metabolites. To provide a useful filter, it is important 
to employ a panel of bioassays that provide a broad picture about bioactivity of the extracts. In my 
PhD project, we employed a modified Haemonchus contortus larval development assay (LDA) to 
search for metabolites with anti-parasitic activity.1,2 The LDA has been optimized to detect active 
metabolites against egg hatching and subsequent development of the larvae to the 3rd stage, which 
serves as the source of infection. In the search for anthelmintics, it is helpful to exclude potent 
cytotoxic metabolites and antimicrobial metabolites, which could generate false positive. Therefore, 
LDA, together with cytotoxicity and antimicrobial assays, was employed. 
For the screening against H. contortus, a microbial library was constructed from samples collected 
from different locations in Australia. The rationale behind the sample collection was; (a) relevance: 
microbes sense their surrounding environment and response accordingly. Therefore, microbes 
isolated from nematode rich samples might produce some defensive metabolites against nematodes; 
(b) novelty: microorganisms have been isolated from a wide range of ecological sources, such that 
microbes from new sources may have a high probability of delivering new chemistry. A total of ×185 
microbes including fungi (×132) and Streptomyces (×53) were isolated and used for my PhD studies. 
In this chapter, I report the construction of the microbial library, the screening of microbial extracts 
using LDA, and the identification, isolation and characterization of active metabolites. 
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2.1. Sample collection and isolating microbes 
During the period of July 2014 to January 2016 a total of ×28 samples including ×9 soil, ×17 sheep 
faecal and ×2 sheep wool samples were collected from an open field in The University of Queensland, 
Veterinary School sheep pens Gatton, based on the hypothesis that microbes reside in nematode rich 
environments may produce defensive metabolites against parasitic nematodes. A total of ×69 strains, 
including ×48 bacteria and ×21 fungi, were isolated. 
In addition, selected fungi (×70 isolates) from the marine fish-derived microbial collection, which 
consists of many chemically rich isolates, were included for bioactivity profiling. The marine fish-
derived microbial library was constructed by an occupational trainee student who assembled ~800 
isolates from fish intestine tissues. To improve the ecological diversity of the collection, ×11 fungal 
strains isolated from a soil sample collected from a Tasmanian rain forest, and ×27 microbes isolated 
from soil samples collected from a mangrove ecosystem near Nudgee Beach, Australia, were also 
incorporated. The mangrove-derived microbial collection was constructed with the help of a visiting 
scientist Dr. Ailian Zhang. A systematic code was given for all microbial isolates, i.e; CMB-NB 
(bacteria isolated from sample collected from Gatton), CMB-NF (fungi isolated from samples 
collected from Gatton), CMB-W (microbes isolated from sheep wool), CMB-F (microbes isolated 
from fish intestine), CMB-TS (microbes isolated from sample collected from Tasmanian soil) and 
CMB-MS (microbes isolated from mangrove). Table 2.1 summarises all the strains gathered for 
bioactivity profiling, while Figure 2.1 showing photographs of some of the isolates.  
Table 2.1: Microbes isolated from samples collected in Australia 
Sample  Number of isolates Fungi Streptomyces 
Gatton soil 4 47 
Sheep faecal 17 2 
Sheep wool 2 − 
Tasmanian soil 11 5 
Fish gut  71 − 
Mangrove soil 21 3 
 
Figure 2.1: Photographs of the isolates cultured on agar media.   
CMB-NB008 CMB-NB040 CMB-NB082 CMB-NF003 CMB-NF037 
CMB-F697 CMB-F191 CMB-TS015 CMB-W002 CMB-MS001 
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2.2. Constructing a crude extract library 
All isolated strains were cultured on solid (agar) and liquid culture media, to generate extracts. To 
address the challenge in handling a large number of cultures, a 24-well plate miniaturized 
microbioreactor (MATRIX) culture approach, greatly simplifying and facilitating the generating of 
extracts for bioactivity profiling, was employed. In our hands, the MATRIX approach is a mature 
alternative to conventional agar plate and flask-based microbial cultures. To facilitate high-
throughput (HTP) analysis, both liquid and solid cultures were extracted in situ with EtOAc and 
transferred into 96-deep well plates (liquid culture; 200 µg/mL, solid culture; 1 mg/mL in DMSO) so 
that extracts are readily available for chemical and biological profiling (Figure 2.2).  
 
Figure 2.2: Photograph of 96-deep well plate containing microbial crude extracts. 
2.3. Screening microbial extracts 
The crude extract library was subjected to in-house LDA, optimized to detect active extracts or 
metabolites against egg hatching (ovicidal effect) and subsequent development of the larvae from the 
1st stage (L1) to the 3rd stage (L3). For this study, we used H. contortus1 resistant to commercially 
available anthelmintic monepantel (Zolvix®)4. The LDA experiments were carried out with the help 
of Dr. Angela A. Salim and Dr. Lea Indjein.  
To obtain a broad bioactivity profile, all extracts were also screened for cytotoxicity and antibacterial 
activity. Active extracts against Gram-negative bacteria could generate false positive results in LDA 
since H. contortus larvae feed on live Gram-negative bacteria, and as result, potent antibacterial 
extracts could generate starving condition, which affects the larval survival. 
Figure 2.3 illustrates the results obtained from bioactivity profiling. Even though the LDA revealed 
×16 hits, many were also highly cytotoxic and/or antibacterial (Figure 2.4). However, HPLC-DAD-
MS profiling of active extracts exhibited rich chemical profiles with structurally unique metabolites. 
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With this result, we speculated that different metabolites in the extracts might have different 
biological properties, and anti-parasitic activity could be from a unique metabolite in the extract. To 
investigate the hypothesis, Purpureocillium sp. CMB-F551 and Penicillium sp. CMB-TS015, both of 
which showed significant anthelmintic activity (>99% inhibition in LDA), were selected for further 
studies. What follows is an account of the analytical and preparative cultivation of CMB-F551 and 
CMB-TS015, and the isolation and characterization of active metabolites.   
 
Figure 2.3: The hits obtained for LDA. The numbers on each bar account for hits found for each sample. 
 
 
Figure 2.4: An illustration of the results obtained from bioactivity profiling. 
  
Ga
tto
n s
oil
Sh
ee
p f
ec
al
Sh
ee
p w
oo
l
Ta
sm
an
ian
 so
il
Fis
h g
ut
Ma
ng
ro
ve
 so
il
0
2
4
6
8
10
N
um
be
r o
f h
its
1
3
2
1
8
1
Potent 
cytotoxic
22
Potent 
antimicrobial
Potent 
antiparasitic 
Potent cytotoxic 
Cytotoxic/antimicrobial 
Potent antiparasitic
Antimicrobial/ antiparasitic
Potent antimicrobial 
Cytotoxic/antiparasitic
5
* Total number of crude extratcs tested is 110
3
13
4
Antimicrobial/ antiparasitic/
cytotoxic
Chapter 2: Bioactivity-guided isolation of anthelmintic metabolites 
 
 
26 
2.4. Fungal phylogenetic analysis of CMB-F551 and CMB-TS015  
Morphological examination of CMB-F551 (Figure 2.5a, 2.5b) and CMB-TS015 (Figure 2.6a, 2.6b) 
exhibited characteristic features of genus Paecilomyces and Penicillium respectively. To further 
confirm the phylogeny, genomic DNA sequencing was performed. Genomic DNA was extracted 
from both strains using a blood and tissue kit (QIAGEN) followed by PCR amplification. The purified 
PCR products were then sequenced for ITS1 and ITS4 regions at Australian Genomic Research 
Facility (AGRF) at The University of Queensland. The sequences were analysed using Basic Local 
Alignment Search Tool (BLAST) of National Center for Biotechnology Information (NCBI). A 
phylogenetic tree (Figure 2.5 and Figure 2.6) was constructed using ×30 nucleotide sequences, which 
showed more than 95% homology. 
The BLAST analysis of CMB-F551 showed 99% homology to both genus Paecilomyces and 
Purpureocillium that was in agreement with morphological features. Paecilomyces, is a ubiquitous 
genus found in a wide range of habitats including soil, decaying vegetation, insects, marine sediment 
and nematodes. The genus Purpureocillium was recently proposed for Ophiocordycipitaceae based 
on a comparison of ITS regions and translation elongation factor 1-α (TEF) sequences.2 These strains 
were previously classified under the genus Paecilomyces. The phylogenetic tree proposed CMB-F551 
to be closely related to Purpureocillium lilacinum. 
Morphological examination for CMB-TS015 showed characteristics features related to the genus 
Penicillium, but the closest match in BLST analysis showed only 84% homology to reported 
Penicillium sp. The phylogenetic tree constructed from the sequences with more than 80% homology 
suggested that CMB-TS015 be closely related to Penicillium decaturense. 
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Figure 2.5: Phylogenetic analysis of CMB-F551. (a) Photograph of CMB-F551 cultured on ISP-2 salt agar. (b) 
Microscopic image of conidia and conidiophore. (c) Phylogenetic tree. The PhyML Maximum Likelihood analysis of ITS 
DNA sequences was performed using optimal nucleotide substitution model determined by jModeltest (JC69)3 using 
Unipro UGENE4 software. The phylogenetic relationship of CMB-F551 to the selected reference strains (nt/nr GenBank) 
that showed more than 95% homology shown with accession numbers indicated in brackets, highlighted in blue. 
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Figure 2.6: Phylogenetic analysis of CMB-TS015. (a) Photograph of CMB-TS015 cultured on PDA. (b) Microscopic 
image of conidia and conidiophore. (c) Phylogenetic tree. The PhyML Maximum Likelihood analysis of ITS DNA 
sequences was performed using optimal nucleotide substitution model determined by jModeltest (JC69)3 using Unipro 
UGENE4 software. The phylogenetic relationship of CMB-TS015 to the selected reference strains (nt/nr GenBank) that 
showed more than 80% homology shown with accession numbers indicated in brackets, highlighted in blue. 
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2.5. Analytical cultivation 
A loop of spores from Purpureocillium sp. CMB-F551 and Penicillium sp. CMB-TS015 was streaked 
on agar plates (×30 for each strain) loaded with ISP-2 salt (3% artificial sea salt) and ISP-2 media, 
respectively, and the plates were incubated at 26.5 oC for 14 days. After incubation, combined agar 
/mycelia was extracted with EtOAc (4 × 250 mL) and the decanted organic phases were evaporated 
to dryness in vacuo to yield the crude extracts, which were resuspended in MeOH and analysed in 
HPLC-DAD-ESIMS (Figure 2.7 and Figure 2.8). The data indicated that both crude extracts are rich 
in chemically diverse metabolites. To probe the biological activity of the metabolites present in the 
crude extracts, the extracts were fractionated using preparative HPLC, and each fraction was 
individually tested for anti-parasitic and cytotoxic activity.  
 
Figure 2.7: HPLC-DAD-ESIMS chromatogram (210 nm) of CMB-F551 crude extract. The extract was eluted with 
Zorbax SB-C8 column, 150 × 4.6 mm, 5 µm, 1 mL/min gradient elution from 10% MeCN/H2O–100% MeCN inclusive 
of isocratic 0.05% formic acid modifier, over 15 min. 
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Figure 2.8: HPLC-DAD-ESIMS chromatogram (210 nm) of CMB-TSF015 crude extract. The extract was eluted with 
Zorbax SB-C8 column, 150 × 4.6 mm, 5 µm, 1 mL/min gradient elution from 10% MeCN /H2O–100% MeCN inclusive 
of isocratic 0.05% formic acid modifier, over 15 min. 
2.5.1. Analytical fractionation of Purpureocillium sp. CMB-F551  
An aliquot of CMB-F551 extract (100 mg) was fractionated (Figure 2.9a) by preparative HPLC 
(Phenomenex® C8 column, 250 × 20 mm, 10 µm, with 20 mL/min gradient elution from 10% 
MeCN/H2O–100% MeCN inclusive of 0.01% TFA modifier). The resulting fractions (×40) were 
tested against the LDA and for cytotoxicity against human colon carcinoma cells (SW620). Fractions 
18-24 showed potent activity (>99% inhibition) in the LDA (Figure 2.9b) and cytotoxicity (>95% 
inhibition) (Figure 2.9b). It is noteworthy that all the cytotoxic metabolites of the CMB-F551 extract 
did not exhibit inhibitory activity in LDA. Chemical profiling of LDA active extracts with UHPLC-
QTOF-MS (Figure 2.10) revealed that the active fractions comprise a series of structurally related 
metabolites with larger molecular weights (m/z 1186.8–1262.9). UHPLC-QTOF-MS/MS 
fragmentation analysis (Figure 2.11), supported by literature search, suggested that these metabolites 
belong to the leucinostatin family of fungal mycotoxins, lipopeptide antibiotics commonly produced 
by Purpureocillium lilacinum (previously known as Paecilomyces lilacinum). This strain is a well-
known biocontrol agent commercialised as a pest control for various plant pathogens, including root-
knot nematode.5  
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Figure 2.9: Bioactivity profiling of the CMB-F551 crude extract. (a) Preparative HPLC chromatogram (210 nm) of CMB-
F551. The extract was eluted with a gradient elution from 10% MeCN/H2O–100% MeCN inclusive of 0.01% TFA 
modifier using Phenomenex® C8 column, over 20 min. (b) Cytotoxic activity of fractions against SW620 colon cancer 
cells analysed using MTT assay. nFractions showed potent activity in LDA and cytotoxicity. nFractions showed potent 
activity only in cytotoxicity. 
 
Figure 2.10: UHPLC-QTOF-MS total ion chromatogram (TIC) of the pooled LDA active fractions (18–24). *Impurities.  
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First reported in 1970,6 leucinostatin A (2.1) is a linear peptide comprise nine amino acid residues 
including non-proteinogenic amino acids, cis-4-methyl-L-proline, (2S,4S)-2-amino-6-hydroxy-4-
methyl-8-oxodecanoic acid (AHMOD), threo-β-hydroxy-L-leucine, α-aminosiobutryric acid (Aib) 
and β-alanine, along with fatty acyl moieties, (4S, 2E)-4-methylhex-2-enoic acid (MeHA) and (2S)-
N,N-dimethylpropane-l,2-diamine (DMPD), at the N-terminus and C-terminus, respectively. MS/MS 
fragmentation analysis (Figure 2.12–2.19), supported by a literature search with the UHPLC-QTOF 
generated molecular formula, identified the major leucionstatins (Table 2.2). 
 
The overlaid UHPLC-QTOF-MS/MS spectra of the major metabolites in the active fractions showed 
a number of similar fragments. This intriguing result encouraged us to visualize all the leucinostatins 
present in the CMB-F551 crude extract using the Global Natural Product Social (GNPS) molecular 
networking platform, which has been developed to organize structurally similar metabolites into 
molecular clusters based on the similarities in MS/MS fragmentation. Leucinostatins present in CMB-
F551 crude extract formed a molecular cluster together with four masses (Figure 2.11, highlighted in 
blue), which were not reported previously for leucinostatins.  
 
Figure 2.11: The leucinostatin molecular cluster. known leucinostatins in the active fractions, known leucinostatins 
detected in the crude extract and new leucinostatins identified from MS/MS fragmentation analysis.  
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Table 2.2: Major metabolites identified from LDA active fractions of CMB-F551 
  tR HR(+)MS [(M+H)+] Molecular formula Error (Δmmu) 
leucinostatin A (2.1) 3.74 1218.8436 C62H111N11O13 −0.8 
leucinostatin A2 (2.2) 4.12 1200.8356 C62H109N11O12 −2.0 
leucinostatin B (2.3) 3.67 1204.8372 C61H109N11O13 −3.7 
leucinostatin B2 (2.4) 3.86 1186.8200 C61H107N11O12 −2.2 
leucinostatin K (2.5) 3.39 1234. 8421 C62H111N11O14 −2.4 
leucinostatin L (2.6) 3.40 1190.8144 C60H107N11O13 −2.4 
leucinostatin V (2.7) 4.11 1188.8346 C61H109N11O12 −1.4 
leucinostatin R (2.8) 4.43 1202.8489 C62H111N11O12 −0.3 
leucinostatin K2 (2.9) 3.19 1262.8681 C58H105N11O12 +1.6 
leucinostatin K3 (2.10) 3.44 1248.8500 C63H113N11O14 −1.0 
leucinostatin H2 (2.11) 3.87 1148.7946 C58H105N11O12 −1.6 
leucinostatin L2 (2.12) 3.68 1172.8057 C60H105N11O12 −2.7 
 
 
Figure 2.12: MS/MS fragmentation analysis of leucinostatin A (2.1).  
 
Figure 2.13: MS/MS fragmentation for leucinostatin A2 (2.2). Green highlight – major differences compared to 2.1. 
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Figure 2.14: MS/MS fragmentation for leucinostatin B (2.3). Green highlight – major differences compared to 2.1.  
 
Figure 2.15: MS/MS fragmentation for leucinostatin B2 (2.4). Green highlight – major differences compared to 2.1. 
 
Figure 2.16: MS/MS fragmentation for leucinostatin K (2.5). Green highlight – major differences compared to 2.1. 
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Figure 2.17: MS/MS fragmentation for leucinostatin L (2.6). Green highlight – major differences compared to 2.1. 
 
Figure 2.18: MS/MS fragmentation for leucinostatin V (2.7). Green highlight – major differences compared to 2.1. 
 
Figure 2.19: MS/MS fragmentation for leucinostatin R (2.8). Green highlight – major differences compared to 2.1. 
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UHPLC-QTOF-MS/MS fragmentation analysis confirmed that 2.9 (Figure 2.20) and 2.10 (Figure 2.21) are close 
homologues of leucinostatin K (2.5), with C-terminus modifications being the only structural variation. Based on 
leucinostatin K (2.5), structures of 2.9 and 2.10 were proposed as shown in figure 2.20 and 2.21, respectively.  
 
Figure 2.20: UHPLC-QTOF-MS/MS fragmentation analysis of leucinostatin K2 (2.9). The proposed structure is based 
on leucinostatin K (2.5).   
 
Figure 2.21: UHPLC-QTOF-MS/MS fragmentation analysis of leucinostatin K3 (2.10). The proposed structure is based 
on leucinostatin K (2.5). 
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The metabolite 2.11 showed a MS/MS spectrum closely resembling leucinostatin H (m/z, 1134), with 
the only difference in the C-terminus modification. A HR(+)MS analysis suggested a structure 
fragment  C9H21N3O2 (Δmmu +0.9). Based on the leucinostatin H, the structure of the 2.11 was 
proposed as shown in figure 2.22.  
 
Figure 2.22: UHPLC-QTOF-MS/MS fragmentation analysis of leucinostatin H2 (2.11). The proposed structure is based 
on leucinostatin H.     
The fragment ion at m/z 403.2613 (Figure 2.23), which is −18Da compared to known leucinostatin L 
(2.6, m/z 1190, Figure 2.17), suggested 2.12 to be AHMOD reduced homologue. This was further 
supported by the fragment ions observed at m/z 208.1328 and 403.2613 correspond to the structure 
fragment C11H17NO2 (Δmmu −2.6). Considering the fragmentation analysis and biosynthesis of co-
metabolites, the structure of the 2.12 was proposed as shown in the figure 2.23.  
The structures of all four new leucinostatins analogues 2.9–2.12 were proposed based on the MS/MS 
fragmentation analysis, further studies are required in order to confirm the proposed structures. 
However, due to lack of novelty in chemistry and biological activity, further investigations did not 
carry out.   
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Figure 2.23: UHPLC-QTOF-MS/MS fragmentation analysis of leucinostatin L2 (2.12). The proposed structure is based 
on leucinostatin L (2.6).     
Leucinostatin A (2.1) was first isolated from a culture filtrate of Penicillium lilacinum by Arai et al.6, 
and was later confirmed to exist as a mixture of two closely related metabolites, named leucinostatin 
A (2.1) and B (2.3).  A 1980 study by Isogai et al.7 reported a similar metabolite, P168, from a 
Paecilomyces lilacinum (Thom) Samson. A desmethyl homologue of the P168, NO 1907, was also 
reported from Paecilomyces lilacinum No. 1907.8 Subsequent analyses proved that leucinostatin A 
(2.1) and B (2.3) to be identical with P168 and NO 1907, respectively, with complete structures 
established by a combination of chemical and spectrometric analysis.7 Further analysis of the 
Paecilomyces lilacinum crude extract revealed that leucinostatins are produced as a 
microheterogeneous mixture of peptides, with tandem mass spectrometry deducing several minor 
metabolites.9,10 To date, over twenty members of this leucinostatin series have been reported although 
the exact number is unclear due to confusion in nomenclature and the likelihood of redundant and 
overlapping classes. The leucinostatins have been attributed to various biological activities such as 
antimicrobial,8 cytotoxic,11 anti-tumour,12  anti-parasitic,13 immunosuppression,14 anti-
trypanosomal,15 and ATPase inhibitory activity.16 The α-helical conformation and amphiphilic nature 
of the leucinostatins is believed to be the key to these biological activities.15  
Of note, leucinostatin producer Purpureocillium lilacinum (previously known as Penicillium 
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nematodes. This strain, known as a nematophagous fungus, exhibits nematocidal and ovicidal 
activity.17 P. lilacinum is a saprobic fungus generally found in soil, plant roots, insects and 
nematodes.2 Interestingly, leucinostatins, serine protease,18 cuticle-degrading protease19 and 
chitinase20 produced by P. lilacinus have been identified as the active substances, which cause a 
pathogenic effect on nematodes.21 However, a 2004 study on Australian isolates by Park et.al22 
reported that the nematocidal activity largely depends on the level of leucinostatin production, 
suggestive of a direct correlation between the leucinostatins and the nematocidal activity of P. 
lilacinus. Other than the primary studies on culture filtrates or the P. lilacinus strain as a biocontrol 
agent against nematode, a detailed investigation on active substances or the cellular mechanism of 
the anti-parasitic activity has not been reported yet. Most likely, this could be due to the difficulty 
with purifying leucinostatins mixture. A recent study on structure-activity relationship of 
leucinostatin A (2.1) showed that the complete structure is vital for the cytotoxic activity of the 
leucinostatin A (2.1), and a subtle change in the structure resulted in substantial changes in the 
activity.23 Given that the Capon lab is equipped with modern analytical and separation techniques, in 
future, it is worth doing a comprehensive study on pure leucinostatins to determine the structure-
activity relationship of leucinostatin analogues.  
2.5.2. Analytical fractionation of Penicillium sp. CMB-TS015 crude extract 
To probe the anthelmintic and cytotoxic metabolites in the CMB-TS015 crude extract, an aliquot (100 
mg) of the EtOAc crude extract was fractionated (Figure 2.17a) by HPLC (Phenomenex® C8 column, 
250 × 20 mm, 10 µm, with 20 mL/min gradient elution from 10% MeCN/H2O–100% MeCN inclusive 
of 0.01% TFA modifier). The resulting ×40 fractions were tested in LDA and growth inhibitory 
activity on human colon carcinoma cells (SW620). Unlike the crude extract from Purpureocillium 
sp. CMB-F551, bioactivity profiling of CMB-TS015 fractions showed that anthelmintic activity and 
cytotoxicity were from two different groups of metabolites (Figure 2.24). Specifically, the 
anthelmintic fraction 22–23 did not show significant toxicity towards SW620 cells, with the cytotoxic 
activity loaded in fractions 5 and 29. The latter contained the mycotoxin terrein (3.7) and 
cyclopiazonic acid (3.6), respectively (see Chapter 3), with neither exhibiting activity in LDA. This 
result led us to scale-up the Penicillium sp. CMB-TS015 to isolate and characterize the anthelmintic 
metabolites. A rice solid medium was selected for scale-up cultivation since fungi produce a larger 
quantity of metabolites on rice solid medium. 
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Figure 2.24: HPLC fractionation of CMB-TS015 crude extract and bioactivity profiling of the fractions. (a) Preparative 
HPLC chromatogram (210 nm) of CMB-TS015 crude extract. The extract was eluted with a gradient elution from 10% 
MeCN/H2O–100% MeCN inclusive of 0.01% TFA modifier using Zorbax C8 column over 20 min. (b) Cytotoxic activity 
of fractions against SW620 colon cancer cells analysed using MTT assay. nFractions with potent anthelmintic activity. 
nCytotoxic fractions. 
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2.6. Preparative cultivation, isolation and characterization of metabolites 
Agar cubes (~1 cm2 × 3) from 7 days old Penicillium sp. CMB-TS015 cultured on ISP-2 medium, 
were inoculated on rice solid medium (2 × 70 g) and incubated at 26 oC for 25 days. After incubation, 
combined rice mass with mycelia was extracted with EtOAc (4 × 250 mL) and concentrated in vacuo 
to obtain a crude extract (2.93 g). The crude extract was partitioned with n-hexane (4 × 50 mL) and 
MeOH (50 mL) and the MeOH soluble fraction (1.3 g) was subjected to flash chromatography 
(Biotage® KP-C18-HS column, 60 g, 50 mL/min stepwise gradient elution 10% MeCN/H2O–100% 
MeCN) to afford ×15 fractions. The subsequent purification yielded citreoviridin A (2.13) as the 
anthelmintic metabolite (Scheme 2.1). In the following sections, the structure elucidation and 
biological activity of citreoviridin A (2.13) is discussed, while Chapter 3 describes the isolation, 
characterization and biological activity of additional metabolites isolated in the cause of purification 
of citreoviridin A (2.13). 
 
Scheme 2.1: Isolation scheme for citreoviridin A (2.13). (a) Solvent partitioning, (b) Flash chromatography, Biotage® 
KP-C18-HS column (60 g), 50 mL/min stepwise gradient elution 10% MeCN/H2O–100% MeCN and (c) Semi-preparative 
Zorbax SB-C18 column, 250 × 9.4 mm, 5 µm, 3 mL/min, isocratic 45% MeCN/H2O inclusive of 0.01% TFA modifier, 
over 20 min. Additional metabolites isolated from the other fractions are discussed in Chapter 3. 
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2.6.1. citreoviridin A (2.13)  
 
Metabolite 2.13 was isolated as a dark yellow pigment. The HRESI(+)MS analysis of 2.13 revealed 
a pseudo-molecular ion ([M+H]+) consistent with a molecular formula (C23H30O6, Δmmu –0.5) 
requiring ×9 double bond equivalents (DBE). The UV-vis spectra of 2.13 exhibited λmax values at 384 
and 400 nm, suggestive of a highly conjugated chromophore. The 1H NMR (600 MHz, methanol-d4) 
data for 2.13, together with COSY correlations, revealed resonances (Figure 2.25 and Table 2.3) for 
three conjugated double bonds, with larger coupling constants (JH-8/H-9 = 15.1, JH-10/H-11 = 14.8, and 
JH-12/H-13 = 14.8) confirming E configurations. The 13C NMR (150 MHz, methanol-d4) data for 2.13 
revealed resonances for a carbonyl and six additional sp2 carbons, accounting for ×7 DBE that 2.13 
be bicyclic. Sharp singlets at δH 1.16, 1.31, 1.90, 2.00 and 3.89 and a doublet at δH 1.14 indicated the 
presence of six methyls including a methoxy. A literature search with the structure fragments 
established through diagnostic 2D NMR correlations (Figure 2.26) suggested 2.13 to be the known 
fungal metabolite citreoviridin A (2.13). A 1947 study by Hirata reported a yellow colour pigment 
from mouldy rice.24 Later, in 1964, Sakabe et al.24 established the structure and the configuration of 
citireoviridin A (2.13). Linnett et al.25 reported that 2.13 was a potent inhibitor of mitochondrial 
ATPase (adenosine triphosphatase) similar to that of structurally related aurovertin B (2.15), D (2.16) 
and F (2.17).  
The dose dependant anthelmintic activity of citreoviridin A (2.13) against drug resistant H. contortus 
was evaluated using our in-house LDA (Figure 2.28), leading to an IC50 of 7.6 µM. However, due to 
its polyene character, citreoviridin A (2.10) was unstable under room illumination, undergoing 
isomerisation at room temperature over 24 h to yield two isomers (Figure 2.27). A 1989 study by 
Sayood et al.26 demonstrated that 30 min exposure to normal light resulted in formation of over 30% 
of isocitreoviridin (2.14), which is nontoxic and has no apparent effect on ATPase. This photo-
isomerisation has been attributed to inconsistent bioactivity observed for citreoviridin A (2.13). 
OO
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HO
OH
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Figure 2.25: 1H NMR (600 MHz, methanol-d4) and UV-vis (HPLC-DAD, H2O/MeCN with 0.05% formic acid modifier 
at 210 nm) spectrum of citreoviridin A (2.13). 
 
Figure 2.26: Key 2D NMR correlations for citreoviridin (2.13). 
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Table 2.3: NMR data (methanol-d4) for citreoviridin A (2.13) 
Position δCa δH, multi, (J in Hz) 
experimental 
COSY 1H-13C HMBC ROESY δH, multi, (J in Hz) 
literature27 
1 13.1 1.14, d (6.3) 2 2, 3  1.13, d (6.3) 
2 79.3 3.76, q (6.3) 1 1, 3 19 3.73, q (6.3) 
3 81.5      
4 86.9 3.89, s  1, 2, 6 6 3.90, s 
5 86.0      
6 145.0 5.94, s   4, 7, 8, 20, 21 4 5.94, s 
7 133.7      
8 143.0 6.41, d (15.1) 9 6, 9, 10, 21  6.41, d (15.0) 
9 128.2 6.63, dd (15.1, 10.2) 8, 10 7, 11  6.34, dd (15.3, 9.0) 
10 140.4 6.36, dd (14.8, 10.2) 9, 11 8, 11, 12  6.62, dd (14.8, 9.0) 
11 132.1 a6.49,  10 9, 10, 13  6.51, dd (15.0, 11.1) 
12 137.8 7.15, dd (14.8, 11.2) 11, 13 10, 11, 14  7.15, dd (15.0, 11.2) 
13 119.7 6.53, d (14.8) 12 11, 12, 14, 15  6.49, d (15.0) 
14 156.2       
15 109.6      
16 
16-OMe 
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Figure 2.27: HPLC-DAD (210 nm)-ESIMS chromatogram of the citreoviridins.     
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Figure 2.28: Dose-response activity of citreoviridin A (2.13) in LDA 
Citreoviridins belong to a family of polyene α-pyrones-type polyketide mycotoxins, which are known 
for their inhibitory activity on ATPase, with no literature evidence for antiparasitic activity. However, 
a 2010 study by Niu et al.28 reported that aurovertin D (2.16) and aurovertin F (2.17) which are 
structurally close to citreoviridin A (2.13) were toxic to the free living nematode Panagrellus 
redivevus with LC50 (48 h) of 88.6 and 41.7 µg/mL, respectively. Interestingly, Gause et al.29 reported 
that citreoviridins and aurovertins non-competitively inhibited yeast F1-ATPase. Of note, 
leucinostatins identified from the LDA active fractions of CMB-F551 are also known for their activity 
against mitochondrial ATPase, suggestive that ATPase inhibitory activity might be a common 
mechanism behind these nematocidal properties.  
 
2.7. ATPase as an antiparasitic drug target 
Collectively, in the search for antiparasitic metabolites against H. contortus, we identified two classes 
of structurally different metabolites as active metabolites from microbial extracts. The common 
feature for both of these classes is their inhibitory activity on ATPase, a well-known drug target.  
ATPases are a class of enzymes that catalyse the dephosphorylation of ATP which generate the 
energy to perform many vital cellular activities. Therefore, dysregulated ATPases have been drug 
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several types of ATPases, vacuolar ATPase (V-ATPase) that pumps energy across membranes has 
been identified as a potential target for nematocidal leads. In free-living as well as parasitic nematodes 
such as s H. contortus, T. circumcincta and T. colubriformis, V-ATPase play crucial role in nutrition, 
osmoregulation, cuticle synthesis, neurobiology and reproduction.31 In a comprehensive review on 
the role of V-ATPase in nematodes by Knight and Behm,32 it was articulated that V-ATPase possess 
all the key characteristics to be a drug target. i.e; 
• Possesses binding sites for small ligands33 
• Express in all the stages of the life cycle34 
• Have potential for selective inhibition 
With the results we observed in our study and the literature support for the V-ATPase as a nematocidal 
drug target, it is intriguing to carry out further studies with identified active metabolites and the hits 
(see section 2.3) obtained via screening. However, designing a high-throughput screening approach 
for V-ATPase inhibitors remains a challenge.  
2.8. Conclusion 
This chapter reports LDA-guided isolation and characterisation of anthelmintic metabolites. The 
results demonstrated that, in the search for anthelmintic metabolites using LDA, parallel screening 
for cytotoxicity and antimicrobial activity is helpful to avoid false positives. However, it was proved 
that a complex microbial extract comprises structurally different metabolites with different biological 
activities. Therefore, HPLC fractionation-guided screening is useful for discovering active 
metabolites for the targeted bioassay. The anthelmintic metabolites described in this chapter belong 
to structure classes that are known for ATPase inhibitors. This finding suggests that ATPase inhibitors 
might have potentials in antiparasitic drug search. 
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2.9. Experimental 
2.9.1. General experimental 
See Appendix I: General Experiments, page 263.  
2.9.2. Sample collection and microbe isolation 
Twenty-eight samples, including ×9 soil, ×17 sheep fecal and ×2 sheep wool samples were collected 
into sterile falcon tubes and samples were stored at 4 oC until processed. Soil samples were air dried 
overnight in a fume cupboard before processed.  An aliquot of air-dried soil or faecal samples (0.1 g) 
were suspended in 1 mL of distilled water. The suspension was placed in a water bath at 56 oC for 10 
min. The samples were then diluted in sterile distilled water to prepare 10-2 and 10-3 dilutions. Then, 
aliquots (50 µL) of each sample were plated on M1 and ISP-2 agar medium containing cycloheximide 
and rifampicin (100 µgmL-1 and 10 µgmL-1 respectively). A loop full of untreated soil was spread 
over the agar plate for stamping. Sheep wool samples were thoroughly washed with sterile water and 
tiny pieces of wool were placed on agar plates loaded with M1 and ISP-2 media. All plates were 
sealed in plastic bags and incubated for 14 days at 26.5 oC with periodic examination. Single colonies 
were transfer into new agar plates (without antibiotics), incubated at 26.5 oC and the process was 
repeated until pure strains were obtained. 
A fresh Mugil cephalus (sea mullet) and Pagrus auratus (snapper) was collected from the fish market, 
transported in an ice-cold container and stored at 4 oC until use. The fish was disinfected with 70% 
ethanol for 1 minute and dissected with a sterile scalpel to remove the mid and hindgut. 
Approximately, 100 µL of the gastrointestinal content was collected with a syringe and incubated 
with 10 ml of peptone water (NaCl 10 g/L, Peptone 10 g/L) for 24 h at 30 °C. Alternatively, 100 µL 
of the gut content was inoculated on ISP-2 salt (3% artificial sea salt) agar. The incubated sample 
was then diluted in sterile distilled water to prepare 10-2 and 10-3 dilutions. An aliquot (50 µL) of each 
dilution was used for the inoculation. 
For preparing culture media plates, ingredients/pre-prepared culture media mixtures were weighed, 
dissolved in distilled water and autoclaved at 121 °C for 20 min. When media was cooled down (~50 
°C) antibiotic solutions were added aseptically and poured into petri plates under sterile conditions. 
Edges of the solidified petri plates were sealed with parafilm. Each petri plate was labelled clearly 
with the media name and the date prepared on bottom. Petri plates were placed in sealed bags and 
stored at 4 °C until used. 
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2.9.3. Cryo-preservation of pure strains 
Pure strains cultured in both solid and agar medium were preserved in glycerol (×4). The 2 mL screw-
cap vials were labelled with the strain code and the date. For solid cultures, sterile 20% aqueous 
glycerol and ISP-2 media (500 µL each) were transferred to the vial. From a viable microbial isolate, 
growing in solid agar medium, few spores/mycelia were transferred to the cryo-vial and was tightly 
capped. For liquid culture, 500 µL of sterile 20% aqueous glycerol was transferred to the vial and 
500 µL microbial cultured grown in ISP-2 liquid medium were added to each vial and capped. 
Cryovials were stored in –80 °C freezer.  
2.9.4. Constructing the crude extract library 
Each pure microbial isolate was cultured on isolating medium and incubated at 26.5 °C for 10 days 
with periodic observations. After incubation, agar/mycelia were cut into small pieces (approx. ~1 
cm2) and transferred into 50 mL falcon tubes containing 20 mL of EtOAc followed by shaking for 2 
h on a platform shaker. The extract was decanted to a round bottom flask and evaporated to dryness 
in vacuo. The dried extract was re-dissolved in 100% MeOH, filtered through 0.45 µm Millipore filter 
into pre-weighted 4 mL vial and dried under N2 (g) on a heating block at 40 oC. The crude extract 
weight was recorded and an aliquot was transferred into 96 deep-well plates (liquid culture; 200 
µg/ml, solid culture; 1 mg/mL in DMSO). The crude extracts plates were stored at –30 oC until used.  
2.9.5. Taxonomic analysis 
The fungus Purpureocillium sp. CMB-F551 was isolated from a gastrointestinal tract specimen of 
sea mullet (Mugil cephalus) fish, on ISP-2 salt (3% artificial sea salt) agar plates incubated at 30 °C 
for 7 days. The fungus Penicillium sp. CMB-TS015 was isolated from a soil sample collected from a 
rain forest in Tasmania, on ISP-2 agar plate incubated at 30 oC for 7 days. Genomic DNA isolation 
and taxonomic analyses were performed as described previously (see section 2.4).  
ITS gene Sequence of CMB-F551 
CCCACTGTGAACCTTACCTCAGTTGCCTCGGCGGGACCGCCCCGGCCGCCGCGCAAGCGGCGCCGGACTC
CAAGGCGCCCGCCGCAGGGACCCAAAACTCTTTTGCATTACGCCCAACGGCGGGAATTTTTTCTCTGAGT
GCATAAGCAAAACAAATGAATCAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAACGC
AGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAACGCACATTGCGC
CCGCCAGCATTCTGGCGGGCATGCCTGTTCGAGCGTCATTTCAACCCTCGAGCCCCCCCGGGGGCCTCGG
TGTTGGGGGACGGCACACCAGCCGCCCCCGAAATGCAGTGGCGACCTCGCCGCAGCCTCCCCTGCGTAGT
AGCACACACCTCGCACCGGAGCGCGGAGACGGTCACGCCGTAAAACGCCCAACTTCTTAGAGTTGACCTC
GGATCAGGTAGGAATACCCGCTGAACTTAAGCTTATCAATAAGCGGAGGA 
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ITS gene Sequence of CMB-TS015 
AAAGGTGACGTCCGTCGTACGTACAGCGTTACAACAGTGTTTACGATCCTTGTTGCTTTGGCGGGCCCGCC
TCCCCTTTTCCGGGGGGCTTCTGCCCTCCGTGTTTCCGCGCCCGCCTACCCTTCTGTGTACTCTGTCTGACG
TATGCATTCTTATACTATTACTAAATTAAATAAATTTTTCAACAATGGATCTCTTGGTTCGGGAATCAATG
AATAAGGCAGCGAAATGCGATATCTAATGAGAATTGTTGAGTTTTTGAATCATCCTGTCTTTTTACGCTTA
TTGCTGCCCTCTGGTATTCTGGAGGGTATGCCTGTCCTAGCGACATTGCTGCCCTCCAGCCCGGCTTGGTG
TGATGGGCCCCGCCCCCCTTTCTGGGGGGGCGGTCCCGATAGGCGTCGGCGGGACCGTGTCCGGTCCTCG
AGAGTATGGGGCTTTGTCACCCGCTCTTGTAGGCACGGCTGGCCAGCCGACCCCCTCAGCTAGTTTTTCAG
ATGACCTCCGATCATGCAGGTATACCCGCTGATCTTGTGAGATCAATAACCCGAGGACACAAGCACGCAA
AGCAAAGCTGCACAGAAGGACTTTTCCGAATAGAACAAATTTCGGCTGACATTCAAAAATATAATGTTCA
ATTTAAAATGGAACATCGAAATTCTCCTATAGATGTTGGAGGTGCCTCAAAACCGTGTTAAGCTCTACAG
ACACACATTCCACCAAGATCGCACAACTCCAGTAAATAAAGGCAAAGAAACGCATAATAAATCAGTTTA
AAAATCCCTTCTTTTAAGTATTCGGGACAGCTAAATACAAAGCCACACCATAACTACCAAAAACTCTAAC
CTGTCCTATACCAAAAATAAAAATCTTACAAACCCAAACCTATTAAAAATTTAACAAAAAAAATAGTACT
AAAAACAATATTAACCT 
2.9.6. GNPS molecular networking analysis 
UHPLC-QTOF analysis was performed in Agilent UHPLC system comprising an Agilent 1290 
Infinity II UHPLC equipped with a Zorbax C8 column (2.1 mm × 50 mm, 1.8 µm particles), running 
with H2O/MeCN inclusive of 0.1% formic acid coupled to an Agilent 6545 Q-TOF with positive ion 
mode, mass range 500–1700 m/z. MS/MS analysis was performed for ions detected in the full scan 
at an intensity above 1000 counts at 10 scans/s, with an isolation width of 4 ~m/z using fixed collision 
energy at 60 eV and a maximum of 3 selected precursors per cycle. The same instrument settings 
mentioned in general experimental section was used (see Appendix I).  
The MS/MS data were converted from MassHunter data files (.d) to mzXML file format using 
MSConvertGUI software and loaded to GNPS platform (https:// gnps.ucsd.edu/ProteoSAFe/static/ 
gnps-splash.jsp), with default parameters. Spectral network data were imported into Cytoscape 2.8.3 
for visualization as a network. 
2.9.7. Scaled-up cultivation of Penicillium sp. CMB-TS015 and isolation of metabolites 
Agar cubes (×3) from 7 days old Penicillium sp. CMB-TS015 cultured on ISP-2 medium, were 
inoculated on rice solid medium (2 × 70 g) and incubated at 26 oC for 25 days. After incubation, 
combined rice mass with mycelia was extracted with EtOAc (4 × 250 mL) and concentrated in vacuo 
to obtain a crude extract (2.93 g). The crude extract was partitioned with n-hexane (4 × 50 mL) and 
MeOH (50 mL) and the MeOH soluble fraction (1.3 g) subjected to flash chromatography (Biotage® 
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KP-C18-HS column, 60 g, 50 mL/min stepwise gradient elution 10% MeCN/H2O–100% MeCN) to 
afford ×15 fractions. The subsequent purification yielded citreoviridin A (2.13). 
Citreoviridin A (2.13): A yellow powder; 1D and 2D NMR (600 MHz, methanol-d4) see Tables 2.4 
and Figures 2.25 and 2.26; HRESI(+)MS m/z 403.2120 [M+H]+ (calcd for C23H31O6, 403.2115). 
2.9.8. Bioassays   
2.9.8.1. Recovering H. contortus eggs for LDA 
The nematode eggs from sheep faecal samples were recovered as described earlier, with slight 
modifications.35 Fresh faeces (<24 h old) obtained from sheep infected with H. contortus, were mixed 
with water to make a slurry, which was sequentially filtered through a 1 mm strainer, followed by 
180 µm and 100 µm Endecotts sieves. The filtrate was centrifuged for 10 min at 2000 rpm, and the 
resulting pellet resuspended in saturated aqueous NaCl, before centrifuged for an additional 10 min 
at 2000 rpm. The supernatant was filtered through 20 µm Endecotts sieves to recover the eggs, which 
were suspended in sterile water, and applied to a sugar gradient (40%, 25% and 10% sucrose solution) 
in a 50 mL Falcon tube and centrifuged for 7 min at 3500 rpm. The eggs were recovered from the 
interface between 10% and 25% sucrose layers, washed over a 20 µm sieve to remove residual 
sucrose, and diluted in sterile water to 50–60 eggs per 10 µL. After the addition of amphotericin B 
(25 µg/mL), eggs were used immediately (same day) for larval development assays.  
2.9.8.2. LDA 
The LDA was performed in 96-well plates containing aliquots of extracts, fractions or pure 
compounds (10 µL), egg solution (50–60 eggs in 10 µL sterile water inclusive of amphotericin B), 8 
µL of growth medium [consisting of Earle’s salt solution (10% v/v), yeast extract 1% w/v, sodium 
bicarbonate (1 mM) and saline solution (0.9% w/v sodium chloride)], 2 µL live E. coli in LB broth 
(OD 1 at 600 nm) and sterile water (130 µL). The resulting assay plates were incubated for 7 days at 
27 °C, 88% humidity, and the number of fully developed L3 larvae present in each well counted under 
an inverted light microscope equipped with a CCD video camera. Inhibition was measured as the % 
development compared to the negative control (0.1% DMSO). Ivermectin (1 µM) was used as a 
positive control. 
2.9.8.3. Cytotoxicity assay 
See Appendix I: General Experiments, page 265.  
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2.9.8.4. Antimicrobial assay 
See Appendix I: General Experiments, page 264.  
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3. Chapter 3: New quinazoline alkaloids from Penicillium sp. CMB-TS015 
The crude extract of Penicillium sp. CMB-TS015, isolated from a soil sample collected from a 
Tasmanian rainforest, showed substantial anthelminthic activity (>99% inhibition) against drug-
resistant Haemonchus contortus larval development. Isolation and characterization of anthelminthic 
metabolites from CMB-TS015 are discussed in Chapter 2. Aiming bioactivity-guided fractionation 
and HPLC-DAD-MS analysis of CMB-TS015 produced a range of structurally diverse non-
anthelmintic secondary metabolites. This chapter focuses on the isolation, structure elucidation and 
bioactivity profiling of these additional metabolites. 
Scale-up cultivation of Penicillium sp. CMB-TS015 followed by subsequent purification yielded 
three new fungal metabolites, (+)-spiroquinazoline B (3.1), (+)-fumiquinazoline J (3.2) and the 
tetramic acid chaunolidine D (3.3), together with four known fungal metabolites, 2-pyridone alkaloid 
PF1140 (3.4), the steroid 7-hydroxy-paxisterol (3.5), the alkaloid cyclopiasonic acid (3.6) and the 
polyketide (+)-terrain (3.7). Bioactivity profiling revealed that the (+)-spiroquinazoline B (3.1) and 
(+)-fumiquinazoline J (3.2) were potent antagonists of human γ-aminobutyric acid (GABA) type A 
receptor (GABAAR). Further screening showed that (+)-fumiquinazoline J (3.2) potently inhibited 
α5β3γ2L GABAAR (IC50 0.35 µM).  
This intriguing finding led us to investigate the possibility of isolating structurally related 
fumiquinazolines from CMB-TS015 for screening against GABAAR. To explore the wider secondary 
metabolite capacity, the recently developed 24-well microbioreactor miniaturized culture approach 
(known in-lab as the MATRIX) was used. UHPLC-DAD and UHLPC-QTOF-MS/MS analysis 
demonstrated that CMB-TS015 produced a series of quinazoline alkaloids, selectively on ISP-4 agar 
medium, providing further evidence for the possible biosynthesis of (+)-spiroquinazoline B (3.1) and 
(+)-fumiquinazoline J (3.2).  
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3.1. Preparative cultivation of Penicillium sp. CMB-TS015 
The analytical study and bioactivity profiling (discussed in Chapter 2) were carried out on a crude 
extract of the Penicillium sp. CMB-TS015 cultured on ISP-2 agar (the isolation medium). Given that 
fungi produce a relatively large amount of secondary metabolites on complex solid media,1 scaled-
up cultivation was carried out on rice solid medium. Two 500 mL Erlenmeyer flasks containing rice 
solid medium (70 g, jasmine rice) were inoculated with CMB-TS015 and incubated at 26.5 oC for 25 
days, after which the combined rice mass with mycelia was extracted with EtOAc (4 × 250 mL) to 
obtain a crude extract (2.93 g). The crude extract was subjected to HPLC-DAD-MS analysis to 
investigate the secondary metabolites production (Figure 3.1). The crude extract was then partitioned 
with n-hexane (4 × 50 mL) and 2% aqueous MeOH (50 mL). The MeOH soluble fraction (1.3 g) was 
subjected to flash chromatography (Biotage® KP-C18-HS column, 60 g, 50 mL/min stepwise gradient 
elution from 10% MeCN/H2O−100% MeCN inclusive of 0.01% TFA modifier) to afford ×15 
fractions, which were subsequently purified by reversed-phase semi-preparative HPLC to yield the 
metabolites of interest (Scheme 3.1). 
 
Figure 3.1: HPLC-DAD (210 nm) chromatogram of CMB-TS015 cultured on rice solid medium. The extract was eluted 
with Zorbax SB-C8 column, 150 × 4.6 mm, 5 µm, 1 mL/min gradient elution from 10% MeCN/H2O–100% MeCN over 
15 min with isocratic 0.05% formic acid modifier. Colour highlights metabolites with similar UV-Vis spectra (i.e. 
chromophore)  
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Scheme 3.1: Isolation scheme for CMB-TS015. (a) Solvent partitioning, (b) Flash chromatography, Biotage® KP-C18-
HS column (60 g), 50 mL/min stepwise gradient elution 90% H2O/MeCN–100% MeCN inclusive of 0.01% TFA 
modifier, (c) Preparative HPLC Phenomenex® C8 column, 250 × 20 mm, 10 µm, with 20 mL/min gradient elution from 
90% H2O/MeCN–100% MeCN inclusive of 0.01% TFA modifier over 20 min, (d) Semi-preparative Zorbax SB-C18 
column, 250 × 9.4 mm, 5 µm, 3 mL/min elution over 20 min, isocratic 26% MeCN inclusive of 0.01% TFA modifier, (e) 
Semi-preparative Zorbax SB-C18 column, 250 × 9.4 mm, 5 µm, 3 mL/min elution over 20 min, isocratic 45% MeCN 
inclusive of 0.01% TFA modifier and (f) Semi-preparative Zorbax SB-CN column, 250 × 9.4 mm, 5 µm, 3 mL/min elution 
over 20 min, isocratic 38% MeCN inclusive of 0.01% TFA modifier.  
   
  
Crude Extract 
2.9 g 
(b) 
n-hexane soluble 
1.6 g 
MeOH soluble 
1.3 g 
(a) 
Fr-1 
178.1 mg 
Fr-2 
178.1 mg 
Fr-3-7 
219.7 mg 
Fr-14 
81.8 mg 
Fr-13 
77.9 mg 
Fr-11-12 
86.6 mg 
Fr-9-10 
88.9 mg 
Fr-8 
100.4 mg 
Fr-15 
18.9 mg 
3.7 
42 mg 
(c) 
3.3 
1.9 mg 
2.13 
6.1 mg 
(e) 
3.4 
6.4 mg 
3.5 
1.1 mg 
3.2 
3.5 mg 
3.6 
14.7 mg 
(f)    (c)    
3.1 
4.2 mg 
(d) 
HO
HN
OH
O
O
OH
N
O
O
OH
H
(+)-spiroquinazoline B (3.1) (+)-fumiquinazoline J (3.2)
PF1140 (3.4)
O
HO
OH
OH
O
H
H H
H
7-hydroxy-paxisterol (3.5)
N
H
H H
HO
O
O
HN
O
HO
OH
cyclopiazonic acid (3.6) (+)-terrein (3.7)
N
N
O
HN
O
N NH
O
OH
H
H N
N
O
HN
O
NH
H
chaunolidine D (3.3)
Chapter 3: New quinazoline alkaloids from Penicillium sp. CMB-TS015 
 
 
55 
3.1.1. (+)-spiroquinazoline B (3.1) 
 
HRESI(+)MS analysis of 3.1 returned a pseudo-molecular ion [(M+H)+] consistent with a molecular 
formula (C25H23N5O4, Dmmu –0.6) requiring ×17 double bond equivalents (DBE). The 1H NMR (600 
MHz, DMSO-d6) data (Figure 3.2, Table 3.1) for 3.1 revealed resonances for two 1,2-disubstituted 
aromatic rings (dH 7.38 H-21, 7.36 H-22, 7.27 H-23, 7.50 H-24 and dH 7.97 H-7, 7.89 H-8, 7.61 H-9, 
8.20 H-10), while the 13C NMR data (Figure 3.3, Table 3.1) indicated the presence of three carbonyls 
(dC 158.4 C-1, 169.6 C-12 and 171.1 C-26) and an imine (dC 153.1 C-4), accounting for ×12 DBE 
and ×5 additional rings. The COSY correlations supported by diagnostic HMBC correlations (Figure 
3.4) from H-10 (dH 8.20) to the amide C-12 (dC 158.4) and from H-8 (dH 7.89) to a deshielded sp2 
quaternary C-6 (dC 146.5) established an anthranilic partial structure. HMBC correlations from H-14 
(dH 7.79) to an imino carbon C-4 (dC 153.1) and amide C-1 (dC 169.6) and from H3-16 (1.58) to C-4 
(dC 153.1) and a quaternary sp3 carbon C-3 (dC 60.9) suggested a quinazoline partial structure. 
Further, diagnostic 2D NMR analysis (Figure 3.5) established the threonine partial structure. A 
literature search, with these structure fragments established through diagnostic 2D NMR correlations 
(Figure 3.5), suggested that 3.1 has a core structure similar to that of known fungal metabolite 
spiroquinazoline (3.8).2 HMBC correlations (Figure 3.5) from H-27 (dH 3.28) to C-18 (dC 79.7) and 
from H-18 (dH 5.40) to C-26 (dC 171.1) confirmed the connectivity of the threonine residue to the 
spiroquinazoline core. Hence, the planar structure for 3.1 was established as a new spiroquinazoline 
alkaloid, with close structural similarity to a rare fungal alkaloid spiroquinazoline (3.8).2  
The relative configuration of 3.1 was established based on key ROESY correlations (Figure 3.6). A 
C3 Marfey’s analysis of 3.1 identified the L-threonine residue (Figure 3.7), which assisted the 
determination of other stereocentres. ROESY correlations from H-27 (dH 3.28) to H-15b  (dH 3.09), 
and from H-28 (dH 3.76) to H-18 (dH 5.40), suggested that 3.1 should have S configurations at C-14 
and C-3, which are opposite to the configuration reported for spiroquinazoline (3.8)3 and 
(+)-spiroquinazoline B (3.1)
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alantrypinone (3.9).4 These assignments were validated by mapping on to an energy minimized 
3D model (Figure 3.8) generated using Chem3D (PerkinElmer). 
 
 
Figure 3.2: 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN inclusive of formic acid) spectra of 
(+)-spiroquinazoline B (3.1). *residual methanol.  
A 1994 study by Barrow and Sun3 first reported a spiroquinazoline (3.8) from a Aspergillus flavips, 
and later Barros and Filho5 isolated four new structurally close spiroquinazolines (3.10–3.13) from 
an Eupenicillium sp. Barrow and Sun established the relative configuration of spiroquinazoline (3.8) 
based on the NOE correlations and the energy minimization using Marcomodel. A 1998 study by 
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Larsen et al.4 reported the absolute configuration of alantrypinone (3.9) by single X-ray 
crystallography. A comparison of NOESY correlations has confirmed that alantrypinone has the 
identical geometry to that of spiroquinazoline.4  
 
The core structure of spiroquinazoline has derived from the condensation of three amino acids, 
anthranilic acid, tryptophan and alanine. It has been reported that the configuration at C-14 and C-3 
is primarily determined by L-tryptophan, one of the three building blocks, which is epimerised to D-
tryptophan during the biosynthesis.6 Based on this knowledge we speculate that the epimerisation 
domain either does not exist or is non-functional in the biosynthesis of (+)-spiroquinazoline B (3.1). 
The co-metabolite (+)-fumiquinazoline J (3.2), a plausible biosynthetic intermediate of (+)-
spiroquinazoline B (3.1), isolated from the same extract (section 3.1.2) further supported this 
hypothesis.        
 
Figure 3.3: 13C NMR (150 MHz, DMSO-d6) spectrum of (+)-spiroquinazoline B (3.1).    
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Table 3.1: NMR data (DMSO-d6) for (+)-spiroquinazoline B (3.1) 
Position δH, multi, (J in Hz)  δC COSY 1H-13C HMBC ROESY 
1  169.6    
2-NH 9.56, d (1.8)  14 3, 4, 14, 16 16, 24 
3  60.9    
4  153.1    
6  146.5    
7 7.79, d (8.2) 127.7 8 9, 11  
8 7.89 ddd (8.1, 7.2, 1.4) 134.7 7, 9 6, 10  
9 7.61, ddd (8.1, 7.2, 1.1) 127.4 8, 10 7, 11   
10 8.2, d (7.6) 126.3 9 6, 8, 12  
11  120.0    
12  158.4    
14 5.43, m 51.8 15a, 15b 1, 4, 17  
15 a 3.09, dd (14.1, 4.3) 32.9 14, 15b 1, 14, 17 27, 14  
b 1.68, dd (14.1, 1.2)  14, 15a 1, 16, 17, 25  24 
16 1.58, s 14.4  3, 4, 17 2, 18, 24 
17  55.6    
18 5.40, d (7.2) 79.7 27-NH 3, 15, 26 16, 28, 15b 
20  137.9    
21 7.38c 115.4 22 23, 25  
22 7.36c 128.7 21, 22 20, 24  
23 7.27, ddd (7.5, 6.9, 1.7) 125.9 24 21, 25  
24 7.50, d (7.5) 124.1 23 17, 20, 22 2-NH, 15b, 16 
25  136.6    
26  171.1    
27 3.28, dd (4.6, 0.9) 69.3 18, 28 18, 26 15a, 29 
27-NH 2.15, brs  18  15a, 28, 29 
28 3.76, m 65.8   18 
28-OH 3.78, d (6.0)    29 
29 0.85, d, (6.3) 20.1  27, 28 27, 27-NH 
 
Figure 3.4: Key HMBC correlations for quinazoline partial structure of (+)-spiroquinazoline B (3.1). 
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Figure 3.5: Key 2D NMR correlations for (+)-spiroquinazoline B (3.1). 
 
Figure 3.6: Key ROESY correlations for (+)-spiroquinazoline B (3.1).  
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Figure 3.7: C3 Marfey’s analysis for (+)-spiroquinazoline B (3.1). Trace (a) is the C3 HPLC-DAD (340 nm) 
chromatogram that exhibits L-FDAA amino acid derivatives. Traces (b) are C3 HPLC-MS-SIE chromatograms for L-
FDAA derivatives of amino acid standards (broken lines) and the acid hydrolysate of 3.1 (shaded peaks). The traces 
confirmed that 3.1 incorporates L-Thr (SIE m/z 372). *Residual Marfey’s reagent. 
 
 
Figure 3.8: Energy-minimized (MM2) structure of (+)-spiroquinazoline B (3.1) showing key ROESY correlations. 
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3.1.2. (+)-fumiquinazoline J (3.2) 
 
HRESI(+)MS analysis of 3.2 returned a pseudo-molecular ion [(M+H)+] indicative of a molecular 
formula (C21H16N4O2, Dmmu –1.6) requiring 16 DBE. The 1H NMR (600 MHz, DMSO-d6) data for 
3.2 (Figure 3.9, Table 3.2) exhibited resonances for two disubstituted aromatic rings (δH 8.15-6.99), 
a deshielded methine (H-4, δH 5.70) and a methyl group (H3-16, δH 2.11). The 13C NMR (150 MHz, 
DMSO-d6,) data for 3.2 (Figure 3.10, Table 3.2) revealed resonances for two amide carbonyls (C-1, 
δC 169.1 and C-6, δC 159.3) and an imino carbon (C-14, δC 154.3), while HSQC data revealed seven 
olefinic quaternary carbons and a diastereotopic methylene (H-15a, δH 3.42 and H-15b, δH 3.23), 
accounting for ´ 12 DBE and requiring four additional rings. Diagnostic 2D NMR correlations (Figure 
3.11) of 3.2 established the quinazoline partial structure similar to that of (+)-spiroquinazoline B 
(3.1), while HMBC correlations from H3-16 (δH 2.11) to C-18 (δC134.0), and from H-4 (δH 5.70) to 
C-18 (δC 105.5), confirmed the connectivity of quinazoline moiety to the indole ring. A literature 
search with the structure fragments deduced from diagnostic 2D NMR analysis suggested that 3.2 
was the known fungal alkaloid fumiquinazoline J (3.26).2  
A 2012 study by Zheng et al.2 first reported fumiquinazoline J (3.26) from Penicillium vinaceum and, 
its absolute configuration was determined by X-ray diffraction analysis. Notwithstanding the close 
similarity in NMR data (Table 3.3), the optical rotation data for 3.2, [α]D22 +22.4 (c 0.15, MeOH), 
was opposite to that reported in literature2 for fumiquinazoline J (3.26), [α]D22 −136 (c 0.16, MeOH), 
indicating that 3.2 as the enantiomer of 3.26. 
The enantiomer of fumiquinazoline J, ([α]D18 +267.1, c 0.243, EtOAc), was first reported as an 
intermediate in the synthesis of ent-alantrypinone.7 The specific rotation value for 3.2, [α]D22 +110.9o 
(c 0.04, EtOAc), was consistent with synthetic intermediate confirming that 3.2 is the enantiomer of 
fumiquinazoline J (3.26). Our measurement of [α]D was validated by comparing the specific rotation 
for an authentic sample of fumiquinazoline D [α]D22 +95.6 (c 0.05, CDCl3) with the literature [α]D 
+68.9 (c 0.27, CDCl3).8 
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Figure 3.9: 1H NMR (600 MHz, DMSO-d6) and UV spectra (at 210 nm) of (+)-fumiquinazoline J (3.2). 
 
Figure 3.10: 13C NMR (150 MHz, DMSO-d6) spectrum of (+)-fumiquinazoline J (3.2). 
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Table 3.2: NMR data (DMSO-d6) for (+)-fumiquinazoline J (3.2) 
 
a, b Overlapping resonances. Values with same letters may be interchanged 
 
 
 
Figure 3.11: Key 2D NMR correlations for (+)-fumiquinazoline J (3.2). 
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Position δH, multi, (J in Hz) δC COSY 1H-13C HMBC ROESY 
1  54.6    
2-NH 9.56, s   4, 14, 16 16 
3  169.1    
4 5.70, dd, (4.5, 2.7) 54.1 15a, 15b 3, 14, 17  
6  159.3    
7  120.1    
8 8.15, dd (8.2, 1.1) 126.3 9 6, 10, 12  
9 7.54, ddd (8.2, 7.1, 1.1) 127.4a 8, 10 7, 11  
10 7.81, ddd (8.4, 7.1, 1.5) 134.8b 9, 11 8, 12   
11 7.65, d (8.2, 1.1) 127.3a 10 7, 9  
12  146.6    
14  154.3    
15 a 3.42, dd (17.2, 2.7) 25.6 4, 15b 17, 18 24  
b 3.23, dd (17.2, 4.5)  4, 15a 3, 4, 17, 18  24 
16 2.11, s 18.3  3, 4, 14, 18 2, 19 
17  105.5    
18  134.0    
19-NH 11.21, s   17, 18, 25 16, 21 
20  134.7b    
21 7.36, dd (8.2, 0.8) 111.7 21, 22 23, 24, 25  
22 7.11, ddd (8.0, 7.0, 0.9)  122.3 21, 23 20, 24  
23 6.99, ddd (8.0, 7.0, 0.9) 119.3 22, 24 21, 22, 25  
24 7.40, dd (8.0, 0.9) 118.1 23 4, 17, 20, 25  
25  127.3a    
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Table 3.3: Comparison of NMR (DMSO-d6) data of (+)-fumiquinazoline J (3.2) with literature 
Experimental Literature 
Position 
(+)-fumiquinazoline J (3.2) (+)-fumiquinazoline J (3.2) (+)-fumiquinazoline J 
δCa δCb (natural product)2 δCc (synthetic intermediate)7 
1 54.6 54.6 54.6 
3 169.1 169.1 169.2 
4 54.1 54.1 54.1 
6 159.3 159.3 159.3 
7 120.1 120.1 120.1 
8 126.3 126.3 126.3 
9 127.4d 127.3 127.3 
10 134.8e 134.8 134.8 
11 127.3d 127.4 127.1 
12 146.6 146.6 146.6 
14 154.3 154.3 154.3 
15 25.6 25.6 25.6 
16 18.3 18.3 18.3 
17 105.5 105.5 105.5 
18 134.0 134.0 134.0 
20 134.7e 134.8 134.6 
21 111.7 118.1 111.7 
22 122.3 122.3 122.2 
23 119.3 119.4 119.4 
24 118.1 111.7 118.1 
25 127.3d 127.4 nr 
a 150 MHz, DMSO-d6, b100 MHz, DMSO-d6, c75.5 MHz, DMSO-d6, d, e overlapping resonances. Values with same letters may be 
interchanged. nr Not reported.  
Fumiquinazolines are NRPS-derived peptidyl alkaloids with a wider structural complexity (Table 
3.4). A 2010 study by Ames et al.6,9 revealed that the simplest member of the class, fumiquinazoline 
F with a 6-6-6 tricyclic core derived from anthranilic acid, tryptophan, and alanine, is the biosynthetic 
precursor to other members. Further, it has been identified that activation of trimodular 
fumiquinazoline biosynthetic gene cluster is anthranilate dependant and adenylation domains are 
substrate specific to select L-Ala and L-Trp as biosynthetic precursors (Figure 3.12).6 The 
epimerisation domain present in module two epimerises the L-Trp to D-Trp, determining the absolute 
configuration of the quinazoline core structure. Ames et al.6 demonstrated that an adjacent 
flavoprotein monooxygenase Af1206 (Figure 13.3) converted fumiquinazoline F to reactive 
intermediates that act as a biosynthetic intermediate for many fumiquinazolines. In agreement with 
the proposed biosynthesis, all the reported fumiquinazoline natural products contain D-Trp. 
Intriguingly, HPLC-DAD-MS analysis of CMB-TS015 cultured on ISP-4 medium (see section 
3.1.2.2 for more detail about culture optimisation) revealed the presence of biosynthetic precursors 
proposed by Ames et al.6 Based on this, we hypothesised that, plausibly, (+)-fumiquinazoline J (3.2) 
is a biosynthetic intermediate of (+)-spiroquinazoline B (3.1). Figure 3.13 illustrates the proposed 
biosynthetic pathway for the (+)-spiroquinazoline B, with an additional NRPS module for the L-Thr 
residue. 
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Figure 3.12: Fumiquinazoline gene cluster. The figure was adopted from Ames et al.6 
 
Figure 3.13: Proposed biosynthetic pathway. *The epimerization domain either does not exist, or is skipped during the 
biosynthesis.  
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Figure 3.14: HPLC-DAD-MS (210 nm) chromatogram that shows the predicted biosynthetic intermediates. Only the 
metabolites highlighted in blue were isolated and characterized. *The predicted biosynthetic intermediates identified by 
HPLC-DAD-MS analysis, need to be validated by isolation and characterization.  
Table 3.4: Summary of fumiquinazolines reported in the literature 
fumiquinazoline Molecular weight 
Molecular 
formula Source 
Optical rotation Reference 
A 445 C24H23N5O4 Aspergillus fumigatus [α]D
33 –214.2 (c 0.47, CHCl3) Numata et al. (1992)10 
B 445 C24H23N5O4 Aspergillus fumigatus [α]D
21 –193.7 (c 0.31, CHCl3) Numata et al. (1992)10 
C 443 C24H21N5O4 Aspergillus fumigatus [α]D
21 –196.7 (c 0.38, CHCl3) Numata et al. (1992)10 
D 443 C24H21N5O4 Aspergillus fumigatus [α]D +68.9 (c 0.27, CHCl3) Takahashi et al. (1995)8 
E 475 C25H25N5O5 Aspergillus fumigatus [α]D –143.3 (c 0.18, CHCl3) Takahashi et al. (1995)8 
F 358 C21H18N4O2 Aspergillus fumigatus [α]D –411.2 (c 1.36, CHCl3) Takahashi et al. (1995)8 
G 358 C21H18N4O2 Aspergillus fumigatus [α]D –462.2 (c 0.001, CHCl3) Takahashi et al. (1995)8 
H 485 C27H27N5O4 Acremonium sp. [α]D –59 (c 0.001, CHCl3) Belofsky et al. (2000)11 
I 487 C27H29N5O4 Acremonium sp. [α]D –138 (c 0.47, CHCl3) Belofsky et al. (2000)11 
J 356 C21H16N4O2 Aspergillus fumigatus Penicillium vinaceum 
[α]D20 –136 (c 0.16, MeOH) Zheng et al.20152 
K 469 C26H23N5O4 Aspergillus sp. [α]D
20 –120.9 (c 0.11, MeOH) Zhou et al. (2013)12 
L 473 C25H23N5O5 Aspergillus sp. [α]D
20 –30.6 (c 0.14, MeOH) Zhou et al. (2013)12 
M 705 C38H35N5O9 Aspergillus sp. [α]D
20 –24.6 (c 0.11, MeOH) Zhou et al. (2013)12 
N 529 C28H27N5O6 Aspergillus sp. [α]D
20 –209.1 (c 0.12, MeOH) Zhou et al. (2013)12 
O 543 C29H29N5O6 Aspergillus sp. [α]D
20 –89 (c 0.12, MeOH) Zhou et al. (2013)12 
P 511 C28H25N5O5 Aspergillus sp. [α]D
20 –73.8 (c 0.12, MeOH) Zhou et al. (2013)12 
Q 431 C23H21N5O4 Penicillium expansum Y32 [α]D
20 +214.2 (c 0.1, MeOH) Fan et al. (2015)13 
S 473 C26H27N5O4 Aspergillus sp. [α]D
25 –105. (c 0.47, MeOH) Liao et al. (2015)14 
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3.1.2.1. GABAA receptor inhibitory activity of (+)-fumiquinazoline J (3.2) 
In the search for active metabolites against insect γ-aminobutyric acid (GABA) receptor, Kuriyama 
et al.15 revealed that spiroquinazoline alkaloids alantrypinone and seratrypinone selectively inhibited 
insect GABA receptor with IC50 of 0.34 and 2.1 µM respectively. Having structurally close 
metabolites in our hand, this intriguing result led us to investigate the GABA receptor inhibitory 
activity of (+)-spiroquinazoline B (3.1) and (+)-fumiquinazoline J (3.2). 
A collaboration with Professor Joe Lynch Laboratory, Queensland Brain Institute (QBI), The 
University of Queensland, provided access to analyse metabolites against human GABAA receptor 
inhibitory activity. In the preliminary screening against α5β3γ2L-GABAA, (+)-spiroquinazoline B (3.1) 
and (+)-fumiquinazoline J (3.2) showed a substantial antagonistic effect on α5β3γ2L-GABAA, with 
(+)-fumiquinazoline J (3.2) being the most potent (Figure 3.15). Interestingly, none of the compounds 
was cytotoxic towards NCI-H460 (human lung carcinoma) or SW620 (human colorectal carcinoma) 
cells. Based on the preliminary study, (+)-fumiquinazoline J (3.2) was selected for further studies. 
Data showed that 3.2 dose-dependently inhibited the α5β3γ2L GABAA with IC50 of 0.35±0.01 µM 
(Figure 3.16).  
Even though structurally close spiroquinazoline alkaloid alantrypinone has been studied for insect 
GABAA receptor modulatory activity and as a potential lead compound for GABAA receptor 
inhibitory activity based insecticides,16 here we report for the first time the GABAA receptor 
inhibitory activity of fumiquinazolines.17 Determine the selectivity of (+)-fumiquinazoline J (3.2) 
towards GABAA receptors is vital, because there are multiple GABAA receptor isomers and binding 
sites with different functionalities. Since the GABAA receptor inhibitory assay required a significant 
amount of material, we decided to perform a culture optimization for CMB-TS015 to increase 
supplies as well as to investigate the possibility of isolating (+)-fumiquinazoline J (3.2) analogues to 
support structure-activity relationship (SAR) investigations. 
 
Figure 3.15: Preliminary screening results against α5β3γ2L GABAA. (a) (+)-spiroquinazoline B (3.1) and (b) (+)-
fumiquinazoline J (3.2). 
α5β3γ2L GABAA stable cell line
GABA 1μM
GABA 1μM + test compound 0.2μg/μL
(a)
(b)
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Figure 3.16: Dose-dependent activity of (+)-fumiquinazoline J (3.2) against α5β3γ2L GABAA. 
3.1.2.2. Culture optimization for quinazoline alkaloids 
To investigate the biosynthetic capacity of CMB-TS015 to produce fumiquinazolines analogues, we 
employed recently introduced miniaturized 24-well plate culture approach (the MATRIX). 
Penicillium sp. CMB-TS015 was cultured on a media MATRIX with ×11 different culture media 
using solid agar, as well as static broth and shaken broth methods (Figure 3.17). The resulting ×33 
crude extracts were subjected to HPLC-DAD-MS and UHPLC-QTOF-MS/MS analysis. The 
characteristic UV-vis profile of fumiquinazoline (Figure 3.18) was used to monitor the expression of 
related metabolites under different culture media and conditions. HPLC-DAD data showed that 
CMB-TS015 produced a series of fumiquinazolines, particularly on ISP-4 agar medium (Figure 3.18). 
This was further confirmed with molecular formulas generated from UHPLC-QTOF-MS data (Table 
3.5). Further, it was observed that growth/production of fumiquinazoline analogues was relatively 
high in cultures with good air permeation (Figure 3.18) compared to cultures sealed with an air 
impermeable lid (Figure 3.19). A similar observation was made for talaropeptide production by 
Talaromyces sp. CMB-TU011 (Section 5.1.1, page 126) as well. Although the importance of 
dissolved oxygen level in submerged fungal cultures for growth and metabolite production is well 
documented,18 studies on solid-state fermentation are limited in the literature.19 Therefore, this 
observation would be useful for the development of solid-state fermentation for fungi. However, 
further investigations are necessary to determine the importance of air permeation for these strains. 
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Figure 3.17: Photographs of 24-well microbioreactor plates inoculated with Penicillium sp. CMB-TS015. 
 
Figure 3.18: The selected HPLC-DAD (210 nm) chromatogram of CMB-TS015 crude extracts. (a) ISP-4 agar, (b) PYG 
agar and (c) M1 agar media.  
Table 3.5: UHPLC-QTOF-MS data for CMB-TS015 cultured on ISP-4 agar medium 
Peak m/z (M+H)+ Molecular formula Error (Δmmu) 
(+)-spiroquinazoline B (3.1) 458.1829 C25H23N5O4 –0.6 
oxy-fumiquinazoline F (3.16) 375.1430 C21H18N4O3 +2.1 
fumiquinazoline F/G (3.14/3.23) 359.1518 C21H18N4O2 –1.6 
* 419.2059 C24H27N4O3 +1.9 
(+)-fumiquinazoline J (3.2) 357.1355 C21H16N4O2 –1.6 
*metabolite could not be identified 
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Figure 3.19: HPLC-DAD (210 nm) chromatogram of CMB-TS015 cultured in (a) a flask sealed with an air permeable 
cotton plug and (b) a flask sealed with an air impermeable lid. Peaks that showed similar UV-Vis spectra to (+)-
fumiquinazoline J (3.2) are coloured in red.*metabolites could not be confirmed with HRMS analysis.  
To visualize the fumiquinazoline production across the culture media MATRIX, the Global Natural 
Product (GNPS) molecular networking analysis was carried out with default parameters. However, 
the GNPS analysis did not return a cluster for fumiquinazolines and related metabolites, presumably, 
due to the inadequacy of the number of matching fragments in MS/MS spectrums. In general, 
metabolites with 6 matching fragments (default value) are clustered into a molecular cluster. Overlaid 
MS/MS fragmentation of fumiquinazoline (Figure 3.20) showed a limited matching fragments, which 
might not be enough to create a cluster with default values (6 matching fragments). Reducing the 
matching requirement for fragments from 6 to 4, allowed the formation of fumiquinazoline cluster 
(Figure 3.21). 
3.1.2.3. Future directions 
HPLC-DAD-MS analysis supported by the GNPS analysis showed that CMB-TS015 cultured on ISP-
4 agar medium with an air permeable cotton plug produced a number of fumiquinazoline related 
metabolites. HR(+)MS analysis suggested that some of those metabolites are, plausibly, biosynthetic 
intermediates. Scale-up cultivation, isolation and characterization of those metabolites would confirm 
the proposed plausible biosynthetic pathway for (+)-spiroquinazoline B (3.1). In addition, structural 
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diversity of fumiquinazolines present in CMB-TS015 extract would enable the GABAA SAR 
investigation on the fumiquinazoline pharmacophore.  
 
Figure 3.20: Overlaid MS/MS spectra of (a) (+)-fumiquinazoline (3.2), (b) fumiquinazoline F/G and (c) (+)-
spiroquinazoline B (3.1). 
 
Figure 3.21: The GNPS molecular networking analysis for CMB-TS015 cultured on ISP-4 agar medium. The analysis 
was performed with 4 minimum matched fragment ions. Thicknesses of the edge line connecting the nodes indicate the 
similarity score (Cosine score). 
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3.1.3. chaunolidine D (3.3) 
 
HRESI(+)MS analysis of 3.3 returned a pseudo-molecular ion [(M+Na)+] indicative of molecular 
formula (C22H29NO5, Dmmu –1.4) requiring 9 DBE. Analysis of the 1H NMR (600 MHz, methanol-
d4) data for 3.3 (Figure 3.22, and Table 3.6) revealed resonances for a para-disubstituted aromatic 
ring (dH 7.13, H-5¢/9¢; dH 6.65, H-6¢/8¢) and four methyl groups (dH 1.55, 1.50, 0.93 and 0.73). COSY 
correlations supported by HMBC correlations established the planner structure of the polyketide side 
chain (C-4 to C-12) inclusive of an ED8,9 where the configuration was assigned by comparison of 
experimental and calculated 13C NMR (Figure 3.23, Table 3.6) chemical shifts for C-7 (dc 49.4) [Ecal 
dC 47.4; Zcal dC 39.6], C-13 (dc 15.6) [Ecal dc 16.2; Zcal dc 23.6] and C-10 (dc 13.) [Ecal dc 13.4; Zcal dc 
13.1]. COSY correlations between H-2¢ (dH 4.12) and H-3¢ (dH 4.94) and HMBC correlation from H-
3¢ to C-5¢ (dc 129.7) confirmed the connectivity of the aromatic ring and the tetramic acid moieties. 
A literature search with the structure fragments established through diagnostic 2D NMR (Figure 3.24) 
suggested that 3.3 is a new analogue of the previously reported tetramic acid F-14329 (3.35),18 with 
an additional resonance for a methyl (dH 1.50, H3-13) attached to C-8 (dc 135.8) (Table 3.6). 
A previous Capon-group member, Dr. Zhuo Shang, reported the isolation of tetramic acid F14329 
and three structurally related new analogues, chaunolidines A–C, from a marine derived 
Chaunopycnis sp.20 The structures inclusive of absolute configurations were determined by detailed 
spectroscopic analysis, X-ray crystallography, electronic circular dichroism (ECD) and chemical 
interconversion. The –ve specific rotation of 3.3 ([α]22D –45.7, c 0.05, MeOH) which is consistent 
with F14329 (3.35) ([α]22D –216.9, c 0.05, MeOH) and chaunolidine B (3.36) ([α]22D –147.3, c 0.05, 
MeOH) suggested that 3.3 might has the similar configuration. However, further studies did not carry 
out due to the limited structural novelty.  
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Figure 3.22: 1H NMR (600 MHz, methanol-d4) and UV-Vis (HPLC-DAD, H2O/MeCN with formic acid at 210 nm) 
spectra of chaunolidine D (3.3).  
Table 3.6: NMR data (methanol-d4) for chaunolidine D (3.3) 
Position δH, multi, (J in Hz) δC COSY HMBC 
1  nd   
2  nd   
3  nd   
4 3.72, br s 37.3* 5a, 5b  
5 a 1.68, m 41.2 5b  
 b 0.95  4, 5a, 6  
6 1.39, m  30.1 5, 7, 12 4 
7 a 1.87, dd (11.6, 4.7) 49.4 6, 7b 6, 8, 9, 12 
 b 1.73, bd (12.5, 6.2)  6, 7a 6, 8, 9, 12 
8  135.8   
9 5.14, q (6.2) 120.8 10 7, 10, 13 
10 1.55, d (6. 2) 13.5 9 8, 9,  
11 0.93, d (6.5) 19.0 4 5  
12 0.73, d (5.3) 20.2 6 5, 6, 7 
13 1.50, s 15.6    7, 8, 9 
1¢  nd   
2¢ 4.12, br s nd 3¢  
3¢ 4.94, d (3.2) 75.3 2¢ 7, 8, 9 
4¢  130.8   
5¢ 7.13, d (8.3) 129.8 6¢ 7¢, 5¢, 3¢ 
6¢ 6.65, d (8.3) 115.6   
7¢  158.4   
nd signals did not detected, *assignment based on the HMBC and HSQC data 
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Figure 3.23: 13C NMR (150 MHz, methanol-d4) spectrum of chaunolidine D (3.3) 
 
 
Figure 3.24: Key 2D NMR correlations for chaunolidine D (3.3) 
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Table 3.7: Comparison of NMR data for chaunolidine D (3.3) and the reported tetramic acid F-14329 (3.35) 
 Experimental 3.3 F-14329 (3.35)20  
Position δH, multi, (J in Hz) δC δH, multi, (J in Hz) δC 
1  c – 176.0 
2  c – 100.6 
3  c – 191.5 
4 † 37.3* 3.49, m 33.4 
5 a 1.57, m 39.1 1.62, ma 39.8a 
 b nd  1.04, m  
6 1.37, m  28.0 1.24, m 30.8 
7 a 1.82, m 47.4 1.86, m 39.9a 
 b 1.70, m  1.74, m  
8  135.8 5.33, mb 129.3b 
9 5.10, m 118.9 5.34, mb 125.9  
10 1.51, d (6. 5) 13.5 1.59, d (5.2)a  17.8 
11 0.85, d (6.2) 18.1 0.88, d (6.3) 18.1 
12 0.71, br, s 19.1 0.77, d (6.3) 19.1 
13 1.45, s 14.9 –  
1¢ nd – – 192.6 
2¢ 4.13, br sa nd 4.16, br s 68.0 
3¢ 4.82, br s 72.3 4.87, br d (3.1) 72.6 
4¢  129.4 – 129.3b 
5¢ 7.01, d (8.4) 128.2 7.00, d (8.5) 128.2 
6¢ 6.59, d (8.4) 114.0 6.59, d (8.5) 114.1 
7¢  156.4 – 156.5 
3¢-OH 5.66, br s  5.65, br s – 
7¢-OH 9.21, br s  9.23, br s – 
-NH nd  9.14, br s – 
a-b Assignments with the same superscript within a column are overlapping. nd signals not detected. †Signals overlapping with the 
solvent (DMSO-d6) peak. *assignment based on the HMBC and HSQC data. 
 
  
Chapter 3: New quinazoline alkaloids from Penicillium sp. CMB-TS015 
 
 
77 
3.1.4. PF1140 (3.4) 
 
HRESI(+)MS analysis of 3.4 returned a molecular ion consistent with a molecular formula C16H23NO3 (Dmmu 
–0.7) requiring 6 DBE. The 1H NMR (methanol-d4) data for 3.4 (Figure 3.25, Table 3.7) revealed resonances 
for four methyl groups (dH 1.28, H3-14; 0.93, H3-17; 0.90, H3-16; 0.71, H3-15), two olefinic protons (dH 
7.58, H-6; 5.92, H-5) and an oxymethine (dH 4.72, H-13). 13C NMR data for 3.4 (Figure 3.26) showed 
resonances for four sp2 carbons (dH 162.1, C-4; 134.2, C-6; 111.6, C-3; 100.2, C-5) and an amide (dH 
162.2, C-2) accounting for 3 DBE, requiring three additional ring systems. Diagnostic 2D NMR 
correlations (Figure 3.27) established the 3,4-disubstituted pyridone moiety. A literature search with 
the structure fragments deduced from 2D NMR analysis suggested that 3.4 was the known fungal 
alkaloid N-hydroxy-2-pyridone, PF1140.21  
 
Figure 3.25: 1H NMR (600 MHz, methanol-d4) and UV-vis (HPLC-DAD, H2O/MeCN with formic acid at 210 nm) 
spectra of  PF1140 (3.4). 
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Table 3.8: NMR data (600 MHz, methanol-d4) for PF1140 (3.4) 
Position δH, multi, (J in Hz) δC COSY HMBC δH, multi, (J in Hz), literature21 
1-OH 
 
    
2  162.3    
3  111.6    
4  162.1    
5 5.92, d (7.7) 100.2 6 2, 3, 6 5.90, d (7.2) 
6 7.58, d (7.7) 134.2 5 3, 4, 5 7.56, d (7.2) 
7 2.23, d (10.8) 46.7 12 3, 4, 8, 12, 13, 15 2.21, d (10.8) 
8  35.0    
9 a 1.05, t (13.4) 
b 0.87, m 
45.8  8, 10, 13,  1.78, br (13.4, 13.8) 
1.02, t (13.3) 
10 1.66, m 28.1 16 11, 12 1.63, m 
11 a 1.88, br (13.8) 
b 1.70, br (13.8) 
45.7 12 10, 11 1.70, br (13.4) 
0.85, m 
12 1.63, m 39.0 17  1.63, m 
13 4.72, q (6.4) 75.7 14 7, 8, 15 4.70, q (6.1)  
14 1.28, d (6.4) 15.1  13 8, 13,  1.26, q (6.1) 
15 0.71, s 22.1  7, 8, 13 0.69, s 
16 0.90, d (6.4) 23.3 10 11 0.88, d (6.4) 
17 0.93, d (6.4) 21.1 12 7, 12 0.90, d (6.4) 
 
 
Figure 3.26: 13C NMR (150 MHz, methanol-d4) spectrum of PF1140 (3.4) 
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Figure 3.27: Key 2D NMR correlations of PF1140 (3.4). 
A 1995 study by Reiko et al.22 reported the isolation of a wide spectrum fungicide named PF1140 
from a Eupenicillium sp. PF1140, and later Fujita et al. (2005) established the absolute configuration 
of PF1140.22 However, neither Reiko et al. nor Fujita et al. 22 reported NMR data for PF1140 (3.4). 
A 2009 study by Silva et al.21 reported 1D, 2D NMR data and assignment of relative configuration 
established through NOESY correlations. Comparison of specific rotation for 3.4 ([α]22D –87.8o, c 
0.26, MeOH) with the literature value ([α]22D –124o, c 0.26, MeOH) confirmed that 3.4 has the same 
absolute configuration as PF1140. 
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3.1.5. 7-hydroxy-paxisterol (3.5)   
 
HRESI(+)MS analysis of 3.5 returned a ion [(M+H)+] indicative of molecular formula (C28H44O5, 
Dmmu –1.3) requiring 7 DBE. The 1H NMR (600 MHz, CDCl3) data for 3.5 (Figure 3.28, Table 3.9) 
exhibited four methyl groups [δH 1.25 (H3-21), 1.00 (H3-28), 0.99 (H3-27), and 0.94 (H3-19)], three 
oxymethines [δH 4.66 (H-15), 4.33 (H-7) and 3.59 (H-3)] and an exomethylene [δH 4.72 (H-28a) and 
4.67 (H-28b)] together with a series of diastereotopic methylenes. 13C NMR (150 MHz, CDCl3) data 
for 3.5 (Figure 3.29, Table 3.9) revealed 28 carbon signals including resonances for two sp2 carbons 
[δC 155.5 (C-24) and δC 106.9 (C-28)] and six oxygenated carbons [δC 71.2 (C-3), 68.5 (C-7), 94.0 
(C-8), 73.8 (C-15), 108.9 (C-18) and 88.5 (C-20)] suggesting that 3.5 could be a sterol. HMBC 
correlations supported by COSY data established the exomethylene containing side chain, C-20 to C-
26. Of note, NMR resonances for C-18/H3-18 were missing, while HMBC correlations from δH 5.39 
(H-18) to C-12 (δC 32.3), C-13 (δC 64.3) and C-14 (δC 62.3) were suggestive of an acetal moiety at 
C-18. A literature search with the structure fragments deduced from diagnostic 2D NMR analysis 
(Figure 3.29) suggested 3.5 was related to known fungal sterol, paxisterol (3.37), which contains an 
acetal group at C-18 connected through ethers to C-15 and C-20. NMR resonances for C-7 
oxymethine (δC 68.5 and δH 4.66) and HMBC correlations from the C-18 acetal proton (δH 5.39, H-
18) to C-8 (δC 94.0) confirmed the C-18 acetal, indicating 3.5 was a new fungal sterol.  
A 1988 study by Nakano et al.23 first reported paxisterol (3.37) from Penicillium paxilli, and later 
Yasuzawa et al.22 in 1990 established the complete structure. The absolute configuration of paxisterol 
(3.37) was confirmed by comparing the CD spectrum of 3-keto derivative of 3.36 with cholesterol. 
The assignment of the epoxide and acetal groups of 3.37 was confirmed by 2D NMR analysis and 
chemical transformation. Significantly, Yasuzawa et al.24 demonstrated that the C-18 acetal group 
connected to C-15 could be migrated to C-8 in acid, suggesting that 3.5 could be an artifact (Figure 
3.32) of 3.37 generated during the HPLC fractionation in the presence of 0.01% TFA modifier.  
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Figure 3.28: 1H NMR (600 MHz, CDCl3) and UV-vis (HPLC-DAD, H2O/MeCN with formic acid at 210 nm) spectra of 
7-hydroxy-paxisterol (3.5). 
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Figure 3.29: 13C NMR (150 MHz, CDCl3) spectrum of 7-hydroxy-paxisterol (3.5).  
 
 
Figure 3.30: Key 2D HMBC correlation for 7-hydroxy-paxisterol (3.5). 
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Table 3.9: NMR data (600 MHz, CDCl3) for 7-hydroxy-paxisterol (3.5) 
Position δH, multi, (J in Hz) δC (experimental) COSY 1H-13C HMBC δC (literature, 3.36)23 
1 a 1.59, m 
b 0.96a 
37.7 1b, 2a/b 
1a, 2a/b 
3, 5  38.1 
2 a 1.72b 
b 1.37c 
30.8 1, 3 
1, 3 
3, 10 
3, 10 
30.7 
3 3.59, m 71.2 2a/b, 4a/b 1, 2 70.8 
3-OH      
4 a 1.59, m 
b 1.32d 
37.7 3 
3 
1, 2, 3 
1, 2, 3 
37.4 
5 1.71b 36.4 4a/b 9, 11 39.8 
6 a 1.74b 
b 1.30d  
33.8 7 
7 
8 
8 
28.6 
7 4.66e 68.5 6 5, 9, 14  56.6 
7-OH      
8  94.0   60.2 
9 1.40, dd (11.6, 6.1) 49.9 11a/b 1, 10, 11, 14  48.7 
10  36.2   33.8 
11 a 1.82, m 20.9 9, 11b, 12b 8, 9, 12, 13  21.7 
 b 1.63f     
12 a 2.06g 32.7 9, 11a  28.4 
 b 1.79h  11a 18  
13  64.3   58.7 
14 1.75b 62.3 15 9, 12, 13 54.5 
15 4.33, brs 73.8 14 13, 17 72.8 
15-OH      
16 a 2.08g  38.6 17 13, 14, 20 35.3 
 b 1.79h  15, 17 13, 14, 18, 20  
17 2.07g 52.4 16 12, 15, 18, 21 49.1 
18 5.39, s 108.9  8, 12, 13, 14  106.7 
19 0.94a 12.0  1, 9, 10 12.8 
20  88.5   85.2 
21 1.25, s 25.0  17, 20, 22 27.3 
22 a 1.92i 36.9 23a/b 17, 20, 24 39.6 
 b 1.65f  23a/b 17, 20, 24  
23 a 2.04g 28.4 22 a/b, 23b 20, 25, 26 29.5 
 b 1.97i  22 a/b, 23b 20, 25, 26  
24  155.5   155.6 
25 2.21, m 34.1 27, 28 23, 24, 25, 28 33.9 
26 0.99, d (2.5) 22.0 26 24, 25, 27 21.9 
27 1.00, d (2.5) 22.0 26 24, 25, 27 21.9 
28 4.72, s 106.9  23, 24, 26 106.4 
 4.67e   23, 24, 26  
a-i overlapping signals, assignments with the same superscript may be interchanged.        
This hypothesis was supported by the detection of an ion [SIE, m/z 443 (M+H)+, C28H42O4 (Dmmu –
0.4] correspond to paxisterol (3.37) in the untreated crude extract (Figure 3.31), but not for 3.5. Based 
on the evidence from the literature,24 we speculate that mild acid (0.01% TFA) in HPLC fractionation, 
directed the acetal migration from C-15 to C-8 (Figure 3.32) to yield 3.5. The smaller peak width at 
half-height (6.5 Hz) suggested equatorial H-7 (δH 4.66). The specific rotation of 3.5, [α]D22 –21.4 (c 
0.52, CHCl3), was consistent with the value reported for paxisterol, [α]D22 –60.8 (c 1.0, CHCl3), 
indicating that 3.5 has the same absolute configuration. 
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Figure 3.31: Single-ion extraction (SIE) analysis on the untreated EtOAc extract of CMB-TS015 cultured on ISP-2 
medium. (a) HPLC-DAD (210 nm) chromatogram, a peak corresponding to paxisterol (3.37) was not detected due to poor 
UV-Vis response of 3.37. (b) SIE profile corresponding to paxisterol (3.37) [ m/z 443 (M+H)+]. 
 
Figure 3.32: Proposed chemical transformation for 7-hydroxy-paxisterol (3.5). 
Bioactivity profiling has shown that paxisterol (3.37) possesses significant analgesic activity in the 
AcOH induced writhing assay, without a significant anti-inflammatory activity, which is common of 
corticosteroid analgesics.21 However, further investigation on the analgesic activity of paxisterol 
(3.37) is not available in the literature.  
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3.1.6. cyclopiazonic acid (3.6) 
 
HRESI(+)MS analysis of 3.6 returned a molecular ion consistent with a molecular formula 
(C20H20N2O3, Dmmu –2.1) requiring 12 DBE. The 1H NMR (600 MHz, methanol-d4) data for 3.6 
(Figure 3.33, Table 3.10) showed resonances for four sp2 methines (δH 7.14, (H-16); 7.08, (H-2); 7.04, 
(H-15); 6.81, H-14), three sp3 methines (δH 4.08, H-5; 3.65, H-4; 2.57, H-11) and three methyl groups 
(δH 2.43, H3-20; 1.65, H3-21; 1.60, H3-22). Diagnostic 2D NMR correlations established a 3,4-
disubstituted indole and a tetramic acid moiety. A literature search with these structure fragments 
suggested that 3.6 was the known mycotoxin cyclopiazonic acid. This was further confirmed by 
comparison of NMR data (Table 3.11). The specific rotation for 3.6, [α]D22 –56.1 (c = 0.06, CHCl3), 
was consistent with the literature23 indicating that 3.6 has the similar configuration. A 1968 study by 
Holzapfel first reported cyclopiazonic acid from Penicillium cyclopium.25 
 
Figure 3.33: 1H NMR (600 MHz, methanol-d4) and UV-vis (HPLC-DAD, H2O/MeCN with formic acid at 210 nm) 
spectra of cyclopiazonic acid (3.6).  
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Table 3.10: NMR data (methanol-d4) data for cyclopiazonic acid (3.6) 
Position δH, multi, (J in Hz) δCa COSY 1H-13C HMBC 
1-NH nd    
2 7.08, s 122.2  13, 17 
3  110.4   
4 3.65, dd (10.5, 5.4) 37.7 5, 11 6, 11, 12, 18 
5 4.08, d (10.5) 73.0 4 3, 4, 6 
6  198.4   
7  106.9   
8  187.5   
10  64.6   
11 2.57, dd (11.1, 5.4) 54.9 4, 12 5, 4, 21 
12 3.06, m 27.6 11 10, 13, 14, 18 
13  129.9   
14 6.81, d (6.9) 116.9  12, 16, 18 
15 7.04, t (7.5) 123.5  13, 17 
16 7.14, d (8.1) 109.8  14, 18 
17  135.2   
18  127.3   
19  nd   
20 2.43, s 20.5  7, 8 
21 1.65, s 26.1  10, 12, 22 
22 1.60, s 24.9  10, 12, 21 
nd reseonances not detected 
 
Figure 3.34: Key 2D NMR correlations for cyclopiazonic acid (3.6). 
Table 3.11: Comparison of 1H NMR (CDCl3) data for 3.6 with the literature25  
Position δH, multi, (J in Hz) experimental δH, multi, (J in Hz) literature 
1-NH 8.06, brs 8.11, brs 
2 7.12, m 7.15, m 
3   
4 3.64, dd (11.0, 5.7) 3.67, dd (11.0, 5.8) 
5 4.05, d (11.0) 4.10, d (11.0) 
6   
7   
8   
10   
11 2.62, m 2.60, dt (11.7, 5.9) 
12 3.03, m 3.06, m 
13   
14 6.89, d (6.9) 6.92, d (6.9) 
15 7.12, m 7.15, m 
16 7.20, d (8.0) 7.22, d (8.2) 
17   
18   
19   
20 2.49, s 2.46, s 
21 1.66, s 1.68, s 
22 1.61, s 1.64, s 
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3.1.7. (+)-terrein (3.7) 
 
HRESI(+)MS analysis of 3.7 returned a molecular ion consistent with a molecular formula (C8H10O3, 
Dmmu –0.5) requiring 4 DBE. The 1H NMR (600 MHz, methanol-d4) data for 3.7 (Figure 3.35) 
showed resonances for three sp2 methines (δH 6.83, H-7; 6.43, H-6; 6.00, H-6) and a methyl (δH 7.14, 
H3-8). A literature search with molecular formula suggested that 3.7 was the known mycotoxin (+)-
terrain.26 This assumption was confirmed by comparing 1H NMR data of 3.7 with literature data 
(Table 3.12).26 The specific rotation of 3.7, [α]D22 +31.6 (c = 0.065, CHCl3) was consistent with the 
literature, indicating that 3.7 has the same configuration.27  
 A 1935 study by Raistrick and Smith27 first reported terrein from Aspergillus terreus, and later 
Clutterbuck et al.27 established the structure. A 1955 study confirmed the absolute configuration of  
terrein by chemical analyses.27 
 
Figure 3.35: 1H NMR (600 MHz, methanol-d4) and UV-vis (HPLC-DAD, H2O/MeCN with formic acid at 210 nm) 
spectra of (+)-terrain (3.7). * residual MeOH.   
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Table 3.12: Comparison of 1H NMR (600 MHz, methanol-d4) data for 3.7 with literature26 (600 MHz, methanol-d4) 
Position δH, multi, (J in Hz) experimental δH, multi, (J in Hz) literature26 
1 
 
 
2 4.68, d (2.4) 4.66, d (2.5) 
3 4.08, d (2.7) 4.1, d (2.8) 
4   
5 6.00, s 6.0, s 
6 6.43, d (15.7) 6.4, d (160) 
7 6.83, m  6.8, m 
8 1.94, dd (6.9, 1.5) 1.92, d (6.9) 
3.2. Conclusion 
This chapter summarises isolation and characterisation of metabolites from Penicillium sp. CMB-
TS015. The novel quinazoline alkaloids (+)-spiroquinazoline B (3.1) and (+)-fumiquinazoline J (3.2) 
were identified with uncommon configurations in the classes, which, presumably, originated from 
biosynthesis. Further, (+)-fumiquinazoline J (3.2) showed potent human GABAA receptors inhibitory 
activity indicating the possible involvement of quinazoline pharmacophore in modulating human 
GABA receptors. The MATRIX analysis, supported by GNPS molecular networking, revealed that 
Penicillium sp. CMB-TS015 is capable of producing structurally diverse metabolites, including 
fumiquinazoline analogues. In particular, isolation, characterization and bioactivity profiling of 
fumiquinazoline analogues would faclilitate the understanding of the biosynthesis of (+)-
fumiquinazoline J (3.2) and SAR in GABA receptor inhibitory activity. 
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3.3. Experimental 
3.3.1. General experiment 
See Appendix I: General Experiments, page 263.   
3.3.2. Isolation and taxonomic analysis of the fungus 
See Chapter 2, section 2.9.2 and 2.9.5 
3.3.3. Scaled up cultivation and isolation of metabolites 
Scaled-up cultivation and isolation of metabolites were carried out as described in Chapter 2, section 
2.9.7.  
(+)-spiroquinazoline B (3.1): A brownish powder; [α]D22 +8.7 (c 0.06, MeOH); 1D and 2D NMR 
(600 MHz, DMSO-d6) see Table 3.1 and Figures 3.2 to 3.6; HRESI(+)MS m/z 458.1829 [M+H]+ 
(calcd for C25H24N5O4, 458.1823). 
(+)-fumiquinazoline J (3.2): A yellow powder; [α]D22 +22.4 (c 0.06, MeOH); 1D and 2D NMR (600 
MHz, DMSO-d6) see Table 3.2 and Figures 3.9 and 3.11; HRESI(+)MS m/z 357.1355 [M+H]+ (calcd 
for C21H17N4O2, 357.1339). 
Chaunolidine D (3.3): A colourless oil; [α]D22 –45.7 (c 0.05, MeOH); 1D and 2D NMR (600 MHz, 
methanol-d4) see Table 3.6 and Figures 3.22 to 3.24; HRESI(+)MS m/z 410.1944 [M+Na]+ (calcd for 
C22H29N1Na1O5, 410.1938). 
PF1140 (3.4): A white powder; [α]D22 –87.8 (c 0.26, MeOH); 1D and 2D NMR (600 MHz, methanol-
d4) see Table 3.8 and Figures 3.25 and 3.26; HRESI(+)MS m/z 278.1769 [M+H]+ (calcd for 
C16H24NO3, 278.1763). 
7-hydroxy-paxisterol (3.5): A white powder; [α]D22 –87.8 (c 0.26, CHCl3); 1D and 2D NMR (600 
MHz, CHCl3) see Tables 3.9 and Figures 3.28 to 3.30; HRESI(+)MS m/z 461.3275 [M+H]+ (calcd 
for C28H45O5, 461.3262). 
Cyclopiazonic acid (3.6): A yellow oil; [α]D22 –56.1 (c 0.06, CHCl3); 1D and 2D NMR (600 MHz, 
MeOH) see Tables 3.10 and Figure 3.28; HRESI(+)MS m/z 337.1573 [M+H]+ (calcd for C20H21N2O5, 
337.1552). 
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Terrein (3.7): A brownish crystals; [α]D22 +31.6 (c 0.065, CHCl3); 1D and 2D NMR (600 MHz, 
MeOH) see Tables 3.12 and Figure 3.35; HRESI(+)MS m/z 155.0713 [M+H]+ (calcd for C8H11O3, 
155.0708). 
3.3.4. Analytical (MATRIX) cultivation  
Penicillium sp. CMB-TS015 was cultured in a 24-well microbioreactor plate using a combination of 
11 culture media and 3 phases (i.e., solid agar, and liquid static and liquid shaken) (Table 4.4). For 
more detail see Chapter 4, section 4.9.3. 
GNPS molecular networking analysis was performed as described in Chapter 2, section 2.9.6. The 
number of matching fragments was set to 4 for this analysis. 
3.3.5. Bioassay 
3.3.5.1. GABA screening by patch clamp 
GABA receptor modulator activity of the metabolites was analysed using stable whole-cell patch 
clamp recording. All experiments were carried out at room temperature (21 – 24 oC), with a clamped 
potential –70 mV. HEK293 cells (human embryonic kidney cells 293) expressing α5b2g2L GABAAR 
cells were suspended in the standard external solution containing (in mM): 140 NaCl, 4 KCl, 2 CaCl2, 
1 MgCl2, 10 HEPES/NaOH and 5 glucose (pH 7.4). The final cell suspension, the pre-prepared 
internal solution containing (in mM) 50 KCl, 10 NaCl, 60 KF, 2 MgCl2, 10 HEPES/KOH (pH 7.2), 
and 20 EGTA, the external solution and the compound-containing solutions were all placed at pre-
defined positions on the patchliner workstation, and were applied to cells via robotic pipette. 
The cells were continuously perfused via a gravity-fed double-barrelled glass tube. An extracellular 
bath solution containing (in mM), 140 NaCl, 5 KCl, 1 MgCl2, 2 CaCl2, 10 HEPES, and 10 D-glucose 
and titrated to pH 7.4 was flowed in one barrel, while the adjacent barrel contained agonist dissolved 
in the same extracellular solution. Glass electrodes were pulled from borosilicate glass (G150F-3; 
Warner Instruments), coated with a silicone elastomer (Sylgard-184; Dow Corning) and heat-
polished to a final tip resistance of 4-15 MΩ when filled with an intracellular solution containing (in 
mM) 145 CsCl, 2 MgCl2, 2 CaCl2, 10 HEPES, and 5 EGTA, pH 7.4. Stock solutions of GABA were 
pH-adjusted to 7.4 with NaOH. Cells were directly perfused with extracellular solution by placing 
them in front of one barrel of the double-barrelled glass tube. Currents were elicited by exposing the 
cell continuously to EC20 agonist and varying concentrations of the drug containing solution, flowing 
through the adjacent barrel. Currents were recorded using an Axopatch 200B amplifier (Molecular 
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Devices), filtered at 5 kHz and digitized at 20 kHz using Clampex (pClamp 10 suite, Molecular 
Devices) via a Digidata 1440A digitizer. 
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4. Chapter 4: Talarolides A–C: New cyclic peptide from Talaromyces sp. CMB-TU011 
The fungus Talaromyces sp. CMB-TU011 was isolated from an unidentified tunicate sample 
collected from the Tweed Heads, NSW, Australia by a previous group member, Rakesh Damodar. 
This fungus yielded a possible new cyclic peptide talarolide A (4.1) together with a known diterpene 
glycoside sordarin (4.4) when grown on M1 saline (3.3% artificial sea salt) agar medium at 26.5 °C 
for 25 days. As the culture conditions failed to yield sufficient material to support the structure 
elucidation of talarolide A (4.1), culture optimization studies were carried out using a range of 
different culture media and conditions.  
A miniaturized 24-well microbioreactor cultivation approach (MATRIX) was used to investigate the 
wider secondary metabolite production capabilities of Talaromyces sp. CMB-TU011, and identify an 
optimum culture condition for 4.1. The fungus was cultured on 24-well microbioreactors, generating 
extracts across a range of culture media (×11), inclusive of solid phase, broth static and broth shaken, 
followed by in situ solvent extraction and chemical profiling using HPLC-DAD-ESIMS and UHPLC-
QTOF (MS/MS). Secondary metabolite production across the different culture conditions was 
visualized using the Global Natural Product Social Molecular Networking (GNPS) analysis approach. 
This chapter focuses on the application of the MATRIX approach to identify an optimum culture 
condition for talarolide A (4.1) supported by GNPS molecular networking analysis, and the isolation 
and structure elucidation of talarolide A (4.1) and its co-metabolites talarolide B (4.2) and talarolide 
C (4.3). 
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4.1. Chemical profiling of Talaromyces sp. CMB-TU011  
4.1.1. DNA taxonomy and phylogenetic analysis  
 
Figure 4.1: Photograph of Talaromyces sp. CMB-TU011 cultivated on (a) M1 salt medium, (b) microscopic image of 
Talaromyces sp. CMB-TU011 stained with lactophenol cotton blue (40X magnification). 
The strain was recovered from a cryo-preserved vial and grown on M1 salt (3.3% artificial sea salt) 
agar medium for 10 days at 26.5 oC. CMB-TU011 initially formed white filaments on M1 saline 
medium which changed to orange yellow during maturation (Figure 4.1a). Genomic DNA was 
extracted from the fungal mycelium using a blood and tissue DNA kit (QIAGEN) and was sequenced 
for ITS1 and ITS2 genes. The resulted sequence was analysed with National Center for 
Biotechnology Information (NCBI) nucleotide collection (nr/nt) database using Basic Local 
Alignment Search Tool BLAST® to identify closely related strains for CMB-TU011. None of the 
reported sequences showed a 100% homology to CMB-TU011. To investigate the possible 
relationship between CMB-TU011 and reference strains from NCBI, a phylogenetic tree was 
constructed using ITS DNA sequences (over 98% homology) acquired from BLAST (Figure 4.2). 
According to the 18S rRNA analysis and morphological examination (Figure 4.1b), the fungus CMB-
TU011 was identified as Talaromyces sp., with a close relationship to Talaromyces helices var. 
MH814 (accession number LN901153.1). Talaromyces is a ubiquitous genus found in both marine 
and terrestrial ecosystem which is known to produce diverse secondary metabolites with potent 
biological activities.1,2 In this study, we aimed to investigate the secondary metabolite capacity of the 
fungus Talaromyces sp. CMB-TU011, while determining the optimum culture conditions to isolate 
talarolide A (4.1).  
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Figure 4.2: Phylogenetic analysis of CMB-TU011. PhyML Maximum Likelihood analysis of ITS DNA sequences was 
performed with the optimal nucleotide substitution model determined by jModeltest3,4 using  Unipro UGENE5 software 
(v1.24.2). Phylogenetic relationship of CMB-TU011 with selected reference strains (nr/nt, NCBI) shown with their 
accession numbers highlighted in blue. 
  
Talaromyces helicus var.CBS 652.66 | AB176623.1 |
Penicillium sp. CCF3782 | FJ430760.1 | 
Talaromyces helicus BL07-13 | JX076934.1 |
Talaromyces helicus | F588641.1 | 
Penicillium sp. CCF2941 | FJ430758.1 |
Talaromyces helicus R2SN01 | KR091820.1 |
Talaromyces helicus  KT184798.1 | DSNA02 |
Penicillium sp. MK-2015 MH848 | LN901122.1 | 
Eurotiales sp. B1A0196EM2CC953 | JQ411391.1 | 
Talaromyces helicus var. helicus AK71/03 | FJ430761.1 |
Talaromyces helicus NRRL 2106 | AF033396.1 | 
Talaromyces sp. OUCMBI101202 | HQ914887.1 |
Talaromyces helicus var. helicus NBRC 31571 | AB176621.1 | 
Talaromyces helicus var. helicus CCF3771 | FJ430759.1 | 
Talaromyces helicus CBS 134.67 | KM066176.1 | 
Talaromyces barcinensis  W109 | KC800596.1 |
Talaromyces barcinensis CBS 649.95 | NR_137078.1 | 
Talaromyces barcinensis CBS 649.95 | JN899349.1 |
Talaromyces sp. M13017-S | KU365892.1 |
Talaromyces sp. M13013-S | KU365888.1 |
Talaromyces helicus var. MH900 | LN901152.1 |
Talaromyces sp. M13012-S | KU365887.1 |
CMB-TU011
Talaromyces helicus var.  MH814 | LN901153.1 | 
Talaromyces helicus var. MH822 | LN901154.1 |
Ascomycota sp. L321 | KU535806.1 |
Talaromyces barcinensis Cd3 | KJ942582.1 | 
Talaromyces helicus Cd9 | KJ942585.1 |
Talaromyces helicus var. CCF3773 | FJ430764.1 | 
Talaromyces helicus var. | FJ430765.1 | 
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4.1.2. Analytical cultivation and chemical profiling of CMB-TU011 
To monitor talarolide A (4.1) expression and secondary metabolite profile under different culture 
conditions, a recently developed miniaturized microbioreactor cultivation approach (MATRIX) was 
used. The fungus was cultured in 24-well microbioreactors (Figure 4.3) at 26.5 oC for 10 days, 
generating extracts across a range of culture media (×11) including solid agar as well as static broth 
and shaken broth. The resulting ×33 cultures were extracted with EtOAc in situ and the secondary 
metabolite production was analysed with HPLC-DAD-ESIMS and UHPLC-QTOF (MS/MS). The 
HPLC-DAD-ESIMS analysis revealed that CMB-TU011 produced a range of secondary metabolites 
in different culture conditions. Figure 4.4 shows the representative HPLC-DAD chromatograms and 
respective UV profiles of the major metabolites in CMB-TU011 extracts from (a) M1 salt agar, (b) 
ISP-2 agar, (c) M2 shaken broth, (d) PYG agar and (e) YES static broth.  
 
Figure 4.3: Photographs of 24-well microbioreactors (a) solid agar (b) static broth (c) shaken broth inoculated with 
Talaromyces sp. CMB-TU011 (highlighted in red).  
4.1.3. Analysis of talarolide A (4.1) production under different culture conditions 
Talarolide A (4.1) production under different culture condition was analysed using the area under the 
peak for single ion extraction on talarolide A (4.1) at m/z 718 (M+H)+ for ×33 HPLC-ESI(+)MS data. 
Figure 4.5 illustrates the relative talarolide A (4.1) production under different conditions. The result 
showed that talarolide A (4.1) was expressed in all the culture condition, with the expression levels 
are culture condition dependent. Talarolide A (4.1) production was considerably higher in some of 
the culture conditions, e.g. M1-salt, ISP-4 agar, PDA, ISP-2 static broth and M1-salt shaken broth, 
while talarolide A (4.1) was detected only with SIE method in some culture conditions. This result 
clearly indicates that culture conditions play a pivotal role in the expression of fungal metabolites and 
selecting an optimal culture condition is important for isolating acceptable amounts of metabolites of 
interest.  Further, it was noticed that CMB-TU011 produce more material, including talarolide A, 
under solid agar, rather than static or shaken broth. 
  
Chapter 4: Talarolides A–C: New cyclic peptides from Talaromyces sp. CMB-TU011 
 
 
96 
 
Figure 4.4: Representative HPLC-DAD (210 nm) chromatograms of Talaromyces sp. (CMB-TU011) cultured on 
different media. (a) M1-salt agar, (b) ISP-2 agar, (c) M2 shaken broth, (d) PYG agar and (e) YES static broth, with inset 
(e) showing four main peaks resolved after a method development (Zorbax SB-C3 column, with isocratic 40% MeCN/H2O 
inclusive of an isocratic 0.01% TFA/MeCN modifier). Metabolites with similar UV profiles are coloured with the same 
colour. ** Media background.  
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Figure 4.5: Talarolide A (4.1) production under different culture conditions. The expression level of talarolide A 
production was calculated based on the area under the peak for SIE at m/z 718 (M+H)+ in HPLC-DAD-ESI(+)MS 
analysis. 
4.1.4. GNPS analysis of CMB-TU011 crude extracts 
Comparing and analysing the metabolite profile of a series of crude extract is often challenging with 
conventional analytical tools such as UHPLC-DAD and HPLC-DAD-MS. As an alternative, the 
MS/MS molecular networking provides a sensitive and rapid analytical platform to compare 
metabolic profiles of microbial culture extracts.4 Therefore, recently introduced Global Natural 
Product Social (GNPS) molecular networking platform6 was used to analyse the UHPLC-QTOF 
(MS/MS) data of the crude extracts generated under different culture conditions (×33). The GNPS 
analysis identified parent ions for metabolites with similar MS/MS fragmentation patterns, which 
were visualized in a molecular network (Figure 4.6a) with node colour and size indicating different 
culture conditions and relative ion abundance, thickness of the lines connecting nodes representing 
similarity indices. Nodes having more than 6 matching MS/MS fragments were clustered.    
The parent ion of talarolide A (4.1) [m/z 718 (M+H)+] formed a cluster (Figure 4.6b) with structurally 
related peptides, with talarolide A (4.1) being the most abundant. All the metabolites clustered with 
talarolide A (4.1) detected in multiple culture conditions as talarolide A (4.1) (Figure 4.7).  
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Figure 4.6: Talaromyces sp. CMB-TU011 molecular network. Related parent ions in extracts of CMB-TU011cultured 
under different conditions were networked based on similarities in MS/MS fragmentation patterns using GNPS molecular 
networking. (a) The molecular network including self-loops, (b) talarolide A (4.1) containing sub cluster, (c) and (d) other 
peptidic sub clusters. Node sizes represent the relative abundance of the metabolites. Metabolites highlighted in are 
discussed in this chapter.  
Even though UHPLC-QTOF (MS/MS) data formed a cluster with several talarolide analogues, 
HPLC-DAD-MS data showed that relative abundance of some of the analogues were low. 
Furthermore, no single culture condition expressed all the talarolide analogues in reasonable amounts. 
Therefore, notwithstanding talarolide A (4.1) production was substantially high on ISP-4 agar, M1-
salt agar medium was selected for scale-up cultivation considering the relative production of all the 
metabolites of interest. In this chapter, isolation and characterization of talarolode A (4.1) and co-
metabolite talarolide B (4.2, m/z 703.2) and talarolide C (4.3, m/z 701.4) are discussed.  
Further analysis of the molecular networking data revealed additional clusters (Figure 4.6c and 4.6d) 
likely corresponding to peptidic natural products, which were identified based on the MS/MS 
fragmentation. Unlike the talarolide analogues, some of the metabolites in those clusters were culture 
condition specific; e.g. m/z 1319.9 detected only in M1 static broth, supporting the proposition that 
fungal secondary metabolite production is highly dependent on culture conditions. Isolation and 
characterization of the major metabolites (m/z 1254.8, 1353.9, 1318.8 and 1417.9) in those clusters 
are discussed in the Chapter 5.  
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Figure 4.7: Schematic representation of relative expression level of talarolides across different culture conditions. The 
heat map was created using ion abundance detected in UHPLC-QTOF-MS/MS analysis.  
4.2. Scale-up fermentation of Talaromyces sp. CMB-TU011  
A loop of spores from 7-day old fungus CMB-TU011 was streaked on agar plates (×100) loaded with 
M1 salt (3.3% artificial sea salt) agar and incubated for 25 days at 26.5 °C. After incubation, the 
combined agar/mycelia was extracted with EtOAc (4×500 mL) and the EtOAc concentrated in vacuo 
to yield a crude extract (465 mg), which was sequentially partitioned with n-hexane (×4, 50 mL) and 
aqueous MeOH (50 mL).  The dried MeOH soluble fraction (253 mg) was subjected to gel 
chromatography (Sephadex® LH-20, MeOH) to obtain ×6 fractions (Scheme 4.1), which were 
selectively combined on the basis of HPLC-DAD-MS analysis (Zorbax SB-C8 column, analytical 
gradient 10% MeCN/H2O–100% MeCN inclusive of an isocratic 0.05% formic acid) to yield a 
fraction of interest (19 mg) that was resolved by optimized semi-preparative HPLC (Zorbax SB-CN 
column, 25–40% MeCN/H2O gradient elution at 3.0 mL/min inclusive of an isocratic 0.01% 
TFA/MeCN modifier) to yield talarolide A (4.1), talarolide B (4.2) and talarolide C (4.3) and sordarin 
(4.4).  
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Scheme 4.1: Isolation scheme for CMB-TU011. (a) n-hexane/MeOH solvent partitioning, (b) gel chromatography 
(Sephadex® LH-20, MeOH), (d) Semi-preparative HPLC: Zorbax SB-CN column (9.4 mm × 25 cm), eluted with 25-40% 
MeCN/ H2O gradient elution at 3 mL/min for 30 min inclusive of an isocratic 0.01% TFA/MeCN modifier. 
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4.3. talarolide A (4.1) 
 
HRESI(+)MS analysis of 4.1 returned a sodium adduct [(M+H)+] consistent with a molecular formula 
(C35H55N7O9, Δmmu −0.5) requiring ×12 double bond equivalent (DBE). The 1H NMR data (DMSO-
d6) (Figure 4.8 and Table 4.1) showed characteristic resonances for a disubstituted aromatic ring (δH 
6.93 and δH 6.64), resonances attributed to amino acid α-protons (δH 4.34–5.06) and three N-methyls 
(δH 2.66, δH 2.70 and δH 3.00). The 13C NMR (DMSO-d6) data for 4.1 (Figure 4.9 and Table 4.1) 
exhibited the characteristic resonances for a p-disubstituted benzene (δc 126.6–155.9) and seven amid 
carbonyls (δc 167.3–169.5), accounting for ×11 DBE, suggesting a peptidic natural product. This was 
supported by the ×7 amino acid α-protons identified from 1H–13C HSQC data of 4.1 (Figure 4.10). 
The TOCSY correlations (Figure 4.11) together with the diagnostic 2D NMR correlations (HSQC, 
HMBC and COSY) identified seven amino acid residues. A C3 and C18 Marfey’s analysis (Figure 
4.12) confirmed six of the proposed amino acid residues as N-Me-L-Tyr, D-allo-Ile, N-Me-L-Ala, N-
Me-D-Leu, L-Ala and D-Ala. The remaining C2H3NO2 fragment required by the molecular formula 
was attributed to an N-OH-Gly residue. This was supported by the diagnostic 2D NMR data (Figure 
4.13), which revealed an isolated C(O)-CH2-NOH [δH 4.75, d (17.1 Hz) and 3.76, d (17.1 Hz); δC 
50.2] exhibiting HMBC correlations to the carbonyl (δc 167.3) of an adjacent N-Me-D-Leu, with an 
additional diagnostic HMBC from N-H (δH 8.87) of an adjacent L-Ala residue. Although the 2D NMR 
data did not permit unambiguous assignment of the amino acid sequence, MS/MS fragmentation 
analysis of 4.1 (Figure 4.14) permitted partial assembly of a cyclic heptapeptide planar structure, 
albeit without differentiation of L-Ala and D-Ala regiochemistry.  
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Figure 4.8: 1H NMR data (600 MHz, DMSO-d6) spectrum of talarolide A (4.1).  
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Table 4.1: NMR (DMSO-d6) data for talarolide A (4.1) 
 δH, mult, (J in Hz) δC COSY HMBC ROESY 
D-allo-Ile     
1  169.5    
2 4.72, m 53.7 N-H 3, 6 4, 5, 9, N-H 
3 1.95, m 38.5 2, 4a, 4b, 6  6 
4 a 1.42, m 26.2 3, 4b, 5 2, 3, 5, 6  
 b 1.07, m  3, 4b, 5 2, 3, 5, 6  
5 0.94, dd (7.3, 7.3) 12.0 4a, 4b 3, 4  
6 0.81, d (6.9) 13.7 3 2, 3, 4 N-Me-L-Tyr-H-2 
N-H 7.24, d (9.6)  2 1, N-Me-L-Tyr-C-1 6, N-Me-D-Leu-H-2 
D-Ala     
1  174.1    
2 4.49, qd (6.8, 4.1) 45.2 3, N-H 3  N-Me-D-Leu) 
3 1.19, d (6.8) 15.7 2 1, 2 N-H 
N-H 8.66, d (4.1)  2  3, Gly-H-2a, Gly-H-2b 
N-Me-D-Leu     
1  167.3    
2 5.05, dd (11.8, 3.9) 54.5 3a, 3b 3, N-Me, D-Ala-C-1 4, 5, N-Me, N-H-D-allo-Ile 
3 a 1.79, ddd (14.4, 10.3, 3.9) 36.0 2, 3b, 4   
 b 1.58, ddd (14.4, 11.8, 3.9)  2, 3a, 4 5 2 
4 1.37, m 24.4 3a, 3b, 5, 6   
5 0.77, d (6.5) 21.0 4 3, 6  
6 0.88, d (6.5) 23.3 4 3, 4, 5  
N-Me 3.00, s 31.0  2, D-Ala-C-1 2, 3b, 5, D-Ala-H-2, N-H-D-allo-Ile 
Gly     
1  172.0    
2 a 4.75, d (17.1) 50.2 2b 1, N-Me-D-Leu-C-1  
 b 3.76, d (17.1)  2a N-Me-D-Leu-C-1 N-OH 
N-OH 9.31, s    N-H-D-allo-Ile, N-Me-L-Ala 
L-Ala     
1  171.1    
2 4.34, qd (7.1, 5.4) 45.8 3, N-H  1, 3 N-Me-L-Ala 
3 1.12, d (7.1) 14.9 2 2, 1  
N-H 8.87, d (5.4)  2 2, 3, Gly-C-1 N-Me-D-Ala-H-2, D-allo-Ile-H-3 
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Figure 4.9: 13C NMR data (150 MHz, DMSO-d6) for talarolide A (4.1). 
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Figure 4.10: 1H–13C HSQC (DMSO-d6) data for talarolide A (4.1). Expansion shows resonances for amino acid α-
protons.  
 
Figure 4.11: Key TOCSY correlations observed for talarolide A (4.1).  
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Figure 4.12: C3 Marfey’s analysis of talarolide A (4.1). (a) C3 HPLC-DAD (340 nm) chromatogram revealing L-FDAA 
amino acid derivatives. (b−f) C3 HPLC-MS-SIE chromatograms for L-FDAA derivatives of authentic standards (broken 
lines) and the acid hydrolysate of 4.1 (shaded peaks), with the inset (c) C18 HPLC-DAD (340 nm) chromatogram. Traces 
confirm that 4.1 incorporates (b) L-Ala and D-Ala (SIE m/z 342), (c) N-Me-L-Ala (SIE m/z 356), (d) N-Me-D-Leu (SIE 
m/z 398) (e) D-allo-Ile (SIE m/z 384) and (f) N-Me-L-Tyr (SIE m/z 700, *di-derivatised tyrosine). Note, the L-FDAA 
derivative of N-OH-Gly was not detected. 
 
Figure 4.13: Key 2D NMR (DMSO-d6) correlations for talarolide A (4.1).  
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Figure 4.14: Diagnostic MS/MS fragmentation for talarolide A (4.1) 
Establishing the regiochemistry of enantiomeric amino acid residues within a peptidic natural product 
is challenging and often uses either partial or total synthesis of multiple isomers. In this study, we 
demonstrate the application of recently described 2D C3 Marfey’s method for establishing the 
regiochemistry of L-Ala and D-Ala residues in 4.1.  
Briefly, an aliquot (150 µg) was partially hydrolysed by heating at 100 0C for 2 h in acid (2 M HCl, 
300 µL) followed by derivatising with Nα-(2,4-dinitro-5-fluorophenyl)-D-alaninamide (D-FDAA) to 
facilitate the detection of the partially hydrolysed fragments under UV (340 nm). An aliquot of the 
hydrolysate was injected into HPLC-DAD-MS to monitor the fragment ions generated by partial 
hydrolysis. The diagnostic dipeptide D-FDAA-D-allo-Ile-Ala (m/z 455.0 [M+H]+, Figure 4.15, green 
highlight) was identified with the aid of SIE chromatogram followed by method development to 
resolve the fragment of interest (m/z 455.0 [M+H]+). The well-resolved peak (i) was isolated using 
analytical reversed phase HPLC fractionation of the derivatized hydrolysate. Without further 
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characterization, the pure fraction (i) was subjected to total acid hydrolysis (6 M HCL) and C3 
Marfey’s analysis to confirm the presence of D-FDAA-D-Ala (inset in Figure 4.16b). The 2D C3 
Marfey’s analysis of 4.1 permitted the unambiguous positioning of L-Ala and D-Ala residues in 4.1. 
This study is another successful case study to prove that 2D C3 Marfey’s analysis is a sensitive 
analytical technique to establish regiochemistry of enantiomeric amino acid residues in peptidic 
natural products.   
 
 
Figure 4.15: 2D C3 Marfey’s analysis of talarolide A (4.1) derivatised with D-FDAA. (a) UV (340 nm) of partial 
hydrolysate of 4.1 (*= residual D-FDAA). (b) SIE revealing (i) D-FDAA-D-allo-Ile-Ala (m/z 455, green peak). Inset 
broken lines correspond to SIE chromatograms for pure D-FDAA standards of D-allo-Ile and D-Ile (m/z 384) and D-Ala 
(m/z 342). Inset shaded peaks correspond to SIE chromatograms for D-FDAA derivatised amino acid residues from the 
hydrolysate (i). 
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4.4. talarolide B (4.2) and C (4.3) 
Scale-up cultivation afforded two new talarolide analogues, talarolide B (4.2) and C (4.3), in sub-
milligram amounts (0.5 mg and 0.3 mg respectively), which were not enough to obtain quality NMR 
data. However, detailed analysis of UHPLC-QTOF-MS/MS fragmentation, supported by C3 and C18 
Marfey’s analysis, permitted assigning the complete structures for talarolide B (4.2) and C (4.3) 
including amino acid configurations. 
 
A GNPS molecular networking analysis clustered 4.2 and 4.3 with talarolide A (4.1) (Figure 4.16a), 
indicating that 4.2 and 4.3 are closely related analogues of talarolide A (4.1). UHPLC-QTOF-MS 
data (Figure 4.16b) suggested that talarolide B (4.2) and C (4.3) be close homologues of talarolide A 
(4.1) (i.e. −14 and −16 Da respectively). HRESI(+)MS analysis of 4.2 and 4.3 returned molecular 
ions consistent with molecular formula (C34H53N7O9, Δmmu −0.2 and C35H55N7O8, Δmmu –1.4 
respectively) supportive of the latter hypothesis. To confirm the amino acids of 4.2 and 4.3, highly 
sensitive C3 Marfey’s analysis was performed. Briefly, an aliquot (50 µg) of 4.2 and 4.3 subjected to 
total hydrolysis by heating at 100 oC for 8 h in acid (6 M HCl, 100 µL) and derivatised with L-FDAA. 
An aliquot (10 µL) was subjected to C3 and C18 Marfey’s analysis. A C3 Marfey’s analysis of 4.2 
(Figure 4.17) identified L-Ala, D-Ala, N-Me-L-Ala, N-Me-D-Leu, N-Me-L-Tyr, and D-Val residues, 
suggestive of D-allo-Ile to D-Val analogue of talarolide A (4.1). By contrast, C3 Marfey’s analysis of 
4.3 (Figure 4.18) showed an additional peak (SIE m/z 328) attributed to a Gly residue, suggesting that 
a dehydroxylated analogue of the hydroxamate 4.1. To further confirm the proposed structures for 
4.2 and 4.3, UHPLC-QTOF-MS/MS fragmentation analyses were performed.   
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Figure 4.16: UHPLC-QTOF-MS analysis of talarolides. (a) talarolide subcluster and (b) expanded UHPLC-QTOF (MS) 
data for talarolides A–C (4.1–4.3).  
 
Figure 4.17: C3 Marfey’s analysis of talarolide B (4.2). (a) C3 HPLC-DAD (340 nm) chromatogram revealing L-FDAA 
amino acid derivatives. (b−f) C3 HPLC-MS-SIE chromatograms for L-FDAA derivatives of authentic standards (broken 
lines) and the acid hydrolysate of 4.2 (shaded peaks). The inset in (c) shows the C18 HPLC-DAD (340 nm) chromatograms. 
Traces confirm that 4.2 incorporates (b) L-Ala and D-Ala (SIE m/z 342), (c) N-Me-L-Ala (SIE m/z 356), (d) N- Me-D-Leu 
(SIE m/z 398), (e) D-Val (SIE m/z 370), and (f) N-Me-L-Tyr (SIE m/z 700, * di-derivatised tyrosine). Note, the L-FDAA 
derivative of N-OH-Gly was not detected. 
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Figure 4.18: C3 Marfey’s analysis of talarolide C (4.3). (a) C3 HPLC-DAD (340 nm) chromatogram revealing L-FDAA 
amino acid derivatives. (b−g) C3 HPLC-MS-SIE chromatograms for L-FDAA derivatives of authentic standards (broken 
lines) and the acid hydrolysate of 4.3 (shaded peaks). The inset in (c) shows the C18 HPLC-DAD (340 nm) chromatograms. 
Traces confirm that 4.3 incorporates (b) Gly (SIE m/z 328) (c) L-Ala and D-Ala (SIE m/z 342), (d) N-Me-L-Ala (SIE m/z 
356), (e) N- Me-D-Leu (SIE m/z 398), (f) D-all-Ile (SIE m/z 384) and (g) N-Me-L-Tyr (SIE m/z 700, *di-derivatised 
tyrosine).  
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UHPLC-QTOF-MS/MS fragmentation of 4.2 and 4.3 (Figure 4.19b and Figure 4.19c) showed spectra 
closely resemble talarolide A (4.1), with a structure fragment (N-Me-L-Tyr−N-Me-L-Ala−L-Ala) 
common for all three talarolides, suggesting that all three talarolides share the same partial sequence.  
 
Figure 4.19: Overlaid UHPLC-QTOF-MS/MS spectra of (a) talarolide A (4.1), (b) talarolide B (4.2) and (c) talarolide C 
(4.3). The structure fragments shared by all three metabolites are highlighted in blue.    
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Talarolide B (4.2) showed a fragment ion (m/z 407.1831) corresponds to the structure fragment N-
Me-L-Tyr−N-Me-L-Ala−L-Ala−N-OH-Gly confirming that talarolide B (4.2) also bears a 
hydroxamate residue consistent with 4.1 (Figure 4.20). In comparison, talarolide C (4.3) showed a 
fragment ion (m/z 391.1929) corresponds to the structure fragment N-Me-L-Tyr−N-Me-L-Ala−L-
Ala−Gly, indicating a deoxy analogue of 4.1. There was an additional structure fragment, N-Me-L-
Ala−L-Ala–Gly, further supported this latter assignment (Figure 4.21).  
 
Figure 4.20: Overlaid UHPLC-QTOF (MS/MS) spectra of (a) talarolide A (4.1), (b) talarolide B (4.2) and (c) talarolide 
C (4.3). The fragments confirming N-OH-Gly and Gly are highlighted in green and magenta, respectively.  
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C3 Marfey’s analysis of talarolide C (4.3) revealed a Gly (SIE m/z 328, Figure 4.18b) residue that 
was not detected either for talarolide A (4.1) or talarolide B (4.2). This is consistent with the 
expectation that N-hydroxylation of Gly precludes Marfey’s derivatisation. The hypothesis was 
proved by detecting mass loss (–57 Da) attributed to Gly for talarolide B (4.3) (Figure 4.21c), with –
73 Da for corresponding fragments in 4.1 and 4.2. 
 
Figure 4.21: Expansion of UHPLC-QTOF-MS/MS spectra of (a) talarolide A (4.1), (b) talarolide B (4.2) and (c) 
talarolide C (4.3). The fragments confirming N-OH-Gly and Gly are highlighted in green and magenta, respectively. 
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Further analysis of MS/MS fragmentation identified the N-Me-D-Leu-L-Ala-D-allo-Ile fragment 
common for talarolide C (4.3) and talarolide A (4.1) (Figure 4.22c). Note – although talarolide A 
(4.1) only showed a fragment ion attributed to the loss of the dipeptide L-Ala−D-allo-Ile, (−184 Da), 
the sequence was confirmed as N-Me-D-Leu-L-Ala−D-allo-Ile with support from diagnostic 2D NMR 
correlations (see section 4.3). For talarolide B (4.2), this tripeptide partial sequence was confidently 
deduced as N-Me-D-Leu−L-Ala−D-Val with the detection of D-Val residue in C3 Marfey’s analysis 
of 4.2.  
 
Figure 4.22: Expanded UHPLC-QTOF-MS/MS spectra of (a) talarolide A (4.1), (b) talarolide B (4.2) and talarolide C 
(4.3) 
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Structure elucidation of talarolide B (4.2) and C (4.3) was achieved by analysing the UHPLC-QTOF 
(MS/MS) fragmentation supported by C3 and C18 Marfey’s analysis. L-Ala and D-Ala of 4.2 and 4.3 
was allocated based on biosynthetic consideration. This study showcases the power of high-resolution 
mass spectrometry coupled with C3 and C18 Marfey’s analysis to establish the complete structure of 
minor peptidic natural products without NMR data. 
Even though Talaromyces are known to produce diverse secondary metabolites, to the best of our 
knowledge, talarolide A (4.1) is only the second cyclic peptide (other than diketopiperazines) to be 
reported from this genus. A 2013 study by Bara et al.7 reported two cyclic heptapeptides, talaromin 
A and B, from the endophytic fungus Talaromyces wortmannii. More significantly, talarolide A (4.1) 
is the second nonribosomal peptide synthase (NRPS) derived natural cyclic peptide incorporating an 
internal hydroxamate residue, with the first being pargamicin8 reported in 2008 from an 
Amycolatopsis sp. Isolation of a minor analogue, talarolide B (4.2), containing N-OH-Gly further 
confirmed the biosynthetic capability of Talaromyces sp. CMB-TU011 to incorporate a natural 
hydroxamate moiety. 
Of note, ROESY data of talarolide A (4.1) showed extensive correlations to N-OH moiety suggesting 
that the N-OH is centrally oriented within the cyclic peptide ring. Based on this, it is speculated that 
through H-bonding N-OH moiety plays a pivotal role in regulating the cyclic peptide tertiary 
structure, which would have a substantial effect on the pharmacology of the metabolite. This 
hypothesis could be further confirmed with comparing the structure-activity of talarolides. In future, 
scale-up cultivation will be carried out to isolate the other related metabolites identified from the 
GNPS study to perform a structure-activity relationship study.  
In the initial report on talarolide A (4.1),10 N-Me-L-Ala was identified as its enantiomer N-Me-D-Ala. 
This could be a reason for the discrepancies observed by Zhang et al.11 for the synthetic and natural 
product data. Here we developed a new method for a better separation of N-Me-Ala enantiomers, and 
unambiguously identified the N-Me-L-Ala residue in talarolide A (4.1). A better analytical method 
has been developed in the Capon lab to address this issue, and a follow up study, including new 
talarolide analogues 4.2 and 4.3, will be published in future. 
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4.5. sordarin (4.4) 
 
HRESI(+)MS analysis of 4.4 returned a sodiated molecular ion ([M+Na]+) consistent with a 
molecular formula (C27H40O8 (Δppm –0.2) requiring 8 DBE. The 1H NMR (600 MHz, DMSO-d6) 
data (Figure 4.23, Table 4.2) revealed resonances for four terminal methyl (δH 1.12, 0.96, 0.89 and 
0.74), an aldehyde (δH 9.61), a methoxy (δH 3.23) and a deoxy sugar (δH 4.17, 3.50, 3.92, 3.00 and 
3.60), which were further supported by 2D NMR data (HSQC, COSY and HMBC) (Figure 4.24). A 
literature search with these structure fragments, and suggestive spectroscopic comparison, confirmed 
4.4 as the known fungal metabolite sordarin.9 
 
Figure 4.23: 1H NMR (600 MHz, DMSO-d6) spectrum for sordarin (4.4)   
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First reported in 1969, sordarin is a well-known antifungal metabolite that has two unique structural 
components, a diterpenoid aglycon named sordaracin and an unusual 6-deoxy-glycoside residue 
termed sordarose, connected through a β(1,2-cis)-glycoside linkage. Diagnostic 2D NMR data 
(Figure 4.24) established the planar structure of 4.4 as sordarin, and this was further confirmed by 
comparing experimental spectroscopic data with the literature (Table 4.3). Comparison of optical 
rotation data [α]23D –38.2 (c 0.05, MeOH) for 4.4 with the literature value [α]23D –34.9 (c 0.48, MeOH) 
suggested that 4.4 has the same configuration as reported for sordarin.9  
Table 4.2: NMR (600 MHz, DMSO-d6) data for sordarin (4.4).    
Pos. δC δH, mult (J in Hz) COSY HMBC 
1 147.6    
2 130.3 6.05, dd (3.4, 1.3) 3 6 
3 45.5 2.71, t (3.9) 2, 4  
4 28.5 a 1.13e  2, 3, 5, 7, 9, 17 
  b 1.80c 3 2, 3, 5, 7, 9, 17 
5 57.9    
6 71.7    
7 65.1    
8 28.8 a 1.63b  3, 7, 9, 13 
  b 1.59d 9 6 
9 40.7 1.66d 8, 13 10 
10 30.5 2.03a 20 13 
11 31.8 a 2.01a  13 
  b 1.16, m  20 
12 25.9 a 1.83c 13 13 
  b 0.90, m 13  
13 40.8 1.95b 9, 12 12 
14 27.2 2.21, m 15, 16 1, 2, 15 
15 22.4 0.90, d (6.8) 14 1, 14, 16 
16 20.9 0.97, d (6.8) 14 1, 14, 15 
17 203.9 9.62, s  5 
18 173.5    
19 73.8 a 3.73, d (9.4)  3, 7, 8 
  b 3.53, d (9.4)   
20 17.4 0.74, d (6.7) 10 9, 10, 11 
1' 98.6 4.42, br s 2' 2', 19 
2' 70.6 3.51, br s 1', 2'-OH, 3'  
3' 66.2 3.92, dd (4.2, 2.3) 2', 4'  
4' 79.4 2.99, dd, (9.4, 2.9) 3', 5' 4', 5' 
5' 67.9 3.60, dq (9.3, 6.2) 4', 5'  
6' 55.8 3.24, s  4' 
2'-OH  4.51, d (4.9) 2'  
3'-OH  4.78, d (3.9) 3'  
18-OH  13.16, brs   
a–f overlapping resonances. 
 
Figure 4.24: Key 2D NMR correlations for sordarin (4.4) 
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Table 4.3: Comparison of experimental 1H NMR (CDCl3) data of 4.4 with the literature  
Position Experimental Literature9 
δH, mult (J in Hz)a δH, mult (J in Hz)b 
1 9.72, s 9.72, s 
2 6.04, d (3.3) 6.08, d (3.2) 
3 4.65, s 4.66, s 
4 4.18, t (3.5) 4.22 dd (3.9, 3.0) 
5 4.10, d (9.3) 4.01 d (9.2) 
6 3.87, d (3.7) 3.90, d (3.9) 
7 3.67, qd (6.2, 9.1) 3.71, qd (6.1, 9.2) 
8 3.60, d (9.3) 3.68, d (9.2) 
9 3.39, s 3.42, s 
10 3.16, dd (9.1, 3.1) 3.21, dd (9.2, 3.0) 
11 2.63, t (3.7) 2.73, dd (4.1, 3.2) 
12 2.31, sp (6.7) 2.33, sp (6.8) 
13 2.07-1.98, m 2.12-2.00, m 
14 1.91, dd (12.7, 4.4) 1.96, dd (13.8, 5.6) 
15 1.88-1.85, m 1.91-1.86, m 
16 1.82, t (6.5) 1.81, dd (13.5, 13.1) 
17 1.77-1.71, m 1.75-1.71, m 
18 1.27, d (6.1) 1.30, d (6.1) 
19 1.27, d (12.9) 1.26, d (12.6) 
20 1.23-1.18, m 1.23-1.19, m 
21 1.00, d (6.7) 1.04, d (6.8) 
22 0.99-0.97, m 1.02-0.99, m 
23 0.96, d (6.8) 0.97, d (6.8) 
24 0.78, d (6.7) 0.79, d (6.6) 
Measured in (a) 600 MHz, CDCl3, (b) 500 MHz, CDCl3 
4.6. Biological assays 
Anti-proliferative activity of both talarolide (4.1) and sordarin (4.4) were tested against human lung 
cancer cell NCI-H460 and human colon cancer cells SW620, and none of the metabolites showed 
toxicity against tested cells. In the case of talarolide B (4.2) and C (4.3), insufficient material 
precluded bioactivity profiling. 
4.7. Conclusion 
 In this study we reported isolation and characterization of rare fungal cyclic peptides talarolides A–
C (4.1–4.3), together with a known metabolite sordarin (4.4). Production of talarolides was highly 
culture dependent, and thus, a culture condition that expressed all the metabolites of interest could 
not be identified. These results concluded that varying culture condition play a pivotal role in fungal 
secondary metabolite production, while demonstrating the power of varying culture conditions to 
explore the silent secondary metabolites. Further, we demonstrated that high-resolution mass 
spectrometry coupled with C3 and C18 Marfey’s analysis is a powerful approach for structure 
elucidation in peptidic natural products, particularly when the isolated quantity precludes accruing 
quality NMR data. 
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4.8. Future Directions 
The results showed that Talaromyces sp. CMB-TU011 has a wider secondary metabolite capacity to 
produce diverse secondary metabolites. Further supporting this, GNPS analysis revealed several 
molecular clusters containing culture-specific metabolites. Therefore, further analysis of GNPS 
molecular network would result in identifying rare secondary metabolites, which were silent under 
many culture conditions.  
4.9. Experimental 
4.9.1. General experimental 
See Appendix I: General Experiments, page 263.  
4.9.2. Fungus collection and taxonomic analysis 
Talaromyces sp. CMB-TU011 was isolated from an unidentified tunicate collected from Tweed 
Heads, NSW, Australia, on seawater based M1 agar medium plates incubated at 26.5 oC for 30 days. 
Genomic DNA from this isolate was extracted from the mycelia using the DNeasy Plant Mini Kit 
(Qiagen) as per the manufacturer’s protocol. The rRNA genes were amplified by PCR using the 
universal primers ITS 1 (5′-TCCGTAGGTGAACCTGCGG-3′) and ITS 4 (5′ TCCTCCGCTTATT 
GATATGC-3′) purchased from Sigma-Aldrich. The PCR mixture (50 µL) contained genomic DNA 
(1 µL, 20–40 ng), EmeraldAmp® GT PCR Master Mix (2X Premix) (25 μL), primers (0.2 μM, each) 
and H2O (up to 50 μL). PCR was performed using the following conditions: initial denaturation at 95 
°C for 3 min, 30 cycles in series of 94 °C for 30 s (denaturation), 55 °C for 60 s (annealing) and 72 
°C for 60 s (extension), followed by one cycle at 72 °C for 6 min. The PCR products were purified 
with PCR purification kit (Qiagen) and sequenced.  
ITS gene Sequence of CMB-TU011  
CTGGGCTCACCTCCCACCCGTGCCGTTATAATACCTGTTGCTTTGGCGGGCCCACTGGGGTCACCTGGTC
GCTGGGGGACGCCTGTCCCCGGGCCCGCGCCCGCCGAAGCACCCCCTGAACTCTGAAGAAGATAGTACT
GTCTGAGTACCTAGAAAATTGTCAAAACTTTCAACAATGGATCTCTTGGTTCCGGCATCGATGAAGAAC
GCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCCGTGAATCATCGAATCTTTGAACGCACATTG
CGCCCCCTGGCATTCCGGGGGGCATGCCTGTCCGAGCGTCATTTCTGCCCTCAAGCACGGCTTGTGTGTT
GGGTGTGGTCCCCCCGGGGACCTGCCCCAAAGGCAGCGGCGACGCCCGTCGGGTCCTCGAGCGCATGGG
GCTTTGTCACTCGCTCGGGAGGGACCTGCGGGGGTTGGTCACCACCAAATCTTTTACGGTTGACCTCGGA
TCAGGTAGGAGTTACCCGCTGAACTTAAGCATA 
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The ITS sequence was subjected to NCBI BLAST® analysis and results showed that the amplified 
ITS sequence has 99% homology with other members of the genus. The sequence was submitted to 
NCBI GenBank, International Nucleotide Sequence Database. Accession number: BankIt1937599 
CRCMQ025_H12 KX579124. A phylogenetic tree was constructed using ITS DNA sequences 
acquired from nucleotide collection (BLAST®, nr/nt) with 95% homology. PhyML Maximum 
Likelihood analysis was performed using optimal nucleotide substitution model JC69 (jModeltest2)3 
using Unipro UGENE (v1.24.2)4,5 and constructed the phylogenetic tree. 
4.9.3. Microbioreactor cultivation of CMB-TU011 
To investigate the wider secondary metabolite production of Talaromyces sp. CMB-TU011, the 
fungus was cultivated in 24-well microbioreactors that generate extracts across a range of culture 
media (×11) including solid, broth static and broth shaken. Briefly, from the well-grown fungal 
culture on Petri plate, mycelia/ spores were transferred using a sterile loop to microbioreactor deep 
well plates (2.5 mL agar or 1.5 ml of broth). The microbioreactor cultures were incubated at 26.5 °C 
for 10 days, with 190 rpm for shaken broth. The resulting ×33 cultures were extracted in situ with 
EtOAC (2.0 mL per well) followed by filtering to 2 mL vial and dried under N2. The secondary 
metabolite production across the different culture media and culture conditions were analysed by 
HPLC-DAD-ESIMS and UHPLC-QTOF. 
Table 4.4: Different culture media and conditioned used for the matrix analysis 
 Culture media 
Solid Static Shaken 
i M1 agar xii M1 broth  xxiii M1 broth  
ii ISP-2 agar xii ISP-2 broth xxiv ISP-2 broth 
iii ISP-4-agar xiv PY broth xxv PY broth 
iv Potato dextrose agar xv Potato dextrose broth xxvi Potato dextrose broth 
v YES agar xvi YES broth xxvii YES broth 
vi Sabouraud dextrose agar xvii Sabouraud dextrose broth xxviii Sabouraud dextrose broth 
vii Tryptic soy agar xviii Tryptic soy broth xxix Tryptic soy broth 
viii Basal agar xix Basal broth xxx Basal broth 
ix Czapek agar xx Czapek broth xxxi Czapek broth 
x M2 Agar xxi M2 broth xxxii M2 broth 
xi PYG agar xxii PYG broth xxxiii PYG broth 
4.9.4. Acquisition of UHPLC-QTOF data for GNPS molecular networking analysis   
UHPLC-QTOF-MS and MS/MS analyses were performed as described in Chapter 2. The MS/MS 
data were acquired with auto MS/MS analysis using fixed collision energy at 30.0 eV. The same 
method described in Chapter 2 was used for the GNPS molecular networking analysis, with default 
parameters. 
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4.9.5. Scale-up cultivation of Talaromyces sp. CMB-TU011 and isolation of 4.1–4.4  
Talaromyces sp. CMB-TU011 was cultivated on M1 salt (3.3% artificial sea salt) agar plates (×100) 
for 25 days at 26.5 °C, after which the combined agar/mycelia were extracted with EtOAc (4 × 500 
mL) to yield a crude extract (465 mg) which was sequentially partitioned between n-hexane (×4, 50 
mL) and 1% aqueous MeOH (50 mL) and dried in vacuo to yield hexane (203 mg) and MeOH (253 
mg) soluble. The MeOH solubles were further fractionated by gel chromatography (Sephadex® LH-
20, MeOH) into ×6 fractions, which were selectively combined on the basis of HPLC analysis 
(Zorbax SB-C8 column, analytical gradient 10% MeCN/H2O–100% MeCN inclusive of an isocratic 
0.05% formic acid/MeCN) to yield a fraction of interest (19 mg) that was resolved by optimized semi-
preparative HPLC (Zorbax SB CN column (9.4 mm × 25 cm) column, 25-40% MeCN/H2O elution 
at 3.0 mL/min inclusive of an isocratic 0.01% TFA/MeCN modifier) to yield talarolide A (4.1) (3.3 
mg), talarolide B (4.2) (0.5 mg) talarolide C (4.3) (0.3 mg) and sordarin (4.4) (4.1 mg) (Scheme 4.1). 
Talarolide A (4.1): white powder; [α]D22 –13.5 (c 0.05), MeOH); UV (MeOH) λmax (log ε) 202 (4.28), 
278 (1.89) nm; 1D and 2D NMR (600 MHz, DMSO-d6) see Tables 4.2 and Figures 4.8–4.11; 
HRESI(+)MS m/z 718.4139 [M+H]+ (calcd for C35H56N7O9 718.4134). 
Talarolide B (4.2): white powder; UHPLC-QTOF (MS/MS) fragmentation see Figure 4.19–4.22; 
HRESI(+)MS m/z 704.3976 [M+H]+ (calcd for C34H54N7O9 704.3978). 
Talarolide C (4.3): white powder; UHPLC-QTOF (MS/MS) fragmentation see Figure 4.19–4.22; 
HRESI(+)MS m/z 702.4198 [M+H]+ (calcd for C35H56N7O9 702.4185). 
Sordarin (4.4): colourless oil; [α]D22 –38.2 (c 0.10, MeOH); 1D and 2D NMR (600 MHz, DMSO-
d6) see Table 4.3 and Figure 4.23–4.24; HRESI(+)MS m/z 515.2617 [M+Na]+ (calcd for C27H40O8Na 
515.2615). 
4.9.6. Marfey’s analysis 
A sample of talarolides (50 µg) in 6 M HCl (100 µL) was heated to 100 °C in a sealed vial for 12 h, 
after which the hydrolysate was concentrated to dryness at 40 °C under a stream of dry N2. The 
hydrolysate was then treated with 1 M NaHCO3 (20 µL) and L-FDAA (1-fluoro-2,4-dinitrophenyl-5-
D-alanine amide) as a 1% (w/v) solution in acetone (40 µL) at 40 °C for 1 h, after which the reaction 
was neutralised with 1 M HCl (20 µL) and filtered (0.45 µm PTFE) prior to analysis. 
C3 Marfey’s analysis – An aliquot (10 µL) of analyte was subjected to HPLC-DAD-MS analysis 
(Agilent Zorbax SB-C3 column, 5 µm, 4.6 × 150 mm, 50 °C, with a 1 mL/min, 55 min linear gradient 
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elution from 15% to 60% MeOH/H2O, with a 5% isocratic modifier of 1% formic acid in MeCN) 
with amino acid content assessed by UV (340 nm) and ESI(±)MS monitoring, supported by single 
ion extraction (SIE) methodology, with comparison to authentic standards. 
C18 Marfey’s analysis – An aliquot (10 µL) of analyte was subjected to HPLC-DAD-MS analysis for 
(Agilent Zorbax SB-C18 HPLC column, 5 µm, 4.6 × 150 mm, 50 °C, with a 1 mL/min, 35 min isocratic 
elution of 23% MeOH/H2O and 34% MeOH/H2O for N-Me-Phe, with a 5% isocratic modifier of 1% 
formic acid in MeCN for N-Me-Ala) with amino acid content assessed by UV (340 nm), with 
comparison to amino acid authentic standards. 
2D C3 Marfey’s method – A sample of 4.1 (150 µg) in 2 M HCl (100 µL) was heated at 100 °C in a 
sealed vial for 2 to 3 h, after which the hydrolysate was concentrated to dryness at 40 °C under a 
stream of dry N2. The hydrolysate was then treated with 1 M NaHCO3 (20 µL) and D-FDAA (1% 
solution in acetone, 40 µL) at 40 °C for 1 h, after which the reaction was neutralised with 1 M HCl 
(20 µL), diluted with MeCN (100 µL), and filtered (0.45 µm PTFE) prior to HPLC-DAD-ESIMS 
analysis. An aliquot (2 µL) of the analyte was subjected to HPLC-DAD-ESIMS analysis (Agilent 
Zorbax SB-C3 column, 5 µm, 150 × 4.6 mm, 30 °C, with a 1 mL/min, 25 min linear gradient elution 
from 10% to 65% MeCN/H2O with a 5% isocratic modifier of 1% formic acid in MeCN) to detect 
the desired D-FDAA derivatisation of dipeptide or tripeptide. The remaining D-FDAA derivatised 
partial hydrolysate was subjected to fractionation by analytical HPLC (Agilent Zorbax SB-C3 
column, 5 µm, 4.6 × 150 mm, 30 °C, with a 1 mL/min, 25 min linear gradient elution from 10% to 
65% MeCN/H2O with a 5% isocratic modifier of 1% formic acid in MeCN) to yield pure sample of 
dipeptide (i). The peptide fragment was further hydrolysed [6 M HCl (100 µL), 100 °C 12 h] in a 
sealed vial after which was subjected C3 Marfey’s analysis (see above for method). 
4.9.7. Bioassays 
See Appendix A: General Experiment, page 265. 
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5. Chapter 5: Talaropeptides A–D: New linear peptides from Talaromyces sp. CMB-TU011 
This chapter describes the continued investigation carried out on Talaromyces sp. CMB-TU011 
cultured under different culture conditions. To identify an optimum culture condition for talarolide A 
(4.1), a new cyclic heptapeptide containing a rare hydroxamate residue, a recently developed 24-well 
microbioreactor approach (MATRIX) was employed. Talaromyces sp. CMB-TU011 was cultured in 
×11 different media, inclusive of solid agar as well as liquid static and shaken. The fungus CMB-
TU011 produced a wide range of metabolites across these culture conditions. The Global Natural 
Product Social Molecular Networking (GNPS) analysis revealed molecular clusters for cyclic as well 
as linear peptides (Figure 5.1). While Chapter 4 focused on cyclic peptide talarolides A–C (4.1–4.3), 
this chapter provides an account of the isolation, characterization and structure elucidation of four 
new linear peptides, talaropeptides A–D (5.1–5.4). Application of the MATRIX approach on CMB-
TU011 revealed N-methylated linear peptides in YES static broth culture, metabolites that were 
absent in M1 saline (3.3% artificial sea salt) agar cultures used to produce talarolide A (4.1). Structure 
elucidation of 5.1–5.4 was supported by detailed analysis of spectroscopic data (NMR and HRMS) 
and C3 and C18 Marfey’s analyses. Further, we report the biological properties of 5.1–5.5, and the 
mega non-ribosomal peptide synthetase (NRPS) responsible for the biosynthesis of talaropeptides. 
 
Figure 5.1: Talaropeptides containing subclusters. Metabolites highlighted in     have been isolated and characterised. 
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5.1. Chemical profiling of Talaromyces sp. CMB-TU011  
5.1.1. Analytical cultivation and chemical profiling 
To investigate the wider secondary metabolite potential and to identify an optimal condition for 
talarolide A (4.1), CMB-TU011 was cultured in 24-well microbioreactors at 26.5 oC for 10 days, 
generated extracts (×33) across a range of culture media (×11) including solid agar, broth static and 
broth shaken. The resulting ×33 cultures were extracted in situ with EtOAc and the secondary 
metabolite production analysed by HPLC-DAD-ESIMS and UHPLC-QTOF (MS/MS). Talaromyces 
sp. CMB-TU011 produced a range of secondary metabolites across the culture conditions, with the 
production of talarolide A (4.1) discussed in Chapter 4. UHPLC-QTOF (MS/MS) analysis supported 
by the GNPS analysis (Figure 5.1, see chapter 4 for more detail) revealed that CMB-TU011 produced 
a series of peptides (Figure 5.2, coloured in blue), m/z 1254.8 [M+H]+, m/z 1353.9 [M+H]+, m/z 1317.8 
[M+Na]+, m/z 1417.9 [M+Na]+), in YES and ISP-2 media, with YES broth static conditions being 
optimal (Figure 5.1). These metabolites were either not detected, or detected only at trace amounts in 
other culture extracts even when using single ion extraction (SIE) methodology.  
 
Figure 5.2: HPLC-DAD (210 nm) chromatogram of the EtOAc crude extract of Talaromyces sp. CMB-TU011 cultured 
on YES static broth eluted using Agilent Zorbax-SB-C8 column, with an analytical gradient 10% MeCN/H2O–100% 
MeCN inclusive of an isocratic 0.05% formic acid modifier. The inset shows four main peaks resolved by HPLC method 
development using Zorbax-SB-C3 column, with isocratic 40% MeCN/H2O inclusive of an isocratic 0.05% formic acid 
modifier. *Media background  
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To investigate the scalability of these new metabolites, CMB-TU011 was cultured in 250 mL conical 
flasks containing YES broth (80 mL) and incubated for 10 days at 26 oC in static condition. Culture 
flasks with an air permeable cotton plug and an air impermeable lid were used to investigate the effect 
of air permeation on growth (Figure 5.3). The fungus CMB-TU011 grew faster and produced 
relatively a thick mycelium in the flask with an air permeable cotton plug. Expression of the 
metabolites of interest was also substantially higher with a cotton plug (Figure 5.3) sugessting that 
good air permeation was preferred for growth/production of the metabolites. 
 
Figure 5.3: UHPLC-DAD (210 nm) chromatograms of the EtOAc crude extract of Talaromyces sp. CMB-TU011 
cultured on YES broth static. (a) with an air permeable cotton plug, (b) with an air impermeable cap and (c) YES media 
blank. The metabolites of interest are highlighted in blue. *Internal calibrant.  
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5.2. Scale-up fermentation of CMB-TU011 and isolation of 5.1–5.4 
Agar dices (~1 cm2 × 3) from seven days old CMB-TU011 M1 saline (3.3% artificial sea salt) agar 
plate cultures were used to inoculate conical flasks (10 × 500 mL) containing YES broth (160 mL), 
each covered with cotton plugs, and incubated for 10 days at 26.5 oC under static condition. After 
incubation, the combined culture broth (1.6 L) inclusive of fungal mycelia was extracted with EtOAc 
(4 × 500 mL) and dried in vacuo to yield the crude extract (1.65 g). This extract was subjected to 
sequential partitioning with n-hexane (200 mL) and aqueous MeOH (2% H2O, 50 mL). The MeOH 
soluble fraction (1150 mg) was subjected to Sephadex® LH-20 open column chromatography with 
MeOH (Scheme 5.1). The fractions with metabolites of interest were pooled and an aliquot was 
subjected to analytical HPLC to optimize a chromatographic method (Zorbax-SB-C3 column, with 
isocratic 40% MeCN/H2O inclusive of an isocratic 0.01% TFA modifier) (Figure 5.2 inset). Semi-
preparative HPLC with the optimized method (Zorbax-SB-C3 column, 250 × 9.4 mm, 5 µm, 3 mL/min 
elution over 30 min, isocratic 40% MeCN/H2O inclusive of 0.01% TFA modifier) afforded 
talaropeptides A–D (5.1–5.4) (Scheme 5.1, Figure 5.4).   
 
Scheme 5.1: The isolation scheme for Talaromyces sp. CMB-TU011. (a) n-hexane/MeOH solvent partitioning, (b) 
Sephadex® LH-20 open column chromatography, (c) Semi-preparative Zorbax-SB-C8 column, 250 × 9.4 mm, 5 µm, 3 
mL/min elution over 30 min, isocratic 40% MeCN/H2O inclusive of 0.01% TFA modifier. *Missing weights accounted 
for the other fractions. 
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Figure 5.4: Linear peptides (5.1–5.4) isolated from Talaromyces sp. CMB-TU011. 
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5.2.1. Talaropeptide A (5.1) 
 
talaropeptide A (5.1) 
HRESI(+)MS analysis of 5.1 returned a protonated molecular ion attributed to a molecular formula 
(C65H111N11O13, Δmmu – 0.1) requiring ´16 double bond equivalent (DBEs). The 1D NMR (DMSO-
d6) data for 5.1 (Figure 5.5 and Table 5.1) revealed resonances attributed to amino acid α-protons (δH 
4.14-5.77) and amide carbonyls (δC 167.5-173.7) (Figure 5.6)] while 1H-13C HSQC data (Figure 5.7) 
suggested ×11 amino acid residues. Further consideration of the 1D NMR data revealed resonances 
for a series of overlapping terminal methyls (δH 0.91-0.57), seven N-methyls (δH 2.85-3.04, δC 29.5-
30.8) and an aromatic amino acid residue (δH 7.12-7.17, δC 126.3, δC 128.0, δC 129.1 and δC 137.1).  
A C3 and C18 Marfey’s analysis (Figure 5.8) performed on 5.1 indicated the presence of L-Thr, L-Pro, 
L-Val, L-Leu, L-N-Me-Ala, L-N-Me-Val, L-N-Me-Phe and L-N-Me-Ile. Despite the highly overlapped 
NMR data, detailed analysis of 1D and 2D NMR (HSQC, COSY, HMBC and TOCSY) data (Table 
5.1) confirmed ×11 amino acid residues, of which seven were N-methylated. Further consideration 
of chemical formula and DBE necessitated that 5.1 be a linear peptide. The highly overlapped 1D and 
2D NMR data appeared could not deliver an unambiguous assignment of the 5.1 amino acid sequence.  
A UHPLC-QTOF-MS/MS analysis of 5.1 (Figure 5.9) exhibited predominantly a b-ion series 
suggestive of structure fragments L-N-Me-Ala1−Lxx−L-Val3−L-Thr4 and Lxx−L-N-Me-Phe9−L-N-
Me-Ile10−Lxx where Lxx could be isobaric L-Leu or L-N-Me-Val. The HMBC correlations (Figure 
5.10) from N-Me-L-Ala1-H3-3 (δH 1.09) and N-Me-L-Val2 (δH 2.87) to N-Me-L-Ala1-C-1 (δc 171.4) 
confirmed the N-terminus fragment as N-Me-L-Ala1−N-Me-L-Val2−L-Val3−L-Thr4. Diagnostic 2D 
NMR correlations (Figure 5.10) suggested a substantive structure fragment L-Pro6−N-Me-L-Val7−N-
Me-L-Val8−N-Me-L-Phe9−N-Me-L-Ile10−L-Leu11. The complete sequence of 5.1 was assigned as 
above considering both QTOF (MS/MS) fragmentation and diagnostic 2D NMR data. 
CO2HN
O
N
O N
N
O
N
O
O N
O
N
H
L-Pro6
L-N-Me-Phe9
L-N-Me-Ile10 L-Leu11N-Me-L-Val5
N-Me-L-Val7
L-N-Me-Val8
O
H
N
HO
O
N
H
O
N
O
N
H
N-Me-L-Ala1
N-Me-L-Val2
L-Val3
L-Thr4
Chapter 5: Talaropeptides A–D: New linear peptides from Talaromyces sp. CMB-TU011 
 
 
131 
 
Figure 5.5: 1H NMR (600 MHz, DMSO-d6) spectrum of talaropeptide A (5.1). X impurity. 
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Figure 5.6: 13C NMR (150 MHz, DMSO-d6) spectrum of talaropeptide A (5.1). 
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Table 5.1: NMR (DMSO-d6) data for talaropeptide A (5.1) 
 δH, multi, (J in HZ) δC COSY HMBC ROESY 
N-Me- L-Ala1       
1  171.4    
2 5.36, m 48.8 3 1 N-Me- L-Val2 
3 1.09a 14.3 2 1, 2  
N-Me 2.96, s 30.3f  1, 2 L-Val3-H-2 
N-Me- L-Val2      
1  167.5    
2 4.82, m 59.0 3 1, 3, N-Me-L-Ala1-C-1  
3 2.10 b 27.1 2, 4, 5   
4 0.87c 18.9g  3, 5  
5 0.71, d (6.4) 18.1h    
N-Me 2.87 29.5i  2, N-Me-L-Ala1-C-1  
L-Val3      
1  171.0    
2 4.42, m 56.2 3, NH 1, 3, 4/5 N-Me-L-Ala1 
3 1.97, m 29.4i 2, 4/5   
4, 5 0.80d 18.1h    
N-H 8.30, d (8.6)  2 1  
L-Thr4      
1  nd    
2 4.15, m 55.1 3  N-Me-L-Val5 
3 3.80, m 66.6 2, 4   
4 1.10a 19.3g 3 2, 3  
4-OH 5.84, d (4.6)  4   
N-H nd     
N-Me-L-Val5      
1  nd    
2 4.68e 61.3    
3 2.10b 26.3j    
4 0.87c 18.9g    
5 0.82d 19.2g    
N-Me 3.04, s 30.4f  2 L-Thr4-H-2 
L-Pro6      
1  172.1    
2 4.69e 56.3 3a, 3b 4 N-Me-L-Val7 
3 a 2.09b 28.5k 2, 4a, 4b, 3b 1, 5  
 b 1.50, m  2, 4a, 4b, 3a 1, 5  
4 a 1.92, m 24.4l 3a, 3b, 5a, 5b 2, 3  
 b 1.79, m  3a, 3b, 5a, 5b 2, 3  
5 a 3.70, m 47.0 4a, 4b 3, 4  
 b 3.53, m  4a, 4b 3, 4  
N-Me-L-Val7      
1  169.3    
2 4.80, m 57.5 3 1, 4/5, L-Pro6-C-1 N-Me-L-Val8 
3 2.15, m 26.2j 2   
4, 5 0.76, m 18.0h 3 2  
N-Me 2.87, s 29.7i  2, L-Pro6-C-1 L-Pro6-H-2 
N-Me-L-Val8      
1  168.5    
2 4.91, d (10.5) 57.7 3 1, 4, 5, N-Me N-Me-L-Phe9 
3 2.10d 26.3j 2 4, 5  
4 0.73, d (6.5) 19.1g 3   
5 0.56, d (6.5) 17.1  2, 3, 5  
N-Me 2.18, s 28.6k  2, N-Me-L-Val7-C-1 2, N-Me-L-Val7 
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N-Me-L-Phe9      
1  170.0    
2 5.77, t (7.6) 53.1 3 1, 3, N-Me, N-Me-L-Val8-C-1 5/9 
3 2.94, m 34.3 2 1, 4, 5  
4  137.3    
5/9 7.17, m  129.1 6, 8 5, 7  
6/8 7.22, m  128.0 5, 9 4, 8  
7 7.17, m  126.3    
N-Me 2.85, s 29.9i  1, 2, N-Me-L-Val8-C-1 2, N-Me-L-Val8 
N-Me-L-Ile10      
1  169.7    
2 4.69e 59.4 3 3, 4  
3 1.94, m 32.1 4, 6   
4 a 1.20, m  24.3l 3, 5   
 b 0.90, m     
5 0.78, m 10.0 4 2, 3  
6 0.86C 15.1 3 2, 3  
N-Me 2.94, s 30.4f  2  L-Leu11-H-2 
L-Leu11      
1  173.7    
2 4.11, m 50.3 3 1, 3, 4, 6, 5  
3 a 1.56, m 39.2 2, 3b, 4 1, 2, 4, 6, 5  
 b 1.48, m   2, 3a, 4 1   
4 1.57, m 24.2l 5, 6   
5 0.88c 22.8 4   
6 0.80d 21.3 4   
N-H 8.17, d (7.4)  2 2, 3, N-Me-L-Ile10-C-1  
OH nd     
a-e Assignments with the same superscript are overlapping. f-l Assignments with the same superscript may be interchanged. nd 
Resonances not detected. 
 
Chapter 5: Talaropeptides A–D: New linear peptides from Talaromyces sp. CMB-TU011 
 
 
135 
 
Figure 5.7: Expanded 1H–13C HSQC (DMSO-d6) spectrum for talaropeptide A (5.1) showing correlations for ×11 amino 
acid residues.  
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Figure 5.8: C3 Marfey’s analysis for talaropeptide A (5.1). Trace (a) is the C3 HPLC-DAD (340 nm) chromatogram that 
exhibits L-FDAA amino acid derivatives. Traces (b–h) are C3 HPLC-MS-SIE chromatograms for L-FDAA derivatives of 
amino acid standards (broken lines) and the acid hydrolysate of 5.1 (shaded peaks). The insets in (d) and (g) show the C18 
HPLC-DAD (340 nm) chromatograms.  Traces confirm that 5.1 incorporates (b) L-Thr (SIE m/z 372), (c) L-Pro (SIE m/z 
368), (d) N-Me-L-Ala (SIE m/z 356) (e) L-Val (SIE m/z 370) (f) N-Me-L-Val and L-Leu (SIE m/z 384), (g) N-Me-L-Phe 
(SIE m/z 432) and N-Me-L-Ile(SIE m/z 398). *Residual Marfey’s reagent. 
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Figure 5.9: UHPLC-QTOF-MS/MS fragmentations for talaropeptide A (5.1). The connectivity of amino acid residues 
confirmed with MS/MS fragmentation is highlighted in blue 
 
Figure 5.10: Key 2D NMR (DMSO-d6) correlations for talaropeptide A (5.1). Expansions (insets) show the key HMBC 
correlations for the amino acids highlighted in blue. 
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5.2.2. Talaropeptide B (5.2) 
 
talaropeptide B (5.2) 
HRESI(+)MS analysis of 5.2 returned a molecular ion [(M+H)+] consistent with a molecular formula 
(C70H120N12O14, Δmmu –1.9) requiring 17 DBEs, suggestive of a Val homologue of 5.1. The 1D NMR 
(DMSO-d6) data of 5.2 (Figure 5.11) revealed resonances closely resembling, and C3 Marfey’s 
analysis of 5.2 (Figure 5.12) identified the same suite of amino acid residues as 5.1. Although the 1H–
13C HSQC (DMSO-d6) data for 5.2 did not reveal resonances attributed to the additional Val residue, 
changing the solvent to methanol-d4  (Figure 5.13–5.15) confirmed the additional resonances (δH 3.50, 
δC 60.3). Diagnostic 2D NMR (HSQC, COSY, HMBC and TOCSY) data (methanol-d4) (Table 5.2) 
of 5.2 established the required ×12 amino acid residues.  
A UHPLC-QTOF-MS/MS fragmentation analysis of 5.2 (Figure 5.16) returned a similar 
fragmentation pattern to 5.1 comprising mostly b-ions, with the fragment N-Me-L-Ala1−N-Me-L-
Val2−L-Val3−L-Thr4−L-Val*− N-Me-L-Val5 incorporated the additional L-Val* residue. Comparison 
of 1H NMR (methanol-d4) data of 5.2 with 5.1 (Figure 5.17) indicated that L-Thr4 (H-2) had shifted 
downfield (δH 4.21 to 4.82) while the other resonances remain more or less same as 5.1, consistent 
with the L-Val3-L-Thr4-L-Val* connectivity suggested by MS/MS fragmentation. Detailed analysis of 
2D NMR (methanol-d4) data (Figure 5.18) established talaropeptide B (5.2) as N-Me-L-Ala1−N-Me-
L-Val2−L-Val3−L-Thr4−L-Val*−N-Me-L-Val5−L-Pro6−N-Me-L-Val7−N-Me-L-Val8−N-Me-L-
Phe9−N-Me-L-Ile10−L-Leu11.   
 
 
 
 
CO2HN
O
H
N
O
N
H
OH
O
H
N
O
N
O
N
O N
N
O
N
O
O N
O
N
H
O
HN
N-Me-L-Ala1
N-Me-L-Val2
L-Val3
L-Thr4
L-Val*
L-Pro6
N-Me-L-Phe9
N-Me-L-Ile10 L-Leu11N-Me-L-Val5
N-Me-L-Val7
N-Me-L-Val8
Chapter 5: Talaropeptides A–D: New linear peptides from Talaromyces sp. CMB-TU011 
 
 
139 
 
 
Figure 5.11: 1H NMR (600 MHz, DMSO-d6) spectrum of talaropeptide B (5.2). 
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Figure 5.12: C3 Marfey’s analysis for talaropeptide B 5.2. Trace (a) is the C3 HPLC-DAD (340 nm) chromatogram that 
exhibits L-FDAA amino acid derivatives. Traces (b-h) are C3 HPLC-MS-SIE chromatograms for L-FDAA derivatives of 
amino acid standards (broken lines) and the acid hydrolysate of 5.2 (shaded peaks). The insets in (d) and (g) show the C18 
HPLC-DAD (340 nm) chromatograms. Traces confirm that 5.2 incorporates (b) L-Thr (SIE m/z 372), (c) L-Pro (SIE m/z 
368), (d) N-Me-L-Ala (SIE m/z 356) (e) L-Val (SIE m/z 370) (f) N-Me-L-Val and L-Leu (SIE m/z 384), (g) N-Me-L-Phe 
(SIE m/z 432) and N-Me-L-Ile (SIE m/z 398). * residual Marfey’s reagents. 
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Figure 5.13: 1H–13C HSQC (methanol-d4) data for talaropeptide B (5.2), which shows resonance for the L-Val* residue 
(highlighted in green) 
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Figure 5.14: 1H NMR (600 MHz, methanol-d4) spectrum for talaropeptide B (5.2). 
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Figure 5.15: 13C NMR (150 MHz, methanol-d4) spectrum for talaropeptide B (5.2). 
 
Figure 5.16: UHPLC-QTOF-MS/MS fragmentation for talaropeptide B (5.2). The connectivity of amino acid residues 
confirmed with MS/MS fragmentation is highlighted in blue.  
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Table 5.2: NMR (methanol-d4) data for talaropeptide B (5.2) 
 δH, mult, (J in HZ δC COSY HMBC ROESY 
N-Me-L-Ala1      
1  174.3    
2 5.43, m 51.4 3 1, 3, N-Me N-Me-L-Val2 
3 1.27, d (6.9) 14.8 2 2  
N-Me 3.14, s 31.7j  2 L-Val3-H-2 
N-Me-L-Val2      
1  170.1    
2 4.98, d (10.8) 61.6 3 1, 3, 4, 5, N-Me-L-Ala1-C-1  
3 2.24a 28.7 2, 4   
4 0.97b 19.8k 3, 5 2, 3, 5  
5 0.82, d (6.6) 19.4l 4 2  
N-Me 3.01, s 31.5m  2, N-Me-L-Ala1-C-1 N-Me-L-Ala1-H-2 
L-Val3      
1  173.6n    
2 4.63, d (7.6) 56.2 3 1 N-Me-L-Ala1 
3 2.05c 31.7j 2, 4/5   
4 0.92d 18.6o 3 2  
5 0.93d 18.9o 3   
L-Thr4      
1  173.6n    
2 4.82f 56.6 3 1, 3, 4  
3 4.01, m 68.9 2, 4   
4 1.19, d (6.3) 20.3k 3 2, 3  
L-Va*      
1      
2 3.50, brs 60.3 3, 4/5   
3 2.08, m 33.4 2, 4/5   
4 0.93e 19.3l    
5 0.96b 17.9 2   
N-Me-L-Val5      
1  171.9    
2 4.69, d (11.0) 63.6 3 1, 3, N-Me  
3 2.23a 28. 0    
4 0.89g 19.9k    
5 0.80, d (6.5) 19.2l 3 2, 4  
N-Me 3.22, s 31.9j  2  
L-Pro6      
1  174.7    
2 4.80f 58.6 3a, 3b 4 N-Me-L-Val7 
3 a 2.21h 30.2p 2, 3b, 4a, 4b 1, 2  
 b 1.66, m  2, 3a, 4a, 4b 1, 2, 4  
4 a 2.04c 25.8q 3a, 3b, 4b, 5 2  
 b 1.91, m  3a, 3b, 4a, 5 2, 3  
5 a 3.71, m 49.0 4a, 4b 3, 4  
      
      
      
      
N-Me-L-Val7      
1  171.6    
2 4.91, d (10.6) 60.2 3 1, 3, N-Me, L-Pro6-C-1  
3 2.27, m 28.2 2, 4, 5   
4 0.89g 20.5 3   
5 0.86i 18.6o 3   
N-Me 3.02, s 31.1m  2, L-Pro6-C-1 L-Pro6-H-2 
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N-Me-L-Val8      
1  171.1r    
2 5.03, d (10.5) 60.1 3 1, 3 5, N-Me-L-Phe9 
3 2.22h 28.4 2, 4, 5   
4 0.83, d (6.7)  20.2k 3   
5 0.67, d (6.7) 18.2 3 3, 4  
N-Me 2.26, s 30.3p  2, N-Me-Val7-C-1 N-Me-L-Val7-H-2 
N-Me-L-Phe9      
1  172.8    
2 5.94, dd (10.3,5.4) 55.4 3 1, 3, N-Me, N-Me-L-Val8-C-1 N-Me-L-Ile10 
3 3.04, m 35.9 2 4, 5/9  
4  138.3 3   
5/9 7.21, m 130.5 6 7, 9  
6/8 7.28, m 129.7 7, 5 4, 8  
7 7.24, m 128.2 6, 8 5, 9  
N-Me 2.98, s 31.5j  2, N-Me-L-Val8-C-1 N-Me-L-Val8-H-2 
N-Me-L-Ile10      
1  171.1r    
2 4.76, d (11.4) 62.6 3 3, N-Me  
3 2.09, m 33.4 2, 4, 6   
4 a 1.31, m 25.9q 3, 5   
 b 1.02, m  3   
5 0.87i 10.7 4a, 4b 3  
6 0.94, d (6.6) 16.0 3 2, 3  
N-Me 3.04, s 31.6j  2, N-Me-L-Phe9-C-1 N-Me-L-Phe9-H-2 
L-Leu11      
1  nd    
2 4.34, br 54.5 3a, 3b   
3 a 1.64, m 43.1 2, 3   
 b 1.55, m     
4 1.59, m 26.5 3b, 5, 6   
5 0.92d 23.8 4   
6 0.91d 22.6    
a-i Assignments with the same superscript are overlapping. j-r Assignments with the same superscripts may be interchanged. nd 
Resonances not detected.  
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Figure 5.17: Comparison of 1H NMR (methanol-d4) data of (a) talaropeptide A (5.1) with (b) talaropeptide B (5.2).  
 
Figure 5.18: Key 2D NMR (methanol-d4) correlations for talaropeptide B (5.2). The connectivity established through the 
2D NMR data is highlighted in blue.    
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5.2.3. Talaropeptide C (5.3) 
 
talaropeptide C (5.3) 
HRESI(+)MS analysis of 5.3 returned a pseudo molecular ion consistent with a molecular formula 
(C67H113N11O14, Δmmu +1.5) requiring 17 double bond equivalent (DBE). The 1D NMR (methanol-
d4) data (Figure 5.19, Table 5.3) showed spectra closely resembling 5.1, with additional resonances 
attributed to an acetyl moiety (δH 1.99, δC 22.3) suggesting 5.3 as an acetylated analogue of 5.1. A C3 
Marfey’s analysis of 5.3 (Figure 5.21) revealed the same suite of amino acids as for 5.1. On UHPLC-
QTOF (MS) analysis (Figure 5.22), 5.3 returned an intense fragment ion at m/z 554.3562 (b5+) [m/z 
42 higher than the corresponding fragment ion (m/z 512.3447) for 5.1], arising from cleavage of the 
labile amide bond between N-Me-L-Val5 and L-Pro6 suggestive of possible connectivity of the acetyl 
moiety to the N-terminus fragment. The UHPLC-QTOF-MS/MS fragment ions b7+ to b10+ confirmed 
the structure fragment N-Me-L-Val7−N-Me-L-Val8−N-Me-L-Phe9−N-Me-L-Ile10−L-Leu11 similar to 
that of 5.1 (Figure 5.22). The HMBC (methanol-d4) data (Figure 5.23, Table 5.3) showed correlations 
from N-Me-L-Ala1 (δH 3.05) and N-COCH3 (δH 1.99) to a carbonyl at δC 173.6 confirming the 
connectivity of acetyl moiety to N-Me-L-Ala1. Diagnostic 2D NMR analysis supported by UHPLC-
QTOF (MS/MS) fragmentation analysis established the structure of 5.3 as an N-acetylated analogue 
of talaropeptide A (5.1). 
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Figure 5.19: 1H NMR (600 MHz, methanol-d4) spectrum for talaropeptide C (5.3). 
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Figure 5.20: 13C NMR (150 MHz, methanol-d4) spectrum for talaropeptide C (5.3).  
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Figure 5.21: C3 Marfey’s analysis for talaropeptide C (5.3). Trace (a) is the C3 HPLC-DAD (340 nm) chromatogram that 
exhibits L-FDAA amino acid derivatives. Traces (b–h) are C3 HPLC-MS-SIE chromatograms for L-FDAA derivatives of 
amino acid standards (broken lines) and the acid hydrolysate of 5.3 (shaded peaks). The insets in (d) and (g) show the C18 
HPLC-DAD (340 nm) chromatograms.  Traces confirm that 5.3 incorporates (b) L-Thr (SIE m/z 372), (c) L-Pro (SIE m/z 
368), (d) N-Me-L-Ala (SIE m/z 356) (e) L-Val (SIE m/z 370) (f) N-Me-L-Val and L-Leu (SIE m/z 384), (g) N-Me-L-Phe 
(SIE m/z 432) and N-Me-L-Ile (SIE m/z 398). *Residual Marfey’s reagents. 
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Figure 5.22. UHPLC-QTOF-MS/MS fragmentation for talaropeptide C (5.3). The connectivity of amino acid residues 
confirmed with UHPLC-QTOF (MS/MS) fragmentation is highlighted in blue. 
 
Figure 5.23. Key HMBC correlation for talaropeptide C (5.3). 
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Table 5.3. NMR (methanol-d4) data for talaropeptide C (5.3) 
 δH, mult, (J in Hz) δC COSY HMBC ROESY 
N-Me-L-Ala1      
1  174.3    
2 5.44, m 51.4 3 1, 3, N-Me N-Me-L-Val2 
3 1.27, d (6.9) 14.8 2 1, 2  
N-Me 3.14, s 31.7i  2, N-COCH3  
N-COCH3  173.6j    
N-COCH3 1.99, s 22.3k  N-COCH3  
N-Me-L-Val2      
1  170.1    
2 4.98, d (10.9) 61.5 3 1, 3, N-Me, N-Me-L-Ala1-C-1  
3 2.24a 28.6 2, 4   
4 0.97, d (6.5) 19.9l 3 2, 3, 5  
5 0.82, d (6.5) 19.3  2, 3,  
N-Me 3.01, s 31.1m  2, N-Me-L-Ala1-C-1 N-Me-L-Ala1-H-2 
L-Val3      
1  173.7    
2 4.63, d (7.6) 56.2 3 1  N-Me-L-Ala1 
3 2.06b 31.8i 2, 4/5   
4 0.91c 19.9l 3 2  
5 0.93c 18.6n 3   
L-Thr4      
1  174.0    
2 4.76d 56.6 3 1, 3, 4, L-Val3-C-1 N-Me-L-Val5 
3 3.99, m 68.9 2, 4 1, 4  
4 1.17, d (6.3) 20.0l 3 2, 3  
N-Me-L-Val5      
1  172.0    
2 4.69, d (11.1) 63.6 3 1, 3, N-Me, N-Me-L-Thr4-C-1  
3 2.24a 28. 0    
4 0.82g 19.9l  2, 3, 5  
5 0.90z 19.1n 3 2, 3, 5  
N-Me 3.19, s 31.8i  2, L-Thr4-C-1 L-Thr4-H-2 
L-Pro6      
1  174.8    
2 4.80, dd (8.4, 4.9) 58.6 3a, 3b 3, 4  
3 a 2.21f 30.2o 2, 3b, 4a,4b 1, 2  
 b 1.66, m  2, 3a, 4a, 4b 1, 2, 4  
4 a 2.05b 25.8p 3a, 3b, 5 2  
 b 1.92, m  3a, 3b, 5 2, 3  
5 3.71, m 48.9 4a, 4b 2, 3, 4  
N-Me-L-Val7      
1  171.7r    
2 4.91, d (10.6) 60.2 3 3, 4, 5, N-Me, L-Pro6-C-1 N-Me-L-Val8 
3 2.28, m 28.2q 4, 5   
4 0.90e 20.6    
5 0.86g 18.6    
N-Me 3.02, s 31.0m  2, L-Pro6-C-1 L-Pro6-H-2 
N-Me-L-Val8      
1  171.1    
2 5.03, d (10.6) 60.1 3 1, 3, 4, 5 N-Me-L-Phe9 
3 2.20f 28.3q 2, 4, 5   
4 0.84, d (6.7) 20.3 3   
5 0.67, d (6.7) 18.2 3 3, 4  
N-Me 2.27, s 30.3o  2, N-Me-L-Val7-C-1 N-Me-L-Val7-H-2 
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N-Me-L-Phe9      
1  172.9    
2 5.94, dd (9.8,5.7) 55.4 3 1, 3, N-Me, N-Me-L-Val8-C-1 N-Me-L-Ile10 
3 3.05, m 35.9 2 4, 5, 9  
4  138.2 3   
5/9 7.21, m  130.5 6/8 7, 9  
6/8 7.28, m  129.7 7, 5/9 4, 8  
7 7.24, m 128.2 6/8 5, 9  
N-Me 2.98, s 31.5i  2, N-Me-L-Val8-C-1 N-Me-L-Val8-H-2 
N-Me-L-Ile10      
1  171.7r    
2 4.75 62.5 3 3, 4, N-Me  
3 2.08, m 33.6 2, 4a, 4b   
4 a 1.32, m 25.9p 3, 4b   
 b 1.00, m  3, 4a   
5 0.87g 10.7  2  
6 0.96, d (6.6) 16.6 3   
N-Me 3.05, s 31.7i  2, N-Me-L-Phe9-C-1 N-Me-L-Phe9-H-2 
L-Leu11      
1      
2 4.30, br nd 3   
3 1.62z, m 42.4 2, 4   
4 1.61, m 26.5 3, 5/6   
5, 6 0.93e 22.6    
a-h Assignments with the same superscript are overlapped. i-r Assignments with the same superscript may be interchanged. nd 
Resonances not detected.  
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5.2.4. talaropeptide D (5.4) 
 
talaropeptide D (5.4) 
HRESI(+)MS analysis of 5.4 returned a pseudo molecular ion consistent with a molecular formula 
(C72H122N12O15, Δmmu −0.7) requiring 18 DBE. The 1H and 13C NMR (methanol-d4) data showed a 
spectrum closely resembling the other talaropeptides (5.1–5.3) (Figure 5.24, 5.25 and Table 5.4). The 
2D HSQC NMR (methanol-d4) data for 5.4 (Figure 5.26) showed resonances attributed to ×12 amino 
acid a-protons (δH 5.94–4.21, δC 63.9–51.7) with additional resonances attributed to an acetyl moiety 
(δH 1.99, δC 22.3), comparable with talaropeptide B (5.2) and suggestive that 5.4 was an acetylated 
analogue. This hypothesis was confirmed by the observation of an abundant ion at m/z 653.4240 (b6+, 
N-terminal fragment), 42 mass units higher than the most abundant ion (m/z 611.4146) observed for 
5.2 (Figure 5.27). By contrast, UHPLC-QTOF-MS/MS fragmentation of 5.4 did not show a clear 
fragment series observed for 5.2, possibly due to the sodiated molecular ion. However, UHPLC-
QTOF-MS/MS fragmentation did confirm the substantive structure fragment N-Me-L-Val7−N-Me-L-
Val8−N-Me-L-Phe9−N-Me-L-Ile10−L-Leu11. A C3 Marfey’s analysis (Figure 5.28) revealed the same 
amino acid residues, L-Thr, L-Pro, L-Val, L-Leu, N-Me-L-Ala, N-Me-L-Val, N-Me-L-Phe and N-Me-
L-Ile, identified for the other co-metabolites 5.1–5.3. Diagnostic 2D NMR data (Figure 5.29) 
identified a HMBC correlation from an acetyl methyl (N-COCH3, δH 1.9) and N-Me-L-Ala1 (δH 3.14) 
to the same carbonyl (δC 173.6) confirming N-terminus as an N-Ac-N-Me-L-Ala1. Further analysis of 
2D NMR data (HSQC, HMBC, COSY, TOCSY and ROESY) proved the structure of talaropeptide 
D (5.4) as shown above, with the following caveat. As the NMR and MS/MS data for 5.4 could not 
provide an experimental assignment of relative regiochemistry for the dipeptide fragment comprised 
of L-Val3 and L-Thr4, we draw on biosynthetic comparisons to the co-metabolite 5.2, as well a 
knowledge of the talaropeptide biosynthetic gene cluster (see Figure 5.30). 
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Figure 5.24: 1H NMR data (methanol-d4) for talaropeptide D (5.4).  
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Figure 5.25: 13C NMR data (methanol-d4) for talaropeptide D (5.4).  
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Table 5.4: NMR data (methanol-d4) for talaropeptide D (5.4)  
 δH, mult, (J in Hz) δC COSY HMBC ROESY 
N-Me-L-Ala1      
1  174.3    
2 5.45, m 51.3 3 1, 3, N-Me N-Me-L-Val2 
3 1.27, d (6.9) 14.8 2 1, 2  
N-Me 3.14, s 31.7g  2, N-COCH3  
N-COCH3  173.6h    
N-COCH3 1.99, s 22.5i  N-COCH3 L-Val2-H-2 
N-Me-L-Val2      
1  170.1    
2 4.98, d (10.9) 61.5 3 1, 3, N-Me, N-Me-L-Ala1-C-1  
3 2.24, m 28.6 2, 4   
4 0.98, d (6.5) 19.9j 3 2, 3, 5  
5 0.82, d (6.5) 19.3k  2, 4  
N-Me 3.01, s 31.5l  2, N-Me-L-Ala1-C-1 L-Ala1-H-2 
L-Val3      
1  173.7h    
2 4.63, d (7.6) 56.2 3 1, 3, 4, 5  N-Me-L-Ala1 
3 2.05a 31.8g 2, 4   
4 0.92b 19.8j 3 2  
5 0.93b 18.9m    
L-Thr4      
1  173.7h    
2 4.80c 56.4 3 1, 3, 4  
3 4.01, m 68.8 2, 4   
4 1.16, d (6.3) 20.0j 3 2, 3  
L-Val*      
1  173.9    
2 4.21, d (7.2) 60.4 3 1, 3, 4/5  
3 2.03a 31.9g 2, 4/5   
4 0.93b 18.8m 3  4/5 
5 0.92b 19.8j    
N-Me-L-Val5      
1  172.0    
2 4.69, d (11.0) 63.6 3 1, 3, N-Me   
3 2.21d 28. 0 2, 5   
4 0.89, d (6.5) 19.8j    
5 0.80, d (6.5) 19.2k 3 2, 4  
N-Me 3.20, s 31.8g  2, L-Val*-C-1  
L-Pro6      
1  174.8    
2 4.80c 58.6 3a, 3b 4  
3 a 2.21d 30.2n 2, 3b, 4a, 4b 1, 2  
 b 1.66e  2, 3a, 4a, 4b 1, 2, 4  
4 a 2.05a 25.8o 3a, 3b, 4b, 5 2  
 b 1.92, m  3a, 3b, 4a, 5 2, 3  
5 a 3.71, m 48.9 4a, 4b 3, 4  
      
N-Me-L-Val7      
1  171.7    
2 4.91, d (10.6) 60.2 3 1, 3, 4, 5, N-Me, L-Pro6-C-1 N-Me-L-Val8 
3 2.28, m 28.2p 2, 4, 5   
4 0.90b 18.6m 3   
5 0.86f 20.6 3   
N-Me 3.02, s 31.0l  2, L-Pro6-C-1  
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N-Me-L-Val8      
1  171.1q    
2 5.03, d (10.6) 60.2 3, 5 1, 3 N-Me-L-Phe9 
3 2.20d 28.3p 2, 4, 5   
4 0.83, d (6.7) 20.3 3 5  
5 0.67, d (6.7) 18.2 2, 3,  2, 3, 4  
N-Me 2.27, s 30.3n  2, N-Me-L-Val7-C-1 N-Me-L-Phe9-H-2 
N-Me-L-Phe9      
1  172.9    
2 5.94, dd (9.8, 5.7) 55.4 3 1, 3, N-Me N-Me-L-Phe9 
3 3.05, m 35.9 2 4, 5, 9  
4  138.3 3   
5/9 7.21, m 130.5 6/8 7, 5/9  
6/8 7.28, m 129.7 7, 5/9 4, 6/8  
7 7.24, m 128.2 6/8 5/9  
N-Me 2.98, s 31.6g  2, N-Me-L-Val8-C-1 N-Me-L-Val8-H-2 
N-Me-L-Ile10      
1  171.7q    
2 4.76, d (11.2) 62.6 3 3, 5, N-Me  
3 2.08, m 33.6 2, 4a, 4b, 6   
4 a 1.32, m 25.9o 3, 4b   
 b 1.00, m  3, 4a   
5 0.87f 1.07  2  
6 0.95, d (6.5) 16.0    
N-Me 3.05, s 31.7g  2, N-Me-L-Phe10-C-1 N-Me-L-Phe9-H-2 
L-Leu11      
1      
2 4.32, br s 54.7 3a, 3b   
3 a 1.65e 43.2 2, 3b   
 b 1.55, m  2, 3a, 4 5/6  
4 1.59, m 26.5 5, 6   
5 0.92b 22.6 4   
6 0.91b 22.5i 4   
a-fAssignments with the same superscript are overlapping. g-qAssignments with the same superscript may be interchanged. nd 
Resonances not detected. 
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Figure 5.26: 1H -13C HSQC data for talaropeptide D (5.4). Expansion shows the ×12 resonances observed for amino acid 
a-protons. The resonance attributed to acetyl moiety highlighted in green.     
 
Figure 5.27: UHPLC-QTOF-MS/MS fragmentation analysis for talaropeptide D (5.4). 
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Figure 5.28: C3 Marfey’s analysis of talaropeptide D (5.4). Trace (a) is the C3 HPLC-DAD (340 nm) chromatogram that 
exhibits L-FDAA amino acid derivatives. Traces (b–h) are C3 HPLC-MS-SIE chromatograms for L-FDAA derivatives of 
amino acid standards (broken lines) and the acid hydrolysate of 5.4 (shaded peaks). The inset in (d) and (g) shows the C18 
HPLC-MS-SIE chromatogram.  Traces confirm that 5.4 incorporates (b) L-Thr (SIE m/z 372), (c) L-Pro (SIE m/z 368), 
(d) N-Me-L-Ala (SIE m/z 356) (e) L-Val (SIE m/z 370) (f) N-Me-L-Val and L-Leu (SIE m/z 384), (g) N-Me-L-Phe (SIE 
m/z 432) and N-Me-L-Ile (SIE m/z 398). *Residual Marfey’s reagent. 
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Figure 5.29: Diagnostic HMBC correlations for talaropeptide D (5.4). 
5.3. Genome mining for Talaromyces sp. CMB-TU011 
The remarkable secondary metabolite capacity of CMB-TU011 demonstrated in this chapter and the 
previous chapter 4 encouraged us to explore the biosynthetic capacity of the CMB-TU011. In 
collaboration with the Australian Institute for Bioengineering and Nanotechnology (AIBN) and The 
University of Queensland, whole genome sequencing was carried out to identify the biosynthetic gene 
clusters, particularly for talaropeptides A–D (5.1–5.4). Dr. Zeinab Khalill extracted genomic DNA 
for genome sequencing with the help of visiting scientist Dr. Pablo Cruz-Morales who performed 
sequencing and the gene clusters identification. 
The genome sequence of Talaromyces sp. CMB-TU011 was obtained with coverage of 31X length 
of 27.5 MB with a GC content of 47 %, which is consistent with related species (Table 5.5). Natural 
product genome mining resulted in the identification of ×17 Biosynthetic Gene Clusters (BGCs, Table 
5.6) including three Non-Ribosomal Peptide Synthetases (NRPS). The original gene prediction by 
AntiSMASH v4.01 included mis-predicted introns that in fact corresponded to NRPS domains which 
were revealed after manual curation of the region coding for the NRPS gene.  
Table 5.5: Draft genome sequence of Talaromyces sp. CMB-TU011 
Length 27,481,273 
GC content 0.47% 
Coverage 31X 
Contigs 1652 
Closest relative (ITS as the marker) Talaromyces helicus (99% sequence identity) 
Biosynthetic gene clusters 17 
A very large intron-less megasynthase that includes ×12 modules and ×44 domains encoded in a 
single gene (45892 bases, 15297 amino acids) was identified from the annotated CMB-TU011 
genome.  Interestingly, this NRPS is only 3.2 kb smaller than the largest NRPS ever reported (49,104 
bases, plu2670, 16,367 amino acids), being that documented for the extensively N-methylated and 
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commercially important fungal cyclic undecapeptide cyclosporine from Tolypocladium inflatum 
(GenBank accesion: CAA82227, 15281 amino acids). 
The putative talaropeptide NRPS (Figure 5.30) showed an N-terminus condensation domain with a 
similar configuration to that of previously reported C domains associated with peptides incorporating 
N-terminal acyl moieties in the final product, which is consistent with N-acylation in talaropeptides 
C (5.3) and D (5.4).  This domain might have skipped during talaropeptide A (5.1) and B (5.2) 
biosynthesis or the N-Ac was hydrolysed post-synthetically. In agreement with the number of residues 
in talaropeptides B (5.2) and D (5.4), ×12 adenylation domains were detected. The predicted 
specificities for these domains are in agreement with the talaropeptide D (5.4) structure except for 
the modules 1, 4 and 7 (Table 5.7).  
Table 5.6: Biosynthetic gene clusters identified from the genome of Talromyces sp. CMB-TU011 
BGC Class Length (bases) 
Cluster 1 Nrps 54341 
Cluster 2 T1pks 25867 
Cluster 3 T1pks 58657 
Cluster 4 Terpene 14498 
Cluster 5 T1pks-Nrps 17407 
Cluster 6 Nrps 54562 
Cluster 7 T1pks-Nrps 59596 
Cluster 8 Indole 11095 
Cluster 9 T1pks 9202 
Cluster 10 Terpene 20118 
Cluster 11 T1pks 4917 
Cluster 12 Nrps 47837 
Cluster 13 Other 25557 
Cluster 14 Other 25196 
Cluster 15 Other 30346 
Cluster 16 Other 26175 
Cluster 17 Other 41913 
Seven methyl transferase domains, which are consistent with the multiple N-methylation sites in 
talaropeptides were found, with exceptions in the N-methyls of residue 1 and 2 which may be installed 
after NRPS assembly. Alternatively, the methyl transferase in module 3 appeared to be inactive on 
its corresponding extension step (Val3) and may be responsible for methylation of the first two 
residues (N-Me-Ala1 and N-Me-Val2). The methylation domain at module 5 (Val*) appears to be 
inactive during talaropeptides B (5.2) and D (5.4) biosynthesis. Despite modules 5 and 6 being 
predicted to incorporate N-Me-Val residues, only module 6 seems to be functional during 
talaropeptide A (5.1) and C (5.3) biosynthesis, which resulted in ×11 residues. Given that the 
methylation domain in module 5 seemed inactive and talaropeptides A (5.1) and C (5.3) incorporate 
Chapter 5: Talaropeptides A–D: New linear peptides from Talaromyces sp. CMB-TU011 
 
 
163 
N-Me-Val5, most likely the module 5 has skipped during the biosynthesis of talaropeptides A (5.1) 
and C (5.3). Finally, a thioesterase domain was detected at the C-terminus end of the talaropeptide 
synthase, which accounts for the release of the peptide product with a C-terminus carboxylic acid. 
 
Figure 5.30: Domain organisation of the talaropeptide synthase and biosynthetic logic of the talaropeptides. Biosynthesis 
of talaropeptide D (5.4) is depicted. Methylation domains marked with an asterisk (*) are skipped during biosynthesis. 
Module five highlighted in green skipped during talaropeptides A (5.1) and C (5.3) biosynthesis. 
Table 5.7: Comparison of a predicted product for ORFX (talaropeptide synthase) and the elucidated structure of 
talaropeptide D (5.4). Adenylation (A) domain specificity was calculated using the LSI based A-domain functional 
predictor.2 
Module Residue Prediction 
A domain 
LSI* score 
talaropeptide D 
Structure Comment 
1 N-Ac-L-Val 0.585 N-Ac-N-Me-L-Ala1 Adenylation domain promiscuity or new sequence motif, 
Post-NRPS methylation, Acylation (starter C domain) 
skipped in talaropeptides A and B 
2 L-Val 0.493 N-Me-LVal2 Post-NRPS methylation 
3 N-Me-L-Val 0.673 L-Val3 Skipped methylation domain 
4 L-Val 0.673 / 0  L-Thr4 Adenylation domain promiscuity or new sequence motif 
5 N-Me-L-Val 0.628 L-Val* Skipped methylation domain in talaropeptide D/ Skipped 
the module in talaropeptide A and C 
6 N-Me-L-Val 0.673 N-Me-L-Val5 Matched prediction 
7 L-Val/L-Pro 0.49 / 0.366 L-Pro6 Matched prediction 
8 N-Me-L-Val 0.673 N-Me-L-Val7 Matched prediction 
9 N-Me-L-Val 0.673 N-Me-LVal8 Matched prediction 
10 N-Me-L-Phe 0.482 N-Me-L-Phe9 Matched prediction 
11 N-Me-L-Ile 0.657 N-Me-L-Ile10 Matched prediction 
12 L-Leu 0.739 L-Leu11 Matched prediction 
* domain skipped during the biosynthesis of talaropeptide A (5.1) and C (5.3) 
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5.4. Screening for biological activities 
Talaropeptides A–D (5.1–5.4) were screened against human lung and colon carcinoma cell 
proliferation, with non-exhibiting cytotoxicity at up to 30 µM (Figure 5.31 and Table 5.8). 
 
Figure 5.31: Cytotoxicity screening data for talaropeptides A–D (5.1–5.4)  
Table 5.8: Cytotoxic activities (IC50 µM) of talaropeptides A–D (5.1–5.4) 
Cell line 5.1 5.2 5.3 5.4 
SW620 >30 >30 >30 >30 
NCI-H460 >30 >30 >30 >30 
We also examined the growth inhibitory activity of talaropeptides A–D (5.1–5.4) against a panel of 
microbes including Gram-positive and Gram-negative bacteria and fungi (Figure 5.32). Only 
talaropeptides A (5.1) and B (5.2) exhibited activity against Gram-positive Bacillus subtillis ATCC 
6051 (1.5 µM and 3.7 µM respectively), talaropeptides C (5.3) and D (5.4) with N-Ac moiety were 
not active (Table 5.9). 
From an ecological perspective, the link between antibacterial activity and acetylation suggests that 
control of N-acetylation, perhaps as a post-NRPS modification by hydrolysis of the acetyl group or 
by an unknown biosynthetic mechanism that leads to domain skipping, may bias production in favour 
of 5.1 and 5.2 as an antibacterial defence, or 5.3 and 5.4 as putative antibacterial prodrugs. In an 
ecological setting rich in microbial competitors, this putative biosynthetic mechanism of control may 
be mediated by inter-species or even inter-kingdom chemical communication. However, further 
research is necessary to confirm this plausible explanation for the antibacterial activity observed for 
N-acetylated talaropeptide A (5.1) and B (5.2).    
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Figure 5.32: Growth inhibitory activity of talaropeptides A-D (5.1–5.4)  
Table 5.9: Antimicrobial activities (IC50 µM) of talaropeptides A-D (5.1–5.4)  
Microbial strain ATCC 5.1 5.2 5.3 5.4 
Staphylococcus aureus 25923 >30 >30 >30 >30 
Staphylococcus aureus 9144 >30 >30 >30 >30 
Bacillus subtilis 6633 1.5 3.7 >30 >30 
Escherichia coli 11775 >30 >30 >30 >30 
Pseudomonas aeruginosa 10145 >30 >30 >30 >30 
Candida albicans 90028 >30 >30 >30 >30 
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Investigation on secondary metabolite production of Talaromycse sp. CMB-TU011 led to isolating 
four novel acyclic peptides talaropeptide A–D (5.1–5.4), a new class of extensively N-methylated 
linear peptide natural product featuring peptide amino acid sequences that are unprecedented in the 
scientific literature. To best of our knowledge, talaropeptides A–D (5.1–5.4) are the first linear 
peptides to be reported from Talaromyces sp. Neither the complete structure of talaropeptides, nor 
the N-terminus or C-terminus fragments (with four amino acid residues), gave close literature match, 
proving the novelty of the talaropeptide structures. 
Although fungi are well known to produce peptides,3 particularly cyclic peptides, the literature from 
Talaromycse sp. is limited to only three cyclic peptides (other than diketopiperazines); penta peptide 
cyclochlorotine4 (5.5) and hepta peptides talaromins A (5.6) and B (5.7)5 and talarolide A (4.1)6 from 
Talaromyces islandicus, Talaromyces wortmannii and Talaromyces sp. (CMB-TU011) respectively, 
with no reported linear peptides. Except non-proteinogenic amino acid containing peptaibols (more 
details are in chapter 6), linear peptides with proteinogenic amino acid are rare in fungal chemistry, 
only a hand full of linear peptides have been reported.  
 
A 2016 study by Liang et al.7 reported eight linear peptides simplicilliumtides A–H (5.5–5.14) 
isolated from a deep sea-derived fungal strain Simplicillium obclavatum EIODSF 020. None of the 
eight simplicilliumtides showed significant biological activity.  
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In contrast, linear lipopeptides cavinafungin A (5.15) and B (5.16) isolated from Colispora cavincola 
exhibited a broad-spectrum antifungal activity by inhibiting Candida sp. (MIC 0.5–4 µg/mL) and A. 
fumigatus (at 8 µg/mL).8 A 1998 study by Toske et al. reported two isomeric linear peptides, 
aspergillamides A and B from a marine-derived Aspergillus sp.9 and, recently, there new analogues 
of aspergillipeptides (aspergillipeptides E–G), were reported from a marine gorgonian-derived fungus 
Aspergillus sp. SCSIO 41501.10 In another study by Meyer et al. (2010) reported lumazine peptides 
penilumamide A (5.17) from a marine-derived Penicillium sp.11 Later, lumazine peptides B–D and 
structurally close lumazine peptides terrelumamides A and B were reported from Aspergillus sp.12 
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A chemical investigation on a red alga-derived fungus (K063) led to isolating rare linear 
dodecapeptides dictyonamides A (5.18) and B (5.19).13 Similar to those of talaropeptides, 5.18 and 
5.19 consist of seven N-methylated amino acids including five N-Me-Val. It is noteworthy that 
dictyonamides A (5.18) has shown inhibitory activity against cyclin-dependent kinase 4 with IC50 
value of 16.5 µg/ mL. Interestingly, the glycosylated analogue dictyonamides B (5.19) has not shown 
the inhibitor activity. A 2006 study by Claudia et al.14 reported isolation and characterization of 
highly N-methylated linear octapeptides RHM 1 (5.20) and RHM 2 (5.21) from a marine sponge-
derived Acremonium sp. 
 
In medicinal chemistry, peptides have limited potentials due to their poor pharmacokinetic properties, 
with a short half-life as a consequence of rapid degradation by exo- and endo-peptidases in cellular 
environment.15 However, naturally occurring immunomodulatory cyclic peptide, cyclosporine 
demonstrated that multiple N-methylated peptides gain remarkable pharmacokinetic properties 
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including oral bioavailability. Inspired by nature’s ingenious technique to modulate the biological 
properties of peptides, N-methylation of peptides has been used as a tool to improve the stability of 
peptides.16 Several N-methylated peptides are currently in the clinical pipeline to be developed as 
future clinical drugs.17 Given that, we can postulate that talaropeptides A–D (5.1–5.4) might have 
substantially higher stability against enzymatic degradation in cells or cell culture.  
To investigate the stability of the talaropeptides in a cellular environment, the stability of 
talaropeptide D (5.4) was tested in rat plasma as described previously.18 As might be predicted for an 
extensively N-methylated linear peptide, talaropeptide D (5.4) proved stable in rat plasma (Figure 
5.33). 
 
Figure 5.33: UHPLC-QTOF-MS data for talaropeptide D (5.4) incubated in rat plasma. Single ion extraction [1417.9, 
(M+Na)+] analysis was performed for samples incubated at different time points (0 – 3 h). 
5.5. Conclusion 
This chapter describes the isolation and characterization of 4 extensively N-methylated linear 
peptides, with amino acid sequences that are unprecedented in the scientific literature. The discovery 
that talaropeptide production was highly culture media and phase dependent (i.e., YES broth, static 
flask with an air permeable seal) raises the possibility that the paucity of published fungal linear 
peptides may be due to a bias for cultivation conditions those disfavour linear peptides. Our 
application of systematic miniaturized microbioreactor approach to trialling cultivation conditions 
(i.e., MATRIX) provides a low cost, practical means to access this silent potential. That the 
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talaropeptide pharmacophore lacks mammalian cell cytotoxicity, and exhibits highly selective 
antibacterial properties (albeit with modest potency), with a clear structure-activity relationship 
requirement built around N-terminal acetylation, is encouraging to investigate the true ecological 
purpose of these fungal metabolites. 
5.6. Future directions 
 The GNPS analysis revealed that Talaromyces sp. CMB-TU011 produces many talaropeptide 
analogues. Isolation and characterization of those metabolites would further the knowledge in the 
structure activity relationship, biosynthesis and ecological role of talaropeptides. Moreover, Genome 
mining also demonstrated that Talaromyces sp. CMB-TU011 holds a great biosynthetic potential (17 
different gene clusters) to produce structurally diverse metabolites, which were further proved by the 
media MATRIX study. Therefore, further studies could be performed to exploit the biosynthetic 
capacity of CMB-TU011. 
5.7. Experimental 
5.7.1. General experimental 
See Appendix A: General Experiments, page 263.   
5.7.2. Fungus collection and taxonomic analysis 
Talaromyces sp. CMB-TU011 was isolated from an unidentified tunicate collected near Tweed 
Heads, NSW, Australia, and taxonomically identified as described in Chapter 4.    
5.7.3. Microbioreactor cultivation of CMB-TU011 
To investigate the wider secondary metabolite production of Talaromyces sp. CMB-TU011, the 
fungus was cultured in 24-well microbioreactors that generate extracts across a range of culture media 
(x11) including solid agar, broth static and broth shaken. Refer to Chapter 4 Experimental section 
4.9.3, page 120.  
5.7.4. Scale-up cultivation of Talaromyces sp. CMB-TU011 and isolation of 5.1–5.4  
Agar cubes (~1 cm2) recovered from 7 day old cultures (3.3% artificial sea salt containing M1 
medium) were used to inoculate ×10 flasks (500 mL) charged with YES broth (160 mL). Individual 
flasks were covered with air permeable sterile cotton plugs and incubated under static conditions for 
10 days at 26.5 oC, after which the combined broths/mycelia were extracted with EtOAc (4 × 500 
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mL) to yield a crude extract (1.65 g) which was partitioned between hexane (200 mL) and 1% aqueous 
MeOH (50 mL) and dried in vacuo to yield hexane (495 mg) and MeOH (1.15 g) solubles. The MeOH 
solubles were further fractionated by gel chromatography (Sephadex® LH-20, MeOH) into ×20 
fractions, which were selectively combined on the basis of HPLC analysis (Zorbax-SB-C8 column, 
analytical gradient 10% MeCN/H2O–100% MeCN inclusive of an isocratic 0.05% formic acid) to 
yield a fraction of interest (49 mg) that was resolved by optimized semi-preparative HPLC (Zorbax-
SB-C3 column (9.4 mm × 25 cm) column, 40% MeCN/H2O elution at 3.0 mL/min inclusive of an 
isocratic 0.01% TFA modifier) to yield talaropeptide A (5.1) (1.3 mg), talaropeptide B (5.2) (1.3 mg), 
talaropeptide C (5.3) (1.8 mg) and talaropeptide D (5.4) (2.8 mg) (Scheme 5.1). 
Talaropeptide A (5.1): white powder; [α]D22 −135.8 (c 0.04, MeOH); 1D and 2D NMR (600 MHz, 
DMSO-d6) see Tables 5.1 and Figures 5.3-5.3 and 5.5, 5.8; HRESI(+)MS m/z 1254.8435 [(M+H)+] 
(calcd for C65H112N11O13, 1254.8436). 
Talaropeptide B (5.2): white powder; [α]D22 −110.0 (c 0.05, MeOH); 1D and 2D NMR (600 MHz, 
methanol-d4) see Tables 5.2 and Figures 5.9, 5.11, and  5.13; HRESI(+)MS m/z 1375.8920 [M+Na]+ 
(calcd for C70H120N11O14Na, 1375.8939). 
Talaropeptide C (5.3): white powder; [α]D22 −151.6 (c 0.05), MeOH); 1D and 2D NMR (600 MHz, 
methanol-d4) see Tables 5.3 and Figures 5.15, 5.18, 5.19; HRESI(+)MS m/z 1318.8376 [(M+Na)+] 
(calcd for C67H113N11O14Na, 1318.8361). 
Talaropeptide D (5.4): white powder; [α]D22 −182.9 (c 0.05), MeOH); 1D and 2D NMR (600 MHz, 
methanol-d4) see Tables 5.4 and Figures 5.20 and 5.23; HRESI(+)MS m/z 1417.9052 [(M+Na)+] 
(calcd for C72H122N12O15Na, 1417.9045). 
5.7.5. Marfey’s analysis 
A sample of talaropeptides (50 µg) in 6 M HCl (100 µL) was heated to 100 °C in a sealed vial for 12 
h, after which the hydrolysate was concentrated to dryness at 40 °C under a stream of dry N2. The 
hydrolysate was then treated with 1 M NaHCO3 (20 µL) and L-FDAA (1-fluoro-2,4-dinitrophenyl-5-
D-alanine amide) as a 1% solution in acetone (40 µL) at 40 °C for 1 h, after which the reaction was 
neutralised with 1 M HCl (20 µL) and filtered (0.45 µm PTFE) prior to analysis. 
C3 Marfey’s analysis - An aliquot (10 µL) of analyte was subjected to HPLC-DAD-MS analysis 
(Agilent Zorbax-SB-C3 column, 5 µm, 4.6 × 150 mm, 50 °C, with a 1 mL/min, 55 min linear gradient 
elution from 15% to 60% MeOH/H2O, with a 5% isocratic modifier of 1% formic acid in MeCN) 
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with amino acid content assessed by UV (340 nm) and ESI(±)MS monitoring, supported by single 
ion extraction (SIE) methodology, with comparison to authentic amino acid standards. 
C18 Marfey’s analysis- An aliquot (10 µL) of analyte was subjected to HPLC-DAD-MS analysis for 
(Agilent Zorbax SB-C18 HPLC column, 5 µm, 4.6 × 150 mm, 50 °C, with a 1 mL/min, 35 min isocratic 
elution of 23% MeOH/H2O and 34% MeOH/H2O for N-Me-Phe, with a 5% isocratic modifier of 1% 
formic acid in MeCN for N-Me-Ala) with amino acid content assessed by UV (340 nm), with 
comparison to authentic standards. 
5.7.6. Genome mining of Talaromyces sp. CMB-TU011 
Genomic DNA from Talaromyces sp. CMB-TU011 was extracted using a standard chloroform 
protocol.19 The extracted DNA was fragmented using a Covaris focused ultrasonicator and the 
resulting fragments (∼1KB) were used for library construction using a Thrulex DNA-Seq kit 
(Rubicon Genomics). The library was sequenced using a Next Seq platform in the paired-end (2 × 
150) format to yield a total of 6,674,290 reads (1 GB). The raw reads were filtered and trimmed using 
Trimmomatic v0.3620 to yield a total of 5,821,558 high-quality reads (0.873 GB), which were 
assembled using Velvet 1.2.1021, Abyss v.2.0.322 and SPAdes v3.11.123 assemblers with a window 
of Kmers between 41 and 121, with iterations every 10 units. The Best assembly (Velvet with Kmer 
=51) was annotated for natural products biosynthetic gene clusters using the Fungal implementation 
of AntiSMASH 4.0.24 The output was manually curated and domain annotation was improved using 
pFAM25 and the NCBI Conserved Domain Search tool. 
5.7.7. Bioassays 
See Appendix I: General Experiment, page 261.  
5.7.8. Plasma stability assay 
An aliquot of talaropeptide D (5.4) (10 µL, 1 mM in DMSO) was added to rat plasma (190 µL) pooled 
from >3 different rats and heated to 37◦C in a circulating water bath. Aliquots (20 µL) were taken at 
time points 0, 60, 120, and 180 min and added to MeCN (80 µL). Samples were centrifuged at 13,000 
g for 3 min, and the supernatants concentrated to dryness under N2. After resuspending in MeOH (30 
µL), an aliquot (1 µL) was analysed by UHPLC-QTOF (MS), to detect and quantify residual 
talaropeptide D (5.4).  
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6. Chapter 6: Emeramides: New peptaibols from marine fish gut-derived fungi  
In the bioactivity profiling (see Chapter 2 for more details), the crude extract of CMB-F206, a fungus 
isolated from Mugil cephalus (sea mullet) intestinal tissues, showed strong cytotoxic activity. 
Chemical profiling revealed that the fungus CMB-F206 produces a series of peptides. A closely 
related strain, CMB-F057 from the same fish gut-derived fungal collection, was observed to produce 
a similar suite of peptides. Sequence analysis of fungal ribosomal DNA showed both fungi to be 
closely related Emericellops sp., a genus known to produce linear peptides, peptaibols. Detailed 
chemical investigation of CMB-F206 and CMB-F057 resulted in the isolation of a series of closely 
related new peptaibols (6.1–6.8), together with the known 16 amino acids peptaibol, antiamoebin I 
(6.9).  
Antiamoebin I (6.9) was first described by Thirumalachar in 1968,1 and later in 1977, Pandey et al.2 
confirmed the structure by detailed analysis of mass spectroscopic data. A 1998 study by Snook et 
al.3 reported the crystal structure of 6.9. To date, a number of closely related metabolites, including 
antiamoebin analogues, have been reported. However, many scientific literature claims are 
incomplete due to a lack of evidence for unambiguous assignment of amino acid configuration, and 
trivial names. In particular, a number of metabolites have been characterized from heterogeneous 
mixtures of the peptides based solely on HPLC-MS/MS analyses.4 Given ambiguities in the literature, 
we set out to characterise and identify emeramides A–H (6.1–6.8) through a combination of 1D and 
2D NMR, UHPLC-QTOF-MS/MS, and Marfey’s analyses. This chapter presents the chemical 
investigation, including the isolation, characterization, identification and biological activity of 
emeramides A–H (6.1–6.8) from Emericellopsis spp. CMB-F206 and CMB-F057. 
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6.1.  Chemical investigation  
6.1.1. Fungal isolation and phylogenetic analysis of the strains 
A previous occupational trainee student in the Capon group, Ms. Pamela Abdala, collected a fresh 
sea mullet, Mugil cephalus, from a local fish market, and following surface sterilization and 
dissection, isolated a library of fungi and bacteria from gastrointestinal tissues. This library included 
the two investigated fungi, CMB-F206 and CMB-F057. A visiting scientist in the Capon group, Dr. 
Tijiang Shan contributed to taxonomical identification of the fungus CMB-F057, analytical 
cultivation, isolation and characterisation of the metabolites.  
Genomic DNA was extracted from both CMB-F206 and CMB-F057 using a blood and tissue kit 
(QIAGEN), and ITS1 and ITS4 regions were sequenced. The sequences were analysed using Basic 
Local Alignment Search Tool (BLAST) of National Center for Biotechnology Information (NCBI), 
and the phylogenetic tree (Figure 6.2) revealed more than 95% homology between CMB-F206 and 
CMB-F057. This analysis also confirmed that CMB-F057 to be closely related to an Emericellopsis 
humicola strain (GU390691.1). By contrast, CMB-F206 showed 99% homology to both Stilbella 
fimetaria (FJ430712.1) and Emericellopsis synnematicola (AY632665.1). As the microscopic 
morphological examination of CMB-F206 and CMB-F057 showed conidia and conidiophores 
characteristic to Emericellopsis sp. (Figure 6.1) we propose both as Emericellopsis sp.  
 
Figure 6.1: Morphology of the fungal strains CMB-F206 and CMB-057. (a) Photograph of the CMB-F206 cultured on 
ISP-2 medium (left) and a microscopic image of the strain (right). (b) Photograph of the CMB-F057 cultured on ISP-2 
medium (left) and a microscopic image of the strain (right). 
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Figure 6.2: Phylogenetic analysis of CMB-F206 and CMB-F057. The PhyML Maximum Likelihood analysis of ITS 
DNA sequences was performed using optimal nucleotide substitution model determined by jModeltest298 using 
UGENE99 software. The relationship of CMB-F206 and CMB-F057 to nucleotide sequences (nr/nt, GenBank) that 
showed more than 95% homology shown with accession numbers indicated in brackets, highlighted in blue.  
Acremonium sp. | LN810517.1 |
Acremonium tubakii | KP131532.1| 
Acremonium sp.  | LN810516.1 |
Stilbella fimetaria | FJ939394.2 | 
Emericellopsis pallida | NR_145052.1 |
Emericellopsis pallida | KU933708.1 |
Acremonium exuviarum | NR_077167.1 |
Acremonium dichromosporum | NR_077122.1 |
Acremonium sp. | KT270068.1 |
 Emericellopsis terricola | KF156303.1 |
Emericellopsis humicola | HQ596913.1 | 
 Emericellopsis sp. | KM268654.1 | 
Acremonium tubakii | KF915990.1 |
Emericellopsis terricola | KT151582.1 |
 Emericellopsis sp. | KX381180.1 | 
Emericellopsis terricola | KT223350.1 |
Emericellopsis humicola | KF246065.1 | 
CMB-F057
Emericellopsis humicola | GU390691.1 | 
Emericellopsis pusilla | AB425989.1 |
Emericellopsis donezkii | AY632658.1 |
Emericellopsis persica | KX668543.1 |
Emericellopsis minima | AY632661.1 | 
Emericellopsis minima | KT290873.1 |
Emericellopsis minima | KT290876.1 |
Emericellopsis minima | JX076954.1 |
Emericellopsis minima | FJ713093.1 | 
Emericellopsis terricola | KM277985.1 |
Emericellopsis sp. | AB563189.1 | 
Emericellopsis sp. | KJ196386.1 | 
Emericellopsis sp. | KP216937.1 |
Emericellopsis microspora | AB425983.1 |
Acremonium sp. | JX535052.1 |
Acremonium sp. | JX535153.1 |
Emericellopsis terricola | FJ430737.1 |
Emericellopsis terricola | U57676.1 | 
Acremonium sp. 86 | JX535094.1 |
Emericellopsis terricola | HQ698592.1 | 
Emericellopsis minima | KC987174.1 |
Emericellopsis minima | KR709200.1 |
Stilbella fimetaria | FJ430712.1 |
Emericellopsis synnematicola | AY632665.1 | 
Stilbella fimetaria | KX446764.1 |
Stilbella fimetaria | AY952467.1 | 
Emericellopsis salmosynnemata |AY632666.1 | 
Stilbella fimetaria | JX967102.1 | 
CMB-F206
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6.2. Chemical profiling of CMB-F206 and CMB-F057 
6.2.1. Analytical scale cultivation and chemical profiling 
The fungal strains were cultured on ISP-2 medium and incubated at 26.5 oC for 10 days. After 
incubation, agar plates together with mycelium were extracted with EtOAc followed by drying in 
vacuo to generate crude extracts. The crude extracts were subjected to HPLC-DAD-MS and UHPLC-
QTOF-MS/MS analysis. HPLC-DAD-MS analysis revealed that both strains produce a suite of 
similar metabolites, while UHPLC-QTOF-MS/MS analysis suggested that metabolites eluting from 
tR 9.5 to tR 11.0 (Figure 6.3) were peptides.  
 
Figure 6.3: HPLC-DAD-MS (210 nm) chromatograms of the crude extracts. (a) CMB-F206 and (b) CMB-F057 cultured 
on ISP-2 agar. The extracts eluted using Zorbax-SB C3 column with 1.0 mL/min, 10% MeCN/H2O to 100% MeCN 
inclusive of 0.5% formic acid modifier over 15 min. 
To investigate the secondary metabolite potential and to find optimum culture conditions for the 
production of peptides, both strains were cultured on ×11 different culture media, including broth 
static and broth shaken, using a 24-well microbioreactor miniaturized culture approach, known in the 
lab as MATRIX (Figure 6.4). The resulting ×33 extracts were subjected to HPLC-DAD-MS and 
UHPLC-QTOF- MS/MS analysis. Despite minor variations, changing culture conditions did not 
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show a noteworthy effect on secondary metabolite capacity of both CMB-F206 and CMB-F057. 
Considering the amount of material produced by the strains, ISP-2 agar and PYG agar were selected 
for scaled-up cultivation for CMB-F206 and CMB-F057, respectively.  
 
Figure 6.4: Photograph of the 24-well microbioreactor plates inoculated with CMB-F206 (highlighted in red) and CMB-
F057 (highlighted in blue). (a) agar, (b) broth statics and (c) broth shaken.   
6.2.2. Preparative cultivation and isolation of peptaibols 
A loop full of spores from 7 day old CMB-F206 and CMB-F057 ISP-2 agar plate cultures were 
streaked on ISP-2 (×35) and PYG (×100) agar plates, respectively, and incubated at 26.5 oC for 10 
days. After incubation whole agar together with mycelia were extracted with EtOAc (4 × 500 mL) 
and dried in vacuo to obtain crude extracts from CMB-F206 (470 mg) and CMB-F057 (2 g). The 
crude extracts were then sequentially partitioned with n-hexane and MeOH followed by evaporated 
to dryness under N2. The MeOH soluble fraction (450 mg) of CMB-F206 was loaded onto an Agilent 
Bond Elute solid phase extraction (SPE) column and eluted with a stepwise gradient (20% 
MeCN/H2O–100% MeCN) to yield 20 fractions. The fractions containing peptides were pooled and 
subjected to semi-preparative HPLC to yield emeramides A–D (6.1–6.4) together with the known 
peptaibol antiamoebin I (6.9) (Scheme 6.1, Figure 6.5). An aliquot (120 mg) of the MeOH soluble 
fraction from CMB-F057 was subjected to semi-preparative HPLC to yield emeramides E–H (6.5–
6.8) (Scheme 6.1, Figure 6.5).  
 
 Scheme 6.1: Isolation scheme for (a) CMB-F206 and (b) CMB-F057.  
Crude Extract
470 mg
(ii)
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11 mg
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n-hexane soluble
20 mg
MeOH soluble
450 mg
(i) Solvent partitioning
(ii) SEP fractionation (MeCN/H2O 20%-100% stepwise gradient)
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Figure 6.5: Analytical HPLC-DAD-MS (210 nm) chromatograms of the fractions containing peptides. (a) MeOH soluble 
fraction of CMB-F206 eluted with Zorbax-SB-C3 column, 1.0 mL/min, isocratic 40% MeCN/H2O inclusive of 0.05% 
formic acid. (b) MeOH soluble fraction of CMB-F057 eluted with Zorbax-SB-C3 column, 1.0 mL/min, isocratic 35% 
MeCN/H2O inclusive of 0.05% formic acid.   
 
. AA5 AA8 AA12 
emeramide A (6.1) Aib Aib Aib 
emeramide B (6.2) D-Iva Aib Aib 
emeramide C (6.3) Aib Aib D-Iva 
emeramide D (6.4) D-Iva L-Ala D-Iva 
emeramide E (6.5) Aib D-Iva Aib 
emeramide F (6.6) D-Iva D-Iva Aib 
emeramide G (6.7) Aib D-Iva D-Iva 
emeramide H (6.8) D-Iva D-Iva D-Iva 
antiamoebin I (6.9) D-Iva Aib D-Iva 
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6.3. emeramide A (6.1) 
 
Emeramide A (6.1) was isolated as a white amorphous powder. HRESI(+)MS analysis of 6.1 returned 
a sodiated ion consistent with a molecular formula (C80H123N17O20, Δmmu –2.8) requiring ×28 double 
bond equivalent (DBEs). The 1H NMR (DMSO-d6) data (Figure 6.6 and Table 6.1) for 6.1 revealed 
resonances attributed to amino acid α-protons (δH 3.83–4.50) and amide methine/methylenes (δH 
7.52–8.61), while the 13C NMR (DMSO-d6) data revealed corresponding amide carbonyls (δc 170.3–
178.5) accounting for ×17 DBE. A series of 1H NMR quaternary methyl resonances (δH 1.49–1.26) 
suggested the presence of nonproteinogenic amino acids, such as Aib (α-aminoisobutyric acid), while 
acetyl resonances (δH 1.82; δC 170.4) indicated single N-acetyl moiety. Aromatic resonances (δH 
7.13–7.29; δc 125.7–139.5) suggested two monosubstituted aromatic rings consistent with Phe 
residues. Notwithstanding these observations, highly overlapping NMR data did not permit 
unambiguous identification of individual amino acids, or the amino acid sequence.  
A C3 Marfey’s analysis performed on 6.1 (Figure 6.7) identified the proteinogenic amino acids Gly, 
L-Glu, L-Pro, L-Phe, as well as the nonproteinogenic amino acids Aib, L-Pheol (L-Phenylalaninol) 
and trans-4-hydroxy-L-Pro (L-Hyp), while analysis of 2D NMR confirmed the presence of 8 × Aib, 
2 × L-Hyp.  
UHPLC-QTOF-MS and MS/MS fragmentation analysis (Figure 6.8) was used to establish the 
substantive structure fragments of emeramide A (6.1). A doubly charge ion at m/z 843.9469 
[(M+2Na)2+] was the most abundant in full MS spectrum (Figure 6.8a), accompanied by the singly 
charged ion at m/z 1664.9100 [(M+Na)+]. The fragment ions at m/z 1422.8019 (b14+), 1224.7014 (b12+) 
and 884.5295 (b9+), arising from the most fragile peptide bonds, were prominent in the total ion 
chromatogram (TIC). The fragment ions at m/z 152.1076 (y1+) and m/z 249.1615 (y2+) confirmed the 
C terminus L-Pro−L-Pheol (Figure 6.8a). A targeted MS/MS analysis of m/z 1664.9100 [(M+Na)+] 
(Figure 6.8b) and 843.9469 [(M+2Na)2+] (Figure 6.8c) revealed an a+ ion [(a+Na)+] series confirming 
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the structure fragments L-Leu7−Aib8−Aib9, Aib3−Aib4−Aib5−Gly6−L-Hyp7−Aib8 and L-Gln11−Aib12, 
respectively. High-resolution MS/MS analysis revealed fragment ions at m/z 694.3851 [(a7+Na)+] 
and m/z 581.3099 [(a6+Na)+] consistant with a L-Leu7 residue (C6H11NO, Δmmu –8.9). This 
assignment was further confirmed with the ROESY correlation observed between L-Leu7-H-2 (δH 
7.66) and Gly6-N-H (δH 7.9) (Figure 6.9 and Table 6.1). Further consideration of chemical formula 
and UHPLC-QTOF-MS/MS fragment ions necessitated that the observed L-Glu residue (generated 
through hydrolysis during C3 Marfey’s analysis) be L-Gln. The complete sequence of 6.1 was 
determined as shown above with support of MS/MS fragmentation and key 2D NMR correlations 
(Figure 6.9).  
 
Figure 6.6:  1H NMR (600 MHz, DMSO-d6) spectrum for emeramide A (6.1). *residual methanol. **solvent (DMSO-d6). 
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Table 6.1: NMR (600 MHz, DMSO-d6) data for emeramide A (6.1) 
 δH, mult, (J in HZ) δC COSY HMBC ROESY 
L-Phe1      
1  172.5a    
2 4.33, m 55.2 3 3, 4 Aib2-N-H 
3 a 2.97a 36.4b 2 2, 4  
 b, 2.83, dd (13.8, 9.0)     
4  137.4    
5, 9 7.29b 128.1c    
6, 8 7.25c 129.2d    
7 7.22, m 126.4    
N-H 8.30, d (5.9)  2 N-COCH3 3a, 3b, N-COCH3, Aib2-N-H 
N-COCH3  170.4e    
N-COCH3 1.82, s 22.3 2 N-COCH3 L-Phe1-N-H 
Aib2      
1  174.9f    
2  55.7g    
3 1.26, s 23.5h  1, 4 N-H 
4 1.28, s 25.5i  3  
N-H 8.61, s   L-Phe1-C-1 3, 4, L-Phe1-H-2, Aib3-N-H 
Aib3      
1  175.1f    
2  55.9g    
3 1.31 s 24.1h  1, 4  
4 1.28 s 24.9i  3  
N-H 7.63, s   2, Aib2-C-1 3, 4, Aib2-N-H, Aib4-N-H 
Aib4      
1  175.5j    
2  56.1g    
3 1.38d 24.7k  1, 4  
4 1.36, s 24.2l    
N-H 7.58, s   Aib4-C-1 3, 4, Aib3-N-H, Aib5-N-H 
Aib5      
1  175.6j    
2  nd    
3 1.38d  25.6i    
4 1.37d  nd    
N-H 7.58, s    3/4, Aib4-N-H, Gly6-N-H 
Gly6      
1  170.3e    
2 a 3.73e 43.3 N-H 1, Aib5-C-1  
 b 3.62f  N-H   
N-H 7.98, t (5.6)  2 Aib5-C-1 Aib5-N-H, L-Leu7-N-H 
L-Leu7      
1  171.8m    
2 4.05, m 52.6n 3 1, 3 Aib8-N-H 
3 a, 1.65g 39.4 2, 4   
 b, 1.53h     
4 1.64g 24.1h    
5 0.90, d (6.2) 22.7 4 3, 4, 6 2 
6 0.85, d (6.2) 21.7 4 3, 4, 5 2 
N-H 7.66, d (5.7)   Gly6-C-1 Gly6-N-H, Aib8-N-H  
Aib8      
1  173.5    
2  nd    
3 1.45i 23.5h  1, 4 N-H 
4 1.34j 24.9i    
N-H 7.80, s    Aib9-N-H, L-Leu7-H-2 
Aib9      
1  175.8j    
2  56.2g    
3 1.45i 25.7i  1, 4 N-H 
4 1.33j 25.6i    
N-H 7.52, s   1, Aib8-C-1 Aib8-N-H, L-Hyp10-H-5a  
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L-Hyp10      
1  171.7m    
2 4.38, t (8.9) 61.1 3a, 3b 1 L-Gln11-N-H 
3 2.13k 36.8 2, 4   
 1.78, m  2, 4   
4 4.29, brs 69.0o 3a, 5a, 5b   
      
      
5 a, 3.74e 56.1g 4  Aib9-N-H 
 b, 3.45, m  4   
L-Gln11      
1  175.1f    
2 4.22l 52.0 3a, 3b   
3 a 2.17k 26.2 2   
 b 1.84m     
4 2.10, m 31.5 3a 2, 3, 5  
5  173.2    
N-H 7.76n    L-Hyp10-H-2 
N-H2 nd     
Aib12      
1  172.1b    
2  55.9    
3 1.49, s 24.1l    
4 1.40, s 25.8    
N-H 7.76n 1  L-Gln11-C-1 3 
L-Hyp13      
1  172.4b    
2 4.50, t (8.9) 60.6 3a, 3b 1 Aib14-N-H 
3 2.13k 37.3 2, 4   
 1.70, m  2, 4  Aib14-N-H 
4 4.22l 69.1o 3a, 5a, 5b   
5 3.66f 56.1g 4   
 3.34, m  4   
Aib14      
1  171.7    
2  55.6    
3 1.39, s 23.5    
4 1.33j 23.9    
N-H 7.96   L-Hyp13-C-1 L-Hyp13-H-2 
L-Pro15      
1  170.7    
2 4.12, dd (8.4, 5.6) 61.8   L-Pheol16-N-H 
3 a 1.83m  2, 4a, 4b 1, 5  
 b 1.85m  2, 4a, 4b 1, 5  
4 a 1.58, m 24.8k 3 a, 3b, 5a, 5b 2, 3, 5  
 b 1.48, m  3 a, 3b, 5a, 5b 2, 3, 5  
5 a 3.80o 47.4 4a, 4b 3, 4  
 b 3.52, m  4a, 4b 3, 4  
L-Pheol16      
1  170.7    
2 3.82o 52.6n 2’a, 2’b, 3a, 3b, N-H   
3 a 2.97a 36.3 2, 3b   
 b  2.57, dd (12.3, 11.2)  2, 3b   
4  137.4    
5, 9 7.29b 127.9c  7  
6, 8 7.23c 129.3d  4  
7 7.13p 125.6    
N-H 7.15p   2, L-Pro15-C-1 L-Pro15-H-2 
OH nd     
2’ a  3.38 63.4    
 b  3.24, dd (10.2, 8.4)     
a-o 1H Assignments with the same superscript are overlapping. a-o 13C Assignments with the same superscript may be interchanged. nd 
Signals not detected. 
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Figure 6.7: C3 Marfey’s analysis for emeramide A (6.1). Trace (a) is the C3 HPLC-DAD (340 nm) chromatogram that 
exhibits L-FDAA amino acid derivatives. Traces (b-h) are C3 HPLC-MS-SIE chromatograms for L-FDAA derivatives of 
amino acid standards (broken lines) and the acid hydrolysate of 6.1 (shaded peaks). Traces confirm that 6.1 incorporates 
(b) trans-4-hydroxy-L-Pro (SIE m/z 384) and L-Leu, (c) Gly (SIE m/z 328), (d) L-Glu (SIE m/z 399 (e) L-Pro (SIE m/z 
368) (f) Aib (SIE m/z 356), (g) L-Pheol (SIE m/z 404) and L-Phe (SIE m/z 418). *Residual Marfey’s reagents. 
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Figure 6.8: UHPL-QTOF analysis of emeramide A (6.1). (a) UHPLC-QTOF-MS full spectrum, (b) targeted MS/MS 
analysis of m/z 1664.9100 [(M+Na)+] and (c) targeted MS/MS analysis of m/z 843.9469 [(M+2Na)2+]. 
 
Figure 6.9: Diagnostic 2D NMR (DMSO-d6) correlations for emeramide A (6.1). Amino acids assigned continuously 
with 2D NMR data are highlighted in blue. 
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6.4. emeramide B (6.2) 
 
HRESI(+)MS analysis of 6.2 returned a molecular formula (C81H125N17O20, Δmmu +0.1) requiring 
×28 DBE. The 1D and 2D NMR (DMSO-d6) data for 6.2 (Figure 6.10 and Table 6.2) closely 
resembled 6.1, with primary methyl resonances (δH 0.80, D-Iva5-H3-4) being the characteristic 
difference. A C3 Marfey’s analysis of 6.2 (Figure 6.11) revealed the same suite of amino acid residues 
as for 6.1, Gly, L-Glu, L-Pro, L-Phe, Aib, L-Pheol and trans-4-hydroxy-L-Hyp, together with an 
additional D-Isovaline (D-Iva) residue, suggestive of replacing an Aib residue by D-Iva, consistent 
with the HRESIMS and NMR data. Analysis of 2D NMR data (Figure 6.12) revealed resonances for 
amide methines, where less useful in establishing the amino sequence, this was the case for 6.1.   
UHPLC-QTOF-MS analysis revealed y+ and b+ ions arising from the most fragile peptide bonds of 
6.2 (Figure 13a). The ions at m/z 152.1072 (y1+), 249.1600 (y2+), 477.2603 (y4+) and 773.4185 (y7+) 
suggested that 6.2 has the same partial structure (Aib8−Aib9−L-Hyp10−L-Gln11−Aib12−L-
Hyp13−Aib14–L-Pro15–L-Pheol16) as 6.1. The ion at m/z 544.3120 (b5+) (m/z 530.2980 for 6.1), 
suggested a substitution of an Aib residue close to the N-terminus. UHPLC-QTOF-MS/MS 
fragmentation analysis performed on both sodiated ion at m/z 1678.9175 [(M+Na)+] (Figure 13b) and 
a doubly charged ion at m/z 850.9526 [(M+2Na)+2] (Figure 13c) suggested a substantive structure 
fragment Aib2−Aib3−Aib4−D-Iva5−Gly6−L-Leu7. The L-leu7 was confidently assigned with fragment 
ions at m/z 595.3167 and m/z 708.4023 accounts for a Leu residue (C6H11NO, Δmmu +1.5). This 
assignment was further supported by the residual masses calculated for –Hyp10–Gln11− (C10H15N3O4, 
Δmmu +1.2) and –Hyp13–Aib14− (C9H14N2O3), Δmmu +1.2). Considering all above, the complete 
structure of 6.2 was proposed as shown above.  
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Figure 6.10: 1H NMR (600, MHz, DMSO-d6) spectrum of emeramide B (6.2). *residual H2O. **solvent (DMSO-d6).  
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Table 6.2: NMR data (DMSO-d6) for emeramide B (6.2) 
 δH, mult, (J in HZ) δC COSY HMBC ROESY 
L-Phe1      
1  172.5    
2 4.33, m 55.2 3a, 3b, N-H 1, 3, 4 Aib2-N-H 
3 a 2.98a  36.3 2, 3b 2, 4, 5/9  
 b 2.83, dd (13.7, 8.9)  2, 3a 2, 4, 5/9  
4  137.4    
5, 9 7.29b 128.1a 6/8   
6, 8 7.25c 129.2b 5/9, 7 4, 3 2, 3a, 3b 
7 7.22, m 126.4c 5/9   
N-H 8.30, d (5.7)  2 2, N-COCH3 3a, 3b, N-COCH3 
N-COCH3  170.3d    
N-COCH3 1.83, s 22.3  1 L-Phe1-N-H 
Aib2      
1  174.8e    
2  55.7f    
3 1.27, s 25.3g  1, 2, 4 N-H 
4 1.28, s 23.7h  1, 2, 3  
N-H 8.64, s   2, L-Phe1-C-1 3, 4, L-Phe1-H-2 
Aib3      
1  175.1    
2  56.2f    
3 1.31, s 24.1i  1, 4  
4 1.29, s 24.8j  1, 3  
N-H 7.63, s   2, Aib2-C-1 3, 4, Aib4-N-H 
Aib4      
1  175.4k    
2  56.2f    
3 1.37d 24.8j    
4 1.33e 25.4g    
N-H 7.73, s   2, Aib3-C-1 3, 4, Aib3-N-H  
D-Iva5      
1  175.5k    
2  59.1    
3 a 1.99, m 28.7 4   
 b 1.70, m  4   
4 0.8, t (7.4) 7.54 3a, 3b 2 N-H 
5 1.34e 21.2    
N-H 7.50, s   1, 2, Aib4-C-1  
Gly6      
1  170.4l    
2 a 3.73f 43.2 2b, N-H 1, D-Iva5-C-1  
 b 3.63g  2a, N-H 1, D-Iva5-C-1  
N-H 7.95i     
L-Leu7      
1  170.4l    
2 4.05, m 52.5m 3a, 3b, N-H 1, 3 Aib8-N-H 
3 a 1.64h 39.3 2, 3b, 4   
 b 1.53, m  2, 3a, 4   
4 1.65h 24.2 3a, 3b, 5, 6   
5 0.90, d (5.9) 22.9 4 3, 4, 6 2 
6 0.85, d (5.9) 21.6 4 3, 4, 5 2 
N-H 7.69, d (5.7)   2, Gly5-C-1  
Aib8      
1  173.6    
2  56.1f    
3 1.45j 23.3  1, 2, 4 N-H 
4 1.32e 25.7g  1, 2, 3  
N-H 8.82, s    3, L-Leu7-H-2 
Aib9      
1  175.9    
2  56.2f    
3 1.45j 25.3g  1 N-H 
4 1.33e 25.7g    
N-H 7.51, s   1, Aib8-C-1  
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L-Hyp10      
1  171.7n    
2 4.38, t (8.9) 61.1 3a, 3b 1, 3  
3 a 2.15k 36.6 2, 4   
 b 1.77, m  2, 4   
4 4.28, brs 69.1o 3a, 5a, 5b, OH-4   
5 a 3.74f 56.0f 4, 5b   
 b 3.46, m  4, 5b 3  
OH-4 5.09, brs  4 3  
L-Gln11      
1  172.1    
2 4.22l 52.0 3a, 3b, N-H 1  
3 a 2.17k 26.2 4   
 b 1.85, m  4   
4 2.11, m 31.5 3a, 3b 5  
5  173.2    
N-H 7.76m     
N-H2 nd     
Aib12      
1  172.3    
2  55.9    
3 1.49, s 23.8  1, 4  
4 1.38d 25.8  1, 3 N-H 
N-H 7.77m    4, L-Hyp13-H-5a 
L-Hyp13      
1  172.8    
2 4.50, t (87) 60.6 3a, 3b 1  
3 a 2.15k 37.3 2, 4 4  
 b 1.70n  2, 4   
4 4.22l 69.1o 3a, 5a, 5b 4, 3  
5 a 3.66f 56.4f 4  Aib12-N-H 
 b 3.34z  4   
Aib14      
1  171.7n    
2  55.8e    
3 1.41, s 25.6g  1  
4 1.37d 24.8    
N-H 7.95i     
L-Pro15      
1  170.7    
2 4.12, dd (8.4, 5.5) 61.8  1, 3, 4 L-Pheol16-N-H 
3 a 1.83o 28.3 2, 4a, 4b   
 b 1.15, m  2, 4a, 4b 1 2'a 
4 a 1.57, m 25.0j 3 a, 3b, 5a, 5b 2, 3, 5  
 b 1.47, m  3 a, 3b, 5a, 5b 2, 3, 5  
5 a 3.80p 47.4 4a, 4b 3, 4  
 b 3.52, m  4a, 4b 3, 4  
Pheol16      
1 a 3.38z 63.4    
 b 3.24z     
2 3.83p 52.6l 1, 2’b, 3a, 3b, N-H   
3 a 2.97a 36.3 2, 3b   
 b 2.57, dd (12.2, 11.2)  2, 3b   
4  137.4    
5, 9 7.28b 127.9a  7  
6, 8 7.23c 129.3b  4  
7 7.14 126.5c    
N-H 7.15   2, L-Pro15-C-1 L-Pro15-H-2 
OH-1 nd     
a-p  1H assignments with the same superscript are overlapping. a-n  13C assignments with the same superscript may be interchanged. z 
resonances overlapping with residual H2O. nd Signals not detected. 
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Figure 6.11: C3 Marfey’s analysis for emeramide B (6.2). Trace (a) is the C3 HPLC-DAD (340 nm) chromatogram that 
exhibits L-FDAA amino acid derivatives. Traces (b-i) are C3 HPLC-MS-SIE chromatograms for L-FDAA derivatives of 
amino acid standards (broken lines) and the acid hydrolysate of 6.2 (shaded peaks). Traces confirm that 6.2 incorporates 
(b) trans-4-hydroxy-L-Pro (SIE m/z 384) and L-Leu, (c) Gly (SIE m/z 328), (d) L-Glu (SIE m/z 399, (e) L-Pro (SIE m/z 
368), (f) Aib (SIE m/z 356), (g) L-Pheol (SIE m/z 404), (h) L-Phe (SIE m/z 418) and and (i) D-Iva (SIE m/z 370). *Residual 
Marfey’s reagents. 
 
Figure 6.12: Diagnostic 2D NMR correlations for emeramide B (6.2). Amino acids assigned continuously with 2D NMR 
data are highlighted in blue.  
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Figure 6.13: UHPLC-QTOF analysis for emeramide B (6.2). (a) UHPLC-QTOF-MS full spectrum, (b) targeted MS/MS 
analysis of m/z 1678.9175 [(M+Na)+] and (c) targeted MS/MS analysis of m/z 850.9526. [(M+2Na)2+] 
To further validate the proposed structure and the assignment of D-Iva and L-Leu7 residues, recently 
reported 2D C3 Marfey’s method5 was employed. Briefly, an aliquot of 6.2 (200 µg) was partially 
degraded by heating at 100 oC for 1 h in acid (1 M HCl, 300 µL was optimal to obtain fragments of 
interest). Aliquots of hydrolysate were analysed with HPLC-DAD-MS and UHPLC-QTOF-MS 
(Figure 6.14). It was clear from the fragments that acid hydrolysis first cleaved the N-terminus acetyl 
group followed by generating a series of structure fragments. All the possible fragments for the 
proposed structure for 6.2 were tabulated to identify the fragments with the desired amino acid 
sequences (Table 6.3). The remaining hydrolysate was subjected to semi-preparative HPLC (Zorbax-
SB C3 column with 1.0 mL/min, 10% MeCN/H2O to 60% MeCN inclusive of 0.05% formic acid 
modifier over 20 min) to purify the targeted fragments, m/z 520 ([M+H]+) and 860 ([M+H]+)]. A C3 
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Marfey’s analysis performed on the isolated fragments confirmed the presence of L-Phe, Aib and D-
Iva residues (Figure 6.15) in fragment m/z 520 ([M+H]+), while revealed Gly, Aib, L-Phe, D-Iva and 
L-Leu in fragment m/z 860 ([M+H]+) (Figure 6.17). UHPLC-QTOF-MS/MS fragmentation 
established the sequence for respective structure fragments (Figures 6.16 and 6.18). 
Table 6.3: All possible fragments for the proposed structure for 6.2   
 
*fragment ions were calculated without the acetyl moiety. The targeted fragments are highlighted in blue.  
 
 
Figure 6.14: UHPLC-QTOF-MS analysis of emeramide B (6.2) partial hydrolysate. An aliquot (1 µL) of diluted 
hydrolysate was eluted with 10% H2O/MeCN to 60% H2O/MeCN inclusive of 0.01% formic acid modifier using Zorbax-
SB-C8 column, over 12 min. The interested fragments are highlighted in blue. The other peaks account for the several 
other fragments generated by acid hydrolysis. 
  
L-Phe1* Aib2 Aib3 Aib4 D-Iva5 Gly6 L-Leu7 Aib8 Aib9 L-Hyp10 L-Glu11 Aib12 L-Hyp13 Aib14 L-Pro15 L-Pheol16
L-Phe1* 165
Aib2 250 103
Aib3 335 188 103
Aib4 420 273 188 103
D-Iva5 519 372 287 202 117
Gly6 576 429 344 259 174 75
L-Leu7 689 542 457 372 287 188 131
Aib8 774 627 542 457 372 273 244 103
Aib9 859 712 627 542 457 358 329 188 103
L-Hyp10 972 825 740 655 570 471 414 301 216 131
L-Glu11 1101 954 869 520 699 600 527 430 345 260 146
Aib12 1186 1039 954 605 784 685 656 515 430 345 231 103
L-Hyp13 1299 1152 1067 718 897 798 741 628 543 458 344 216 131
Aib14 1384 1237 1152 803 982 883 854 713 628 543 429 301 216 103
L-Pro15 1481 1334 1249 900 1079 980 939 810 725 640 526 398 313 200 115
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Figure 6.15: C3 Marfey’s analysis of the fragment m/z 520 ([M+H]+). (a) C3 HPLC-DAD (340 nm) chromatogram 
revealing L-FDAA amino acid derivatives. (b–d) C3 HPLC-MS-SIE chromatograms for L-FDAA derivatives of authentic 
standards (broken lines) and the acid hydrolysate of the fragment (shaded peaks). Traces confirm that the fragment 
incorporates (b) L-Phe (SIE m/z 418), (c) Aib (SIE m/z 356) and (d) D-Iva (SIE m/z 370). 
 
Figure 6.16: UHPLC-QTOF-MS/MS fragmentation for the ion m/z 520.3114 [M+H]+. 
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Figure 6.17: C3 Marfey’s analysis of the fragment m/z 860 ([M+H]+). (a) C3 HPLC-DAD (340 nm) chromatogram 
revealing L-FDAA amino acid derivatives. (b–f) are C3 HPLC-MS SIE chromatograms for L-FDAA derivatives of 
authentic standards (broken lines) and the acid hydrolysate of the fragment (shaded peaks). Traces confirm that the 
fragment incorporates (b) L-Phe (SIE m/z 418), (c) Aib (SIE m/z 356), (d) D-Iva (SIE m/z 370), (e) Gly (SIE m/z 328) and 
L-Leu (SIE m/z 384) 
 
Figure 6.18: UHPLC-QTOF-MS/MS fragmentation for the ion m/z 860.5214 [M+H]+. 
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6.5. emeramide C (6.3) 
 
HRESI(+)MS analysis of 6.3 returned a sodiatated ion [(M+Na)]+ consistent with a molecular formula 
C81H125N17O20 (Δmmu –1.3) requiring ×28 DBE. The 1H and 13C NMR (DMSO-d6) data for 6.3 
(Figure 6.19 and Table 6.4) showed spectra closely resembling 6.2. A C3 Marfey’s analysis of 6.3 
(Figure 6. 20) revealed the same suite of amino acids, Gly, L-Glu, L-Pro, L-Phe, Aib, L-Pheol, L-Hyp, 
L-Leu and D-Iva residues as for 6.2. Despite overlapping resonances, 2D NMR data (DMSO-d6) for 
6.3 revealed resonances consistent with all the amino acids residues identified by C3 Marfey’s 
analysis, including seven 7 × Aib, 2 × L-Hyp and a N-Ac- L-Phe.  
UHPLC-QTOF-MS analysis of 6.3 (Figure 6.21a) revealed similar fragment ions observed for 6.1 
[(m/z 530 (b5+); m/z 870 (b9+)], suggesting a structure fragment Ac-L-Phe1−Aib2−Aib3−Aib4− Aib5− 
Gly6−L-Leu7−Aib8−Aib9. The fragment ions m/z 152 (y2+) and m/z 249 (y4+) confirmed the structure 
fragment L-Hyp13−Aib14−L-Pro15−L-Pheol16, while suggested the replacement of Aib12 by D-Iva. 
UHPLC-QTOF targeted MS/MS fragmentation analysis performed on both sodiated ion (m/z 
1678.9262, Figure 6.21b) and doubly charged ion (m/z 1678.9265, Figure 6.21c) further confirmed 
the proposed amino acid sequence as shown above. Diagnostic 2D NMR correlations (Figure 6.22) 
further supported the proposed structure for 6.3.   
  
O
N
H
H
N
O
N
H
H
N
O
N
H
H
N
O
N
H
H
N
O
O O O O
N
H
O
N
NH
O
H
NO
NH2
O
OH
N
O
NHO
N
O
OH
NHO
HO
L-Pheol16
N-Ac-L-Phe1
Aib2
Aib3
Aib4
Aib5
Gly6
L-Leu7
Aib8
Aib9
L-Hyp10
Gln11 D-Iva12
Aib14
L-Pro15
L-Hyp13
emeramide C (6.3)
Chapter 6: Emeramides: New peptaibols from marine fish gut-derived fungi 
 
 
196 
 
 
Figure 6.19: 1H NMR (600 MHz, DMSO-d6) spectrum for emeramide C (6.3). *Residual MeOH, **Solvent (DMSO-
d6).    
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Table 6.4: NMR (600 MHz, DMSO-d6) data of emeramide C (6.3) 
 δH, mult, (J in Hz) δC COSY HMBC ROESY 
L-Phe1      
1  172.5    
2 4.33, m 55.17 3a, 3b, N-H 3, 4 Aib2-N-H 
3 a 2.96a 36.4 2, 3b 2, 4  
 b, 2.83, dd (13.7, 9.0)     
4  137.4    
5, 9 7.29b 128.1a 6/8   
6, 8 7.25c 129.2b 5/9, 7 4, 3 2, 3a, 3b 
7 7.22 c 126.4c 5/9   
N-H 8.30, d (5.8)  2 N-COCH3 3a, 3b, N-COCH3 
N-COCH3  170.4d    
N-COCH3 1.82, s 22.3   N-H 
Aib2      
1  174.9e    
2  55.7f    
3 1.28, s 25.4g  1, 2, 4 N-H 
4 1.27, s 23.5h  2, 3  
N-H 8.61   2, L-Phe1-C-1 3, 4, L-Phe1-H-2, Aib3-N-H 
Aib3      
1  175.1e    
2  55.9f    
3 1.31, s 24.1i  1, 4  
4 1.29, s 24.7j  3  
N-H 7.64, s   2, Aib2-C-1 3, 4, Aib2-N-H  
Aib4      
1  175.6k    
2  55.9f    
3 1.36, s 24.5j    
4 1.33d 25.4g    
N-H 7.69, s   Aib3-C-1 3, 4, Aib5-N-H 
Aib5      
1  175.6k    
2  56.2f    
3 1.39e  23.5h    
4 1.38f 24.8j    
N-H 7.58, s   Aib4-C-1 3/4, Aib4-N-H, Gly6-N-H 
Gly6      
1  170.4d    
2 a 3.73g 43.3 N-H 1, Aib5-C-1  
 b 3.63h  N-H 1, Aib5-C-1  
N-H 7.98, t (5.6)  2a, 2b Aib5-C-1 Aib5-N-H, L-Leu7-N-H 
L-Leu7      
1  171.7l    
2 4.05, m 52.7m 3a, 3b, N-H 1, 3 Aib8-N-H 
3 a, 1.65i 39.1 2, 4   
 b, 1.54, m  2, 4   
4 1.64i 24.1i    
5 0.90, d (5.9) 22.7 4 3, 4, 6 2 
6 0.85, d (5.9) 21.6 4 3, 4, 5 2 
N-H 7.69, d (5.7)   Gly6-C-1 Gly6-N-H 
Aib8      
1  173.5    
2  nd    
3 1.45, s 23.2  1, 4 N-H 
4 1.38f 25.0g    
N-H 7.73, s    Aib9-N-H, L-Leu7-H-2 
Aib9      
1  175.9    
2  56.2f    
3 1.44, s 25.3g  1, 4 N-H 
4 1.33d 25.7g    
N-H    1, Aib8-C-1 L-Hyp10-H-5a, Aib8-N-H 
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Hyp10      
1  171.7l    
2 4.37, t (8.9) 61.1 3a, 3b 1 L-Gln11-N-H 
3 a 2.15j 36.7 2, 4  Aib9-N-H 
 b 1.78k  2, 4   
4 4.29, brs 69.0n 3a, 5a, 5b   
5 a 3.76g 55.9f 4 
 
 
 Aib9-N-H 
 b 3.46, m  4 3  
L-Gln11      
1  172.2    
2 4.17, m 52.5m 3a, 3b, N-H   
3 a 2.15j 26.7 2   
 b 1.88l     
4 2.11m 31.5 3a, 3b   
5  173.1    
N-H 7.85, d (7.8)  2 L-Hyp10-C-1 L-Hyp10-H-2, D-Iva12-N-H 
N-H2 nd     
D-Iva12      
1  172.9o    
2  58.5    
3 a 2.13m 28.1 4   
 b 1.80k  4  N-H 
4 0.74, t (7.4) 7.0 3a, 3b,  2, 3 N-H 
5 1.41, s 20.4  1, 2  
N-H 7.46, s   L-Gln11-C-1 3, L-Gln11-N-H, L-Hyp13-H-5a 
L-Hyp13      
1  172.8o    
2 4.52, t (8.9) 60.6 3a, 3b 1 Aib14-N-H 
3 a 2.16j 37.4 2, 4 4  
 b 1.67i  2, 4   
4 4.21, brs 69.1n 3a, 5a, 5b   
5 a 3.67h 56.2f 4  D-Iva12-N-H 
 b 3.37z  4   
Aib14      
1  175.6k    
2  55.8f    
3 1.39f 23.5h  2 N-H 
4 1.33d 25.4g  2 N-H 
N-H 7.95, s   L-Hyp13-C-1 3, 4, L-Hyp13-H-2, L-Pro15-H-5a  
Pro15      
1  170.7d    
2 4.12, dd (8.4, 5.6) 61.8  1, 3, 4 L-Pheol16-N-H 
3 a 1.83l 28.3 2, 4a, 4b   
 b 1.15, m  2, 4a, 4b 1  
4 a 1.57, m 25.0g 3 a, 3b, 5a, 5b 2, 3, 5  
 b 1.47, m  3 a, 3b, 5a, 5b 2, 3, 5  
5 a 3.79g 47.3 4a, 4b 3, 4 L-Aib14-N-H 
 b 3.50, m  4a, 4b 3, 4  
L-Pheol16      
1 a 3.38z 63.4    
 b 3.24, dd (10.2, 8.4)     
2 3.83, m 52.7f 2’a, 2’b, 3a, 3b, N-H   
3 a 2.97a 36.3 2, 3b   
 b 2.57, dd (12.3, 11.2)  2, 3b   
4  137.4    
5, 9 7.28b 127.9a  7  
6, 8 7.23c 129.3b  4  
7 7.14n 126.5c    
N-H 7.15n   2, L-Pro15-C-1 L-Pro15-H-2 
OH      
a-n 1H assignments with the same superscript are overlapping. a-o  13C assignments with the same superscript may be interchanged. z 
resonances overlapping with residual H2O. nd Signals not detected. 
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Figure 6.20: C3 Marfey’s analysis for emeramide C (6.3). Trace (a) is the C3 HPLC-DAD (340 nm) chromatogram that 
exhibits L-FDAA amino acid derivatives. Traces (b–i) are C3 HPLC-MS-SIE chromatograms for L-FDAA derivatives of 
amino acid standards (broken lines) and the acid hydrolysate of 6.3 (shaded peaks). Traces confirm that 6.3 incorporates 
(b) trans-4-hydroxy-L-Pro (SIE m/z 384) and L-Leu, (c) Gly (SIE m/z 328), (d) L-Glu (SIE m/z 399, (e) L-Pro (SIE m/z 
368), (f) Aib (SIE m/z 356), (g) L-Pheol (SIE m/z 404), (h) L-Phe (SIE m/z 418) and (i) D-Iva (SIE m/z 370). *Residual 
Marfey’s reagents. 
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Figure 6.21: UHPLC-QTOF analysis of emeramide C (6.3). (a) UHPLC-QTOF-MS full spectrum, (b) targeted MS/MS 
analysis of m/z 1678.9265 [(M+Na)+] and (c) targeted MS/MS analysis of m/z 850.9526 [(M+2Na)2+] 
 
Figure 6.22: Diagnostic 2D NMR (DMSO-d6) correlations for emeramide C (6.3). Amino acids assigned continuously 
with 2D NMR data are highlighted in blue.  
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6.6. emeramide D (6.4) 
 
HRESI(+)MS analysis of 6.4 returned a pseudo ion [(M+Na)+] consistent with a molecular formula 
(C81H125N17O20, Δmmu +0.8) requiring ×28 DBE. The 1H NMR (DMSO-d6) data for 6.4 showed a 
spectrum closely resembling 6.2 (Figure 6.23). However, the limited material (0.9 mg) precluded 
acquiring quality 2D NMR data. 
Instead of relying on NMR data, UHPLC-QTOF-MS/MS fragmentation analysis, supported by C3 
Marfey’s analysis, was used to deduce the complete structure of 6.4. A C3 Marfey’s analysis of 6.4 
(Figure 6.24) identified the same suite of amino acids residues, Gly, L-Glu, L-Pro, L-Phe, Aib, L-
Pheol, L-Hyp, and D-Iva, with an addition of L-Ala, suggestive of replacing an Aib residue by L-Ala. 
The UHPLC-QTOF-MS spectrum for 6.4 revealed fragment ions, m/z 152.1070 (y1+), m/z 249.1597 
(y2+) m/z 447.2609 (y4+) and m/z 787.4364 (y7+), (Figure 25a) confirming a structure fragment 
Hyp10−Gln11−Iva12−Hyp13−Aib14−Pro15−Pheol16. The L-Hyp10 and L-Hyp13 were confidently 
assigned by analysing UHPLC-QTOF-MS/MS fragmentation of 6.4 (Figure 6.25). The fragment ions 
a9+–a11+ and a12+–a14+ (Figure 6.25b and 6.25c) were consistent with the structure fragments –Hyp10–
Gln11− (C10H15N3O4, Δmmu –5.3) and –Hyp13–Aib14− (C9H14N2O3, Δmmu –7.9), respectively. 
Targeted MS/MS analysis of the doubly charged ion (m/z 850.9526, Figure 6.25c) of 6.4 confirmed 
the structure fragment Aib3−Aib4−Iva5−Gly6−Leu7−L-Ala8−Aib9. The fragment ion a6+–a7+ was 
consistent with L-Leu7 (C6H11NO, Δmmu –7.9). The complete sequence of emeramide D (6.4) was 
determined as shown above with MS/MS fragmentation analysis, supported by C3 Marfey’s analysis.  
Having demonstrated that UHPLC-QTOF-MS/MS fragmentation analysis coupled with C3 Marfey’s 
analysis can be a useful approach for complete structure elucidation of peptides, without the need for 
NMR data, this approach was used to deduce the complete structures of the other co-metabolites 6.5–
6.8. 
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Figure 6.23: 1H NMR (600 MHz, DMSO-d6) spectrum for emeramide D (6.4).   
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Figure 6.24: C3 Marfey’s analysis for emeramide D (6.4). Trace (a) is the C3 HPLC-DAD (340 nm) chromatogram that 
exhibits L-FDAA amino acid derivatives. Traces (b–J) are C3 HPLC-MS-SIE chromatograms for L-FDAA derivatives of 
amino acid standards (broken lines) and the acid hydrolysate of 6.4 (shaded peaks). Traces confirm that 6.4 incorporates 
(b) trans-4-hydroxy-L-Pro (SIE m/z 384) and L-Leu, (c) Gly (SIE m/z 328), (d) L-Glu (SIE m/z 399, (e) L-Ala (SIE m/z 
342), (f) L-Pro (SIE m/z 368), (g) Aib (SIE m/z 356), (h) L-Pheol (SIE m/z 404), (i) L-Phe (SIE m/z 418) and (j) D-Iva (SIE 
m/z 370). *Residual Marfey’s reagents. 
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Figure 6.25: UHPLC-QTOF analysis of emeramide D (6.4). (a) UHPLC-QTOF-MS full spectrum, (b) targeted MS/MS 
analysis of m/z 1678.9217 [(M+Na)+] and (c) targeted MS/MS analysis of m/z 850.9526 [(M+2Na)2+]. 
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6.7. emeramide E (6.5) 
 
HRESI(+)MS analysis of 6.5 return a sodiated ion [(M+Na)+] consistent with a molecular formula 
C81H125N17O20 (Δmmu –0.4). The 1H NMR (600 MHz, DMSO-d6, Figure 6.26) data for 6.5 closely 
resembled emeramide B (6.2). Instead of relying on overlapping NMR data, the complete structure 
of 6.5 was deduced using MS/MS fragmentation analysis, supported by C3 Marfey’s analysis.  
A C3 Marfey’s analysis of 6.5 (Figure 6.28) confirmed the presence of the amino acids Gly, L-Glu, 
L-Pro, L-Phe, Aib, L-Pheol, L-Hyp, L-Leu and D-Iva. UHPLC-QTOF-MS analysis of 6.5 (Figure 
6.27a). exhibited the fragment ions m/z 152.1068 (y1+), m/z 249.1604 (y2+) and m/z 447.2606 (y4+) 
confirming a structure fragment –L-Hyp13−Aib14−L-Pro15−L-Pheol16, with L-Hyp13 confidently 
assigned by the fragment ions [m/z 249.1604 (y2+); m/z 447.2606 (y4+)] observed for the structure 
fragment –L-Hyp13−Aib14– (C9H14N2O3, ∆mmu +0.2). The targeted MS/MS analysis of m/z 
1678.9281 [M+Na)+] (Figure 6.27b) revealed fragment ions, (a9+Na)+ to (a14+Na)+, that suggested a 
substantive structure fragment –L-Hyp10−L-Gln11–Aib12–L-Hyp13−Aib14−L-Pro15−L-Pheol16. The 
fragment ions [(a9+Na)+; (a11+Na)+] corresponding to a structure fragment –L-Hyp10−L-Gln11 
(C10H15N3O4, ∆mmu +7.8) further validated the assignment of L-Hyp10. Further, analysis of targeted 
MS/MS fragmentation of the doubly charged ion m/z 850.9526 [(M+2Na)2+] (Figure 6.27c), 
confirmed a substantive fragment Aib2−Aib3−Aib4−Aib5−Gly6−L-Leu7−D-Iva8. Considering all the 
above, the complete amino acid sequence of 6.5 was unambiguously assigned as shown above. 
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Figure 6.26:  1H NMR (600 MHz, DMSO-d6) spectrum for emeramide E (6.5). 
 
Figure 6.27: UHPLC-QTOF analysis of emeramide E (6.5). (a) UHPLC-QTOF-MS full spectrum, (b) targeted MS/MS 
analysis of m/z 1678.9281 [(M+Na)+] and (c) targeted MS/MS analysis of m/z 850.9526 [(M+2Na)2+]. 
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Figure 6.28: C3 Marfey’s analysis for emerimide E (6.5). Trace (a) is the C3 HPLC-DAD (340 nm) chromatogram that 
exhibits L-FDAA amino acid derivatives. Traces (b–i) are C3 HPLC-MS-SIE chromatograms for L-FDAA derivatives of 
amino acid standards (broken lines) and the acid hydrolysate of 6.5 (shaded peaks). Traces confirm that 6.5 incorporates 
(b) trans-4-hydroxy-L-Pro (SIE m/z 384) and L-Leu, (c) Gly (SIE m/z 328), (d) L-Glu (SIE m/z 399, (e) L-Pro (SIE m/z 
368), (f) Aib (SIE m/z 356), (g) L-Pheol (SIE m/z 404), (h) L-Phe (SIE m/z 418) and (i) D-Iva (SIE m/z 370). *Residual 
Marfey’s reagents. 
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6.8. emeramide F (6.6) 
 
HRESI(+)MS analysis of 6.6 return a sodiated ion [(M+Na)+] consistent with a molecular formula 
C82H127N17O20 (Δmmu –0.9). The 1H NMR (600 MHz, DMSO-d6, Figure 6.29) data for 6.6 showed 
spectra closely resembling the known fungal peptaibol, antiamoebin I (6.9). A C3 Marfey’s analysis 
of 6.6 (Figure 6.31) revealed the same suit of amino acids, Gly, L-Glu, L-Pro, L-Phe, Aib, L-Pheol, L-
Hyp, L-Leu and D-Iva as for 6.9. On UHPLC-QTOF-MS analysis (Figure 6.30a), 6.6 showed 
fragment ions, [m/z 152.1067 (y1+); m/z 249.1599 (y2+); m/z 447.2594 (y4+); m/z 773.4939 (y7+)], 
consistent with a structure fragment, –L-Hyp10−L-Gln11–Aib12–L-Hyp13−Aib14−L-Pro15−L-Pheol16. 
Assignment of L-Hyp10 and L-Hyp13 were confirmed independently with the fragment ions observed 
for –L-Hyp10−L-Gln11– (C10H15N3O4, ∆mmu –9.2) and –L-Hyp13−Aib14– (C9H14N2O3, ∆mmu +0.9). 
UHPLC-QTOF-MS/MS analysis of 6.6 (Figure 6.30b) and the targeted MS/MS analysis of the doubly 
charged ion m/z 857.9626 [(M+2Na)2+] (Figure 6.30c) confirmed the N-terminus fragment, 
Aib2−Aib3−Aib4−D-Iva5−Gly6−L-Leu7−D-Iva8. Based on these structure fragments, the complete 
sequence of 6.6 was confirmed as shown above, as a regeoisomer of antiamoebin I (6.9).  
O
N
H
H
N
O
N
H
H
N
O
N
H
H
N
O
N
H
H
N
O
O O O O
N
H
O
N
NH
O
H
NO
NH2
O
OH
N
O
NHO
N
O
OH
NHO
HO
L-Pheol16
N-Ac-L-Phe1
Aib2
Aib3
Aib4
D-Iva5
Gly6
L-Leu7
D-Iva8
Aib9
L-Hyp10
Gln11 Aib12
Aib14
L-Pro15
L-Hyp13
emeramide F (6.6)
Chapter 6: Emeramides: New peptaibols from marine fish gut-derived fungi 
 
 
209 
 
Figure 6.29: 1H NMR (600 MHz, DMSO-d6) spectrum for emeramide F (6.6). 
 
Figure 6.30: UHPLC-QTOF analysis of emeramide F (6.6). (a) UHPLC-QTOF-MS full spectrum, (b) targeted MS/MS 
analysis of m/z 1692.9389 [(M+Na)+] and (c) targeted MS/MS analysis of m/z 857.9626 [(M+2Na)2+]. 
Mass-to-Charge (m/z)
R
el
at
iv
e 
io
n 
ab
un
da
nc
e
R
el
at
iv
e 
io
n 
ab
un
da
nc
e
R
el
at
iv
e 
io
n 
ab
un
da
nc
e
26
9.
12
54
O
N
H
H
N
O
N
H
H
N
O
N
H
H
N
O
N
H
H
N
O
O O O O
N
H
O
N
NH
O
H
NO
NH2
O
OH
N
O
NHO
N
O
OH
NHO
HO
a2+ a3+ a4+ a5+ a6+ a7+ a8+
a9+
a11+ a12+
b5+ b9+
b12+
b14+
y4+
y2+
y1+
y11+
y7+
y1+
y2+
y4+ b5+
b9+
b12+
b14+y7+
[a7+Na]+
[a8+Na]+
[a9+Na]+
[a11+Na]+
[a12+Na]+
[a14+Na]+
[a2+Na]+ [a3+Na]+[a4+Na]+
[a5+Na]+
[a7+Na]+
[M+Na]+
[M+Na]+
(a)
(b)
(c)
Chapter 6: Emeramides: New peptaibols from marine fish gut-derived fungi 
 
 
210 
 
Figure 6.31: C3 Marfey’s analysis for emeramide F (6.6). Trace (a) is the C3 HPLC-DAD (340 nm) chromatogram that 
exhibits L-FDAA amino acid derivatives. Traces (b–i) are C3 HPLC-MS-SIE chromatograms for L-FDAA derivatives of 
amino acid standards (broken lines) and the acid hydrolysate of 6.6 (shaded peaks). Traces confirm that 6.6 incorporates 
(b) trans-4-hydroxy-L-Pro (SIE m/z 384) and L-Leu, (c) Gly (SIE m/z 328), (d) L-Glu (SIE m/z 399, (e) L-Pro (SIE m/z 
368), (f) Aib (SIE m/z 356), (g) L-Pheol (SIE m/z 404), (h) L-Phe (SIE m/z 418) and (i) D-Iva (SIE m/z 370). *Residual 
Marfey’s reagents. 
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6.9. emeramide G (6.7) 
 
HRESI(+)MS analysis of 6.7 return a sodiated ion [(M+Na)+] consistent with a molecular formula 
C82H127N17O20 (Δmmu +1.7) isomerise with emaramide F (6.6) and antiamoebin I (6.9) The 1H NMR 
(600 MHz, DMSO-d6, Figure 6.32) data for 6.7 also closely resembled emeramide F (6.6). A C3 
Marfey’s analysis of 6.7 (Figure 6.34) confirmed the same suite of amino acid identified for 6.6 and 
6.9, Gly, L-Glu, L-Pro, L-Phe, Aib, L-Pheol, L-Hyp, L-Leu and D-Iva. UHPLC-QTOF-MS analysis of 
6.7 (Figure 6.33a) revealed fragment ions [m/z 152.1058 (y1+), m/z 249.1589 (y2+) and m/z 447.2604 
(y4+)] consistent with the C-terminus fragment –L-Hyp13−Aib14−L-Pro15−L-Pheol16. In contrast to 6.6, 
fragment ion (m/z 787.4382, (y7+) (+14 Da on the corresponding fragment ion for 6.6), indicated 
replacing Aib12 in 6.6 by D-Iva12 in 6.7. UHPLC-QTOF-MS/MS analysis of 6.7 (Figure 6.33b) 
established the structure fragment –D-Iva8–Aib9–L-Hyp10−L-Gln11–D-Iva12–L-Hyp13−Aib14− L-
Pro15−L-Pheol16, while targeted MS/MS analysis of the doubly charged ion m/z 857.9606 
[(M+2Na)2+] (Figure 6.33c) identified a substantive fragment –Aib2−Aib3−Aib4− Aib5−Gly6−L-Leu7. 
Assignment of L-Leu7 was unambiguously confirmed with the mass difference of fragment ions 
(a6+Na)+ and (a7+Na)+, consistent with C6H11NO (∆mmu –5.1) (i.e L-Leu). Based on these 
fragmentation analyses, the complete structure of 6.7 was established as shown above. 
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Figure 6.32: 1H NMR (600 MHz, DMSO-d6) spectrum for emeramide G (6.7). 
 
Figure 6.33: UHPLC-QTOF analysis of emeramide G (6.7). (a) UHPLC-QTOF-MS full spectrum, (b) UHPLC-QTOF-
MS/MS analysis and (c) targeted MS/MS analysis of m/z 857.9626 [(M+2Na)2+]. 
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Figure 6.34: C3 Marfey’s analysis for emerimide G (6.7). Trace (a) is the C3 HPLC-DAD (340 nm) chromatogram that 
exhibits L-FDAA amino acid derivatives. Traces (b–i) are C3 HPLC-MS-SIE chromatograms for L-FDAA derivatives of 
amino acid standards (broken lines) and the acid hydrolysate of 6.7 (shaded peaks). Traces confirm that 6.5 incorporates 
(b) trans-4-hydroxy-L-Pro (SIE m/z 384) and L-Leu, (c) Gly (SIE m/z 328), (d) L-Glu (SIE m/z 399, (e) L-Pro (SIE m/z 
368), (f) Aib (SIE m/z 356), (g) L-Pheol (SIE m/z 404), (h) L-Phe (SIE m/z 418) and (i) D-Iva (SIE m/z 370). *Residual 
Marfey’s reagents. 
  
  
 
  
    
  
 
 
 
 
  
 
  
  
  
 
 
 
 
 
 
 
15 454035302520
Retention time
10
A
bs
or
ba
nc
e
 3
40
 n
m
 (m
A
U
)
Io
n 
ab
an
da
nc
e 
i ii iii
iv
i) trans-4-hydroxy-D-Pro
ii) trans-4-hydroxy-L-Pro
iii) cis-4-hydroxy-L-Pro
iv) cis-4-hydroxy-D-Pro
L-Pheol D-Pheol
    
L-Phe D-Phe
D-IvaL-Iva
Aib
L-Pro L-Pro
L-Glu L-Glu
Gly
L-Leu D-Leu
a)
b)
c)
d)
e)
f)
g)
h)
i)
* 
Chapter 6: Emeramides: New peptaibols from marine fish gut-derived fungi 
 
 
214 
6.10. emeramide H (6.8) 
 
HRESI(+)MS analysis of 6.8 return a sodiated ion [(M+Na)+] consistent with a molecular formula 
C83H129N17O20 (Δmmu –0.5), a CH2 homologue of emeramide F (6.6), emeramide G (6.7) and 
antiamoebin I (6.9). The 1H NMR (600 MHz, DMSO-d6, Figure 6.35) data for 6.8 closely resembled 
emeramide F (6.6) and G (6.7). A C3 Marfey’s analysis of 6.8 (Figure 6.34) confirmed the presence 
of amino acid residues Gly, L-Glu, L-Pro, L-Phe, Aib, L-Pheol, L-Hyp, L-Leu and D-Iva. UHPLC-
QTOF-MS (Figure 6.36a) and MS/MS analysis (Figure 6.36b) of 6.8 confirmed the structure 
fragment, –D-Iva8–Aib9–L-Hyp10−L-Gln11–D-Iva12–L-Hyp13−Aib14− L-Pro15−L-Pheol16 as in 6.7. In 
contrast to 6.7, 6.8 showed a fragment ion with +14 Da [m/z 538.3112, (a5+Na)+] indicative of 
replacing Aib5 in 6.7 by D-Iva5 in 6.8. Collectively, these structure fragments confirmed the complete 
sequence of 6.8 as shown above. 
 
Figure 6.35: 1H NMR (600 MHz, DMSO-d6) spectrum for emeramide H (6.8). 
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Figure 6.36: UHPLC-QTOF analysis of emeramide H (6.8). (a) UHPLC-QTOF-MS full spectrum, (b) UHPLC-QTOF-
MS/MS analysis and (c) targeted MS/MS analysis of m/z 864.9698 [(M+2Na)2+]. 
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Figure 6.37: C3 Marfey’s analysis for emeramide E (6.8). Trace (a) is the C3 HPLC-DAD (340 nm) chromatogram that 
exhibits L-FDAA amino acid derivatives. Traces (b–i) are C3 HPLC-MS-SIE chromatograms for L-FDAA derivatives of 
amino acid standards (broken lines) and the acid hydrolysate of 6.8 (shaded peaks). Traces confirm that 6.8 incorporates 
(b) trans-4-hydroxy-L-Pro (SIE m/z 384) and L-Leu, (c) Gly (SIE m/z 328), (d) L-Glu (SIE m/z 399, (e) L-Pro (SIE m/z 
368), (f) Aib (SIE m/z 356), (g) L-Pheol (SIE m/z 404), (h) L-Phe (SIE m/z 418) and (i) D-Iva (SIE m/z 370). *Residual 
Marfey’s reagents. 
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6.11. antiamoebin I (6.9) 
 
HRESI(+)MS analysis of 6.9 returned a sodiatated ion [(M+Na)]+ consistent with a molecular formula 
(C82H127N17O20, Δmmu –2.2) requiring ×28 DBE isomerise with emeramide F (6.6) and emeramide 
G (6.7). The 1H NMR (600 MHz, DMSO-d6) data for 6.9 (Figure 6.38) revealed resonances attributed 
to amino acid α-protons (δH 3.83–4.53) and amide methines/methylenes (δH 7.46–8.60), while the 13C 
NMR (150 MHz, DMSO-d6) data revealed corresponding amide carbonyls (δc 170.4–175.9) 
accounting for ×17 DBE. A C3 Marfey’s analysis performed on 6.9  (Figure 6.39) identified the amino 
acid residues L-Hyp, Gly, L-Glu, L-Pro, L-Phe, Aib, L-Pheol and D-Iva residues. Diagnostic NMR 
(DMSO-d6, Figure 6.40) data identified N-Ac-L-Phe, L-Pheol, L-Pro, 2 × L-Hyp, 2 × D-Iva and 6 × 
Aib residues. However, overlapping resonances did not permit to unambiguously establish the 
complete amino acid sequence.  
UHPLC-QTOF-MS analysis of 6.9 showed fragment ions, m/z 152.1067 (y1+), m/z 249.1615 (y2+) 
m/z 447.2618 (y4+), m/z 249.1615 (y7+) and m/z 1127.6489 (y11+), (Figure 6.40a) suggesting the 
structure fragment Gly6−L-Leu7−Aib8−Aib9−Hyp10−Gln11−Iva12−Hyp13−Aib14−Pro15−Pheol16. This 
was further confirmed with targeted MS/MS fragmentation analysis of both sodiated ion (m/z 
1692.9459, Figure 6.40b) and doubly charged ion (m/z 858.4603, Figure 6.40c). Further analysis of 
MS/MS fragmentation confirmed a substantive structure fragment Aib2−Aib3−Aib4−Iva5. The 
MS/MS fragmentation analysis, supported by diagnostic 2D NMR analysis, (Figure 6.41) confirmed 
6.9 was the known peptaibol antiamoebin I.1 
Peptaibols are nonribosomal peptide synthase derived linear polypeptides6 synthesised by fungi, 
which usually have 5-20 amino acid residues, with a high proportion of nonproteinogenic amino 
acids, such as α-aminoisobutyric acid (Aib) and isovaline (Iva). Acetylated N-terminus and a reduced 
C-terminus with amino alcohol (e.g., L-leucinol, L-valinol, or L-phenylalaninol) are characteristic 
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structural features of peptaibols.7 Followed by first reported alamethicin (1967) from Trichoderma 
viride,8-10 hundreds of peptaibols, with various amino acid chain lengths, have been reported from 
fungi, mostly from the genera of Acremonium11, Emericellopsis12 and Trichoderma.7 According to 
the chain length, peptaibols can be generally categorized into, long-sequence 18-20 residue 
peptaibols,8 short-sequence 11-16 residue peptaibols14 and 6-10 residues lipopetaibols15 with acylated 
(e.g., short fatty chain) N-terminus.  
 
Figure 6.38: 1H NMR (600, MHz, DMSO-d6) spectrum for antiamoebin I (6.9). * residual H2O, **solvent (DMSO-d6).    
1.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.5 ppm
3.
19
3.
06
1.
10
3.
45
6.
04
5.
01
2.
17
1.
05
5.
91
1.
50
1.
12
2.
20
2.
05
2.
05
4.
27
1.
06
1.
06
1.
06
1.
02
1.
06
1.
08
1.
01
1.
05
1.
10
2.
19
1.
09
2.
04
12
.0
2
1.
02
2.
01
1.
00
1.
08
2.
00
1.
02
2.
02
1.
08
1.
08
7.67.88.08.28.48.6 ppm 7.27.3 ppm
2.83.03.23.43.63.84.04.24.44.6 ppm 1.31.4 ppm
0.8 ppm
*
**
L-Hyp13-H-2
L-Hyp10-H-2
Aib2-N-H
L-Phe1-N-H
O
N
H
H
N
O
N
H
H
N
O
N
H
H
N
O
N
H
H
N
O
O O O O
N
H
O
N
NH
O
H
NO
NH2
O
OH
N
O
NHO
N
O
OH
NHO
HO
L-Pheol16
N-Ac-L-Phe1
Aib2
Aib3
Aib4
D-Iva5
Gly6
L-Leu7
Aib8
Aib9
L-Hyp10
L-Gln11 D-Iva12
Aib14
L-Pro15
L-Hyp13
Gly6-N-H
Aib14-N-H L-Gln11-N-H
Aib8-N-H
Aib4-N-H
L-Leu7-N-H
Aib3-N-H
Aib9-N-H
D-Iva5-N-H
D-Iva12-N-H
L-Pheol16-OH L-Phe1-H-2
L-Hyp10-H-4
L-Hyp13-H-4
L-Gln11-H-2
L-Pro15-H-2
L-Leu7-H-2
L-Phe16-H-2
Gly6-H-2a, 2b
L-Pheol16-H-1a
L-Phe1-H-3a
L-Pheol16-H-3a
L-Phe1-H-3b
L-Pheol16-H-3b
D-Iva12-H3-4
D-Iva1-H3-4
D-Iva5-H3-4
L-Leu7-H3-6
N-COCH3
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Table 6.5: NMR (600 MHz, DMSO-d6) data for antiamoebin I 6.9 
 δH, mult, (J in Hz) δC COSY HMBC ROESY 
L-Phe1      
1  172.4    
2 4.33, m 55.2 3a, 3b, N-H 1, 3, 4 Aib2-N-H 
3 a 2.97a 36.3 2, 3b 1, 2, 4  
 b, 2.83, dd (13.8, 9.0)  2, 3b 1, 2  
4  137.4    
5, 9 7.29b 128.0a 6/8   
6, 8 7.23c 129.2b 5/9, 7 4, 3 2, 3a, 3b 
7 7.21c 126.4c 5/9   
N-H 8.30, d (5.8)  2 N-COCH3 3a, 3b, N-COCH3,  
N-COCH3  170.4d    
N-COCH3 1.83, s 22.4   L-Phe1-N-H 
Aib2      
1  174.8e    
2  55.7e    
3 1.28, s 25.4f  1, 2, 4 N-H 
4 1.27, s 23.7g  2, 3  
N-H 8.60, s   2, 1-Phe1 3, 4, L-Phe1-H-2 
Aib3      
1  175.0d    
2  55.9f    
3 1.31,p s 24.1h  1, 2, 4  
4 1.29,q s 24.7i  1,2,3  
N-H 7.62, s   2, Aib2-C-1 3, 4, Aib2-N-H, Aib4-N-H 
Aib4      
1  175.6j    
2  56.0f    
3 1.37d 24.8i    
4 1.37d 25.0i  2  
N-H 7.73, s 
, s 
  2, Aib3-C-1 3/4, Aib3-N-H, D-Iva5-N-H 
D-Iva5      
1  175.5j    
2  59.0    
3 a 1.99, m 28.4 4 1, 2 4 
 b 1.69, m  4 1, 2 4 
4 0.79, t (7.3) 7.5 3a, 3b 2, 3  
5 1.34, s 21.2  2, 3  
N-H 7.51, s 
, s 
  2, Aib4-C-1 3, 4, Aib4-N-H, Gly6-N-H 
Gly6      
1  170.4j    
2 a 3.74f 43.3 N-H 1, D-Iva5-C-1  
 b 3.64g  N-H 1, D-Iva5-C-1  
N-H 7.97, t (5.6)  2a, 2b D-Iva5-C-1 D-Iva5-N-H, L-Leu7-N-H 
L-Leu7      
1  171.6k    
2 4.04, m 52.6l 3a, 3b, N-H 1, 3 Aib8-N-H 
3 a, 1.65h 39.2 2, 4   
 b, 1.53, m  2, 4   
4 1.65h 24.1h 3a, bb, 5, 6   
5 0.90, d (6.1) 22.7 4 3, 4, 6  
6 0.85, d (6.1) 21.6 4 3, 4, 5 2 
N-H 7.67, d (5.5)  2 2, 3, Gly6-C-1 2, Gly6-N-H, Aib8-N-H 
Aib8      
1  175.9    
2  56.1f    
3 1.46i 25.5g  1, 4 N-H 
4 1.34j 24.9i    
N-H 7.75, s   L-Leu7-C-1 3, Aib9-N-H, L-Leu7-N-H 
Aib9      
1  173.5    
2  56.2f    
3 1.45i 25.5g  1, 4 NH 
4 1.33j 25.7g    
N-H 7.52, s   1, 3, 1-Aib8 3, L-Hyp10-H-5a, Aib8-N-H 
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L-Hyp10      
1  171.7k    
2 4.38, t (8.5) 61.1 3a, 3b 1, 4, 5  L-Gln11-N-H 
3 a 2.16k 36.7 2, 4   
 b 1.78l  2, 4   
4 4.28, brs 69.0m 3a, 5a, 5b, OH-4   
5 3.75f 56.0f 4 
 
 
 Aib8-N-H 
 3.46m  4 3  
OH-4 5.09, s     
L-Gln11      
1  172.1    
2 4.16, m 52.5n 3a, 3b, N-H 1, 3, 4 L-Hyp10-H-2, L-Hyp10-H-3a 
3 a 2.15k 26.6 2   
 b 1.88, m     
4 2.11k 31.5 3a, 3b 5  
5  173.1    
N-H-5a 7.20   5  
N-H-5b 6.71, s   4, 5  
N-H 7.85, d (7.8)  2 L-Hyp10-C-1 3a, 3b, L-Hyp10-H-2, D-Iva12-N-H 
D-Iva12      
1  172.8o    
2  58.5    
3 a 2.14k 28.1 4   
 b 1.78l  4 2, 4 N-H 
4 0.74, t (7.4) 7.0 3a, 3b,  2, 3, 5 N-H 
5 1.41, s 20.4  1, 2  
N-H 7.46, s   2, 3, L-Gln11-C-1 3, L-Gln11-N-H, L-Hyp13-H-5a 
L-Hyp13      
1  172.8o    
2 4.52, t (8.8) 60.6 3a, 3b 1 Aib14-N-H 
3 a 2.16k 37.3 2, 4 4  
 b 1.67h  2, 4  Aib14-N-H 
4 4.28, brs 69.4m 3a, 5a, 5b   
OH-4 5.09, s   3, 4, 5  
5 a 3.67g 56.5f 4  D-Iva12-N-H 
 b 3.37h  4   
Aib14      
1  175.9    
2  55.8f    
3 1.39, s 23.5  2 N-H 
4 1.33j 25.7g  1, 2  
N-H 7.94, s   L-Hyp13-C-1 4, D-Iva12-H3-5, L-Pro15-H-5b 
     L-HyP13-H-2, L-HyP13-H-3b, 
L-Pro15      
1  170.7j    
2 4.12, dd (8.5, 5.6) 61.8 3a, 3b 1, 3, 4 L-Pheol16-N-H 
3 a 1.83l 28.3 2, 4a, 4b 1, 5  
 b 1.15,x m  2, 4a, 4b 1 L-Pheol16-H-1a 
4 a 1.58, m 24.8i 3a, 3b, 5a, 5b 2, 3, 5  
 b 1.47, m  3a, 3b, 5a, 5b 2, 3, 5  
5 a 3.79o 47.4 4a, 4b 3, 4  
 b 3.50m  4a, 4b 3, 4 Aib14-N-H 
L-Pheol16      
1 a  3.38n 63.4    
 b  3.24, dd (10.2, 8.4)     
OH-1 4.59, t (5.9)  1a, 1b   
2 3.83o 52.7o 1a, 1b, 3a, 3b, N-H   
3 a 2.97a 36.3 2, 3b   
 b  2.57, dd (12.3, 11.2)  2, 3b   
4  137.4    
5, 9 7.28b 127.9a  7  
6, 8 7.23c 129.3b  4  
7 7.14p 126.5c    
N-H 7.15p   2, L-Pro15-C-1  
a-p 1H assignments with the same superscript are overlapping. a-o  13C assignments with the same superscript may be interchanged. nd 
Signals not detected. 
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Figure 6.39: C3 Marfey’s analysis for antiamoebin I (6.9). Trace (a) is the C3 HPLC-DAD (340 nm) chromatogram that 
exhibits L-FDAA amino acid derivatives. Traces (b-i) are C3 HPLC-MS-SIE chromatograms for L-FDAA derivatives of 
amino acid standards (broken lines) and the acid hydrolysate of 6.9 (shaded peaks). Traces confirm that 6.9 incorporates 
(b) trans-4-hydroxy-L-Pro (SIE m/z 384) and L-Leu, (c) Gly (SIE m/z 328), (d) L-Glu (SIE m/z 399 (e) L-Pro (SIE m/z 
368), (f) Aib (SIE m/z 356), (g) L-Pheol (SIE m/z 404), (h) L-Phe (SIE m/z 418) and (i) D-Iva (SIE m/z 370). *Residual 
Marfey’s reagents. 
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Figure 6.40: UHPLC-QTOF analysis of antiamoebin I (6.9). (a) UHPLC-QTOF-MS full spectrum, (b) targeted MS/MS 
analysis of m/z 1692.9459 [(M+Na)+] and (c) targeted MS/MS analysis of m/z 856.4603[(M+2Na)2+]. 
 
Figure 6.41: Diagnostic 2D NMR (DMSO-d6) correlations for antiamoebin I (6.9). Amino acids assigned continuously 
with 2D NMR data are highlighted in blue.  
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The 16-residue peptaibol antiamoebin I (6.9) was first discovered during a screening of 
Emericellopsis poonensis extract against Entamoeba histolytica.1 The linear structure and the 
complete amino acid sequence for antiamoebin I (6.9) was proposed later (1977) using high-
resolution field desorption and gas chromatographic mass spectrometry studies.2 However, originally 
proposed L-Iva enantiomers were proved to be D-Iva by a gas chromatographic analysis using a glass 
capillary columns coated with the chiral stationary phase N-propionyl-L-valine tert-butylamide 
polysiloxane (Chirasil Val).16 Later, this assignment was confirmed with the crystal structure of 
antiamoebin I.3 In a fast atom bombardment (FAB) mass spectrometry study on peptides, Rinehart 
(1985) reported the antiamoebin III sequence.17 A 1985 study by Stroh et al.18 reported that the sample 
used for structure determination of antiamoebin I (6.9), in the original study, was a mixture of several 
peptides. In this study, Stroh et al.18 reported two new sequences, antiamoebins IV and V. 
A 2000 study by Jaworski and Bruckner4 reported a series of known and new antiamoebins from 
Stilbella erythrocephala ATCC 28144, Stilbella fimetaria CBS 548.84 and Gliocladium catenulatum 
CBS 511.66. The amino acid sequences were established based on the on-line HPLC-ESI-MS 
analysis of peptide mixtures, while assigned the amino acid configuration using GC-MS equipped 
with a Chirasil-L-Val quartz capillary column. However, the structure determination of many minor 
metabolites was unclear, due to their low abundance in heterogeneous peptide mixtures (e.g., only 
0.9% of antiamoebin X) (Table 6.6). The bbsolute configuration of the amino acids was determined 
by analysing acid hydrolysates of peptide mixtures. 
 A 2001 study by Schiell et al.14 reported planer structures of closely related 16-residue pepetaibols, 
chephaibols A-E from Acremonium tubakii. The structures of chephaibols A-E were determined by 
analysis of 1D and 2D NMR data. The amino acid sequences of cephaibol E and D were identical to 
previously reported antiamoebins III and V, respectively. The crystal structures of the cephaibols A–
C were reported later in 2003, confirming the presence of D-Iva.19 
  
Chapter 6: Emeramides: New peptaibols from marine fish gut-derived fungi 
 
 
224 
Table 6.6: A summary of characterization of 6.1–6.9, and closely related metabolites reported in the literature 
 
Metabolite AA5 AA6 AA8 AA12 AA13 Pure 1D 
NMR 
2D 
NMR 
Abso.  
conf. 
HR 
MS 
MS/ 
MS 
Crystal 
Struc. 
Ref. 
      
emeramide A (6.1) a Aib Gly Aib Aib L-Hyp ✓ ✓ ✓ ✓ ✓ ✓ × – 
emeramide B (6.2) b D-Iva Gly Aib Aib L-Hyp ✓ ✓ ✓ ✓ ✓ ✓ × – 
emeramide E (6.5) c Aib Gly D-Iva Aib L-Hyp ✓ ✓ ✓ g ✓ ✓ ✓ × – 
emeramide C (6.3) d Aib Gly Aib D-Iva L-Hyp ✓ ✓ ✓ ✓ ✓ ✓ × – 
emeramide F (6.6) e D-Iva Gly D-Iva Aib L-Hyp ✓ ✓ ✓ g ✓ ✓ ✓ × – 
antiamoebin I (6.9) D-Iva Gly Aib D-Iva L-Hyp ✓ ✓ ✓ ✓ ✓ ✓ ✓ 3,4 
emeramide G (6.7) f Aib Gly D-Iva D-Iva L-Hyp ✓ ✓ ✓ g ✓ ✓ ✓ × – 
emeramide H (6.8) g D-Iva Gly D-Iva D-Iva L-Hyp ✓ ✓ ✓ g ✓ ✓ ✓ × – 
emeramide D (6.4) D-Iva Gly L-Ala D-Iva L-Hyp ✓ ✓ × ✓ ✓ ✓ × – 
Literature  
antiamoebin VI a Aib Gly Aib Aib L-Hyp ✓ × × ?h × ?i × 4 
cephaibol D a Aib Gly Aib Aib L-Hyp ✓ ✓ ✓ g × × ?i × 4,14 
antiamoebin VIII d D-Iva Gly Aib Aib L-Hyp ✓ × × ?h × ?i × 4 
cephaibol C c Aib Gly D-Iva Aib L-Hyp ✓ ✓ ✓ g ?h × ?i ✓ j 4,14,19 
antiamoebin III b Aib Gly Aib D-Iva L-Hyp ✓ × × ?h × ?i × 17 
cephaibol E b Aib Gly Aib D-Iva L-Hyp ✓ ✓ ✓ g × × ?i × 4,14 
cephaibol A f Aib Gly D-Iva D-Iva L-Hyp ✓ ✓ ✓ g ?h × ?i ✓ j 4,14,19 
antiamoebin XII Aib Gly L-Ala D-Iva L-Hyp ✓ × × ?h × ?i × 4 
cephaibol A2 Aib L-Ala D-Iva D-Iva L-Hyp ✓ ✓ ✓ g × × ?i × 4,14 
antiamoebin XI Aib L-Ala Aib D-Iva L-Hyp × × × ?h × ?i × 4 
antiamoebin V D-Iva L-Ala Aib D-Iva L-Hyp × × × ?h × ?i × 18 
cephaibol B g D-Iva Gly D-Iva D-Iva L-Hyp ✓ ✓ ✓ g ?h × ?i ✓ j 4,14,19 
antiamoebin X e D-Iva Gly D-Iva Aib L-Hyp × × × ?h × ?i × 4 
antiamoebin II D-Iva Gly Aib D-Iva L-Pro × × × ?h ✓ ?i × 4 
 
 AA1 AA2 AA3 AA4 AA5 Pure 1D 
NMR 
2D 
NMR 
Absol. 
con. 
HR 
MS 
MS/ 
MS 
Crystal 
Struc. 
Ref. 
      
antiamoebin XIII L-Val Aib Aib Aib Aib ✓ × × ?h × ?i × 4 
antiamoebin XIV L-Val Aib Aib Aib L-Val ✓ × × ?h × ?i × 4 
antiamoebin XV L-Leu Aib Aib Aib Aib ✓ × × ?h × ?i × 4 
antiamoebin XVI L-Leu Aib Aib Aib D-Iva ✓ × × ?h × ?i × 4 
antiamoebin VII Phe L-Ala Aib D-Iva Aib × × × ?h × ?i × 4 
antiamoebin IX Phe Aib L-Ala Aib D-Iva × × × ?h × ?i × 4 
antiamoebin IV Phe Aib Aib L-Ala D-Iva ✓ × × ?h × ?i × 18 
 a-f Metabolites with the same superscripts have identical amino acid sequences according to literature 
 g Acquisition of 2D NMR reported, data not available for comparison 
 h Absolute configurations determined using a mixture of peptides 
 i Low resolution MS/MS experiments did not unambiguously confirmed the isobaric amino acids, L-Leu and L-Hyp. 
 j No information about absolute configuration of Hyp 
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6.12. Biological activities of 6.1–6.9 
All the isolated metabolites were screened for cytotoxicity against human lung (NCI-H460) and 
colorectal (SW620) carcinoma cells using an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra 
zolium bromide) assay. Emeramide F (6.6), emeramide H (6.8) and antiamoebin I (6.5) showed 
moderate, but non-selective cytotoxicity (Figure 6.42, Table 6.7). Emeramide G (6.7) showed a 
moderate cytotoxic activity against NCI-H460, while showing a weak activity towards SW620. 
Comparison of cytotoxicity across the isolated metabolites revealed that the number of D-Iva residues 
correlates with potency. The metabolites with more than one D-Iva residues (6.6–6.9) exhibited 
cytotoxicity, with those with three D-Iva residues (6.8) exhibiting greater activity. By contrast, 
analogues with two D-Iva together with L-Ala (6.4) did not show cytotoxicity against any tested cells. 
This preliminary structure-activity assessment indicated the biological importance of D-Iva, at least 
in respect of cytotoxicity. This same effect was noted in a 2018 study by a Jiao et al. from Capon 
group, where studying 11 amino acid residue peptaibol from a termite nest-derived fungus 
Trichoderma virens CMB-TN16.20 A similar structure activity relationship was reported for recently 
described lipovelutibols, where D-Iva incorporating lipovelutibols B and D showed significant 
cytotoxicity against HL-60 cells, while Aib incorporating lipovelutibol A and C were inactive.15 
  
Figure 6.42: Graphs for cytotoxic activities of 6.1–6.9.  
Table 6.7: Cytotoxic activities (IC50, µM) of 6.1–6.9 
 NCI-H460  SW620 IC50  
emeramide A (6.1) >30 >30 
emeramide B (6.2) >30 >30 
emeramide C (6.3) >30 >30 
emeramide D (6.4) >30 >30 
emeramide E(6.6) >30 >30 
emeramide F (6.7) 16.8 20.1 
emeramide G (6.8) 18.5 >30 
emeramide H (6.9) 6.1 12.4 
antiamoebin I (6.5) 18.4 20.2 
NCI-H460: Human lung carcinoma cells; SW620: Human colorectal carcinoma 
0.01 0.1 1 10 100
0
50
100
150
concentration (µM)
%
 c
el
l v
ia
bi
lit
y 
emeramide A (6.1)
emeramide B (6.2)
emeramide C (6.3)
doxorubicin (30 µM)
DMSO (1%)
NCI-H460 (human lung cancer cell line)
emeramide D (6.4)
emeramide E (6.5)
emeramide F (6.6)
emeramide G (6.7)
emeramide H (6.8)
antiamoebin I (6.9)
0.01 0.1 1 10 100
0
50
100
150
concentration (µM)
%
 C
el
l v
ia
bi
lit
y
emeramide A (6.1)
emeramide B (6.2)
emeramide C (6.3)
emeramide D (6.4)
emeramide E (6.5)
emeramide F (6.6)
SW620 (human colorectal cancer cell line)
emeramide G (6.7)
emeramide H (6.8)
antiamoebin I (6.9)
doxorubicin
DMSO (1%)
Chapter 6: Emeramides: New peptaibols from marine fish gut-derived fungi 
 
 
226 
Growth inhibitory activities of 6.1–6.9 were also tested against a panel of Gram-positive and negative 
bacteria, and a fungus. Consistent with the literature account14 for 16 residue peptaibols, 6.1–6.9 
exhibited only moderate to weak growth inhibitory activity (Figure 6.43–6.44 and Table 6.8) against 
Gram-positive bacteria. As with cytotoxic activity, antibacterial potency correlated with numbers of 
D-Iva residue. Notwithstanding the comments made above, 6.1–6.9 are not especially cytotoxic or 
antibacterial, suggesting an alternate ecological role, and mechanism of action.   
Table 6.8: Antimicrobial activities (IC50, µM) of 6.1–6.9 
 6.1 6.2 6.3 6.4 6.5 6.6 6.7 6.8 6.9 
Bacillus subtilis ATCC6051 20.4 11.0 22.2 15.6 >30 9.7 9.8 2.2 11.3 
Staphylococcus aureus ATCC25923 >30 >30 >30 >30 >30 4.7 6.6 3.6 4.7 
Pseudomonas aerugnosa ATCC 10145 >30 >30 >30 >30 >30 >30 >30 >30 >30 
Escherichia coli >30 >30 >30 >30 >30 >30 >30 >30 >30 
Candia albican ATCC 10231 >30 >30 >30 >30 >30 >30 >30 >30 >30 
  
         
Figure 6.43: Graphs for antibacterial screening for 6.1–6.9 in broth micro-dilution assay.   
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Figure 6.44: Graphs for antifungal screening for 6.1-6.9 in broth micro-dilution assay. DMSO and amphotericin B (30 
µM) was used as negative and positive controls, respectively. 
The wide spectrum biological activities reported for peptaibols are attributed to the helical motif of 
peptaibol structure, which plays a major role in the generally accepted mode of action, forming ion 
channels in the bilayer lipid membrane.21 The bioactive potency of emeramides, antiamoebins and 
cephaibols, which has the same chain length, were relatively low compared to long-chain peptaibol 
alamethicin (6.10). It has been identified that the longer chain peptaibols form more stable ion 
channels in lipid bilayer.21 It was speculated that the shorter chain length and a relatively large helix 
bend at the Hyp10 make antiamoebins somewhat shorter, which might result in the poor channel 
forming properties.3 However, Snook et al.3 reported that unlike other closely related peptaibols, 
antiamoebins modify the cell membrane to act as ion carriers. Despite the same amino acid chain 
length and the structural similarities, we showed the modest potency of cytotoxicity and antibacterial 
activity (Table 6.6 and 6.7) correlates with numbers of D-Iva residues. This was also consistent with 
antibacterial activities reported for cephaibols.14 Crystal structure analysis of cephaibols confirmed 
that three-dimensional structures of cephaiblos are very similar to each other and the variation on 
anbacterial activity might not due to the three-dimensional structure. 
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6.13. Conclusion 
Chemical investigation on fish-gut derived fungi Emericellopsis sp. CMB-F206 and Emericellopsis 
sp. CMB-F057 led us to isolate, characterize and bioactivity profiling of 6.1–6.9. In this process, we 
developed a structure elucidation workflow capable of complete unambiguous structure elucidation, 
even for very minor metabolites, where the acquisition and/or reliability of NMR data was not helpful. 
In particular, we demonstrated that high-resolution mass spectroscopy coupled with C3 and 2D C3 
Marfey’s analysis is a powerful combination capable of determining the absolute structure for 
complex peptaibols. Bioactivity profiling revealed that potency of cytotoxicity and antibacterial 
actvity of 6.1–6.9 correlates with the numbers of D-Iva presence in the structure.  
6.14. Experimental 
6.14.1. General experimental 
See Appendix A: General Experiments, page 263.   
6.14.2. Scale-up cultivation and isolation of 6.1–6.9  
Scale-up cultivation for Emericellopsis sp. CMB-F206 and Emericellopsis sp. CMB-F057 and 
purification of metabolites were carried out as outlined in section 6.2.2.  
Emeramide A (6.1): white powder; [α]D22 −0.6 (c 0.05, MeOH); 1D and 2D NMR (600 MHz, 
DMSO-d6) see Tables 6.1 and Figures 6.7 and 6.9; HRESI(+)MS m/z 1664.9050 [(M+H)+] (calcd for 
C80H123N17O20Na, 1664.9023). 
Emeramide B (6.2): white powder; [α]D22 +1.7 (c 0.05, MeOH); 1D and 2D NMR (600 MHz, 
DMSO-d6) see Tables 6.2 and Figures 6.10 and  6.12; HRESI(+)MS m/z 1678.9178 [M+Na]+ (calcd 
for C81H125N17O20Na, 1678.9179). 
Emeramide C (6.3): white powder; [α]D22 −2.9 (c 0.05, MeOH); 1D and 2D NMR (600 MHz, 
DMSO-d6) see Tables 6.4 and Figures 6.19 and 6.22; HRESI(+)MS m/z 1678.9192 [(M+Na)+] (calcd 
for C81H125N17O20Na, 1678.9179). 
Emeramide D (6.4): white powder; [α]D22 −14.5 (c 0.05, MeOH); 1H (600 MHz, DMSO-d6) see 
Figures 6.23; HRESI(+)MS m/z 1678.9171 [(M+Na)+] (calcd for C81H125N17O20Na, 1678.9179). 
Emeramide E (6.5): white powder; [α]D22 +1.7 (c 0.05, MeOH); 1H (600 MHz, DMSO-d6) see 
Figures 6.26; HRESI(+)MS m/z 1678.9183 [(M+Na)+] (calcd for C81H125N17O20Na, 1678.9179). 
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Emeramide F (6.6): white powder; [α]D22 +0.4 (c 0.05, MeOH); 1H (600 MHz, DMSO-d6) see 
Figures 6.29; HRESI(+)MS m/z 1692.9344 [(M+Na)+] (calcd for C82H127N17O20Na, 1692.9336). 
Emeramide G (6.7): white powder; [α]D22 −4.4 (c 0.05, MeOH); 1H (600 MHz, DMSO-d6) see 
Figures 6.32; HRESI(+)MS m/z 1692.9318 [(M+Na)+] (calcd for C81H125N17O20Na, 1692.9336). 
Emeramide H (6.8): white powder; [α]D22 +2.1 (c 0.05, MeOH); 1H (600 MHz, DMSO-d6) see 
Figures 6.35; HRESI(+)MS m/z 1706.9498 [(M+Na)+] (calcd for C81H125N17O20Na, 1706.9498). 
Antiamoebin I (6.9): white powder; [α]D22 +8.5 (c 0.05, MeOH); 1D and 2D NMR (600 MHz, 
DMSO-d6) see Tables 6.5 and Figures 6.38 and 6.41; HRESI(+)MS m/z 1692.9357 [(M+H)+] (calcd 
for C80H123N17O20Na, 1692.9336). 
6.14.3. UHPLC-QTOF analysis 
UHPLC-QTOF-MS analysis was performed on UHPLC-QTOF instrument comprising an Agilent 
1290 Infinity II UHPLC equipped with a Zorbax C8 column (2.1 mm × 50 mm, 1.8 µm particles), 
running with H2O/MeCN inclusive of 0.1% formic acid coupled to an Agilent 6545 Q-TOF 
(fragmenter voltage 180.0 V), with an acquisition range 50–3200 m/z. MS/MS analyses were 
performed on the same instrument for ions detected in the full scan at an intensity above 1,000 counts 
at 10 scans/s, with an isolation width of 4 ∼m/z using a fixed collision energy (40 eV) and a maximum 
of 3 selected precursors per cycle. Targeted MS/MS analyses were carried out for the ions of interest, 
with isolation width of 1.3 m/z and ΔtR 1.3 min. The general instrument settings were similar to those 
outlined in general experimental procedures (see Appendix I, page 263).  
6.14.4. C3 and 2D C3 Marfey’s analysis 
C3 Marfey’s analyses were performed as described in Chapter 4, section 4.9.6.  
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7. Chapter 7: Co-cultivation for activating silent fungal secondary metabolism 
This chapter describes the application of microbial co-cultivation to discover bioactive metabolites 
by activating silent fungal secondary metabolism. During the construction of the microbial library 
(discussed in chapter 2), it was noticed that co-cultivation of antifungal producing Streptomyces 
CMB-NB090 with co-existing fungi CMB-NF041 led to the production of silent fungal secondary 
metabolites, which were completely undetectable in the monocultures. DNA taxonomic identification 
revealed that two strains are Streptomyces sp. and Fusarium sp., respectively. Further investigations 
on Streptomyces sp. CMB-NB090 and Fusarium sp. CMB-NF041 co-cultivation revealed a 
substantial upregulation of two fungal secondary metabolites, which were only detectable 
exceptionally low trace amounts in the monoculture. Scale-up co-cultivation followed by subsequent 
purification of the crude extract yielded three new amides (7.1–7.3), a known antifungal amycin B 
(7.6), and two known fungal metabolite 8-O-methylbostrycoidin (7.4) and bostrycoidin (7.5). The 
structure elucidation of 7.1–7.6 was achieved by detailed analysis of spectroscopic data. Bioactivity 
profiling of the isolated metabolites showed that bostrycoidin (7.5) showed a strong antibacterial 
activity, while amycin B (7.6) from Streptomyces sp. CMB-NB090 showed a potent antifungal 
activity. The following sections of this chapter discuss (i) the isolation, characterization and 
bioactivity profiling of isolated metabolites, and (ii) the chemical cross-talk between these two strains 
leading to the activation of putative silent fungal defence.  
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7.1. Analytical cultivation  
During isolation, a noticeable interaction was observed between co-isolated Streptomyces CMB-
NB090 and fungus CMB-NF041 (Figure 7.1a). These strains were purified and subjected to chemical 
profiling with HPLC-DAD-MS. Based on the chemical profiling, CMB-NB090 and CMB-NF041 
were selected for further investigations. 
 
Figure 7.1: Photographs of (a) M1 agar plate inoculated with sheep faeces and (b) co-cultured CMB-NB090 and CMB-
NF041 purified from M1 agar plate. 
7.1.1. DNA taxonomy and phylogenetic analysis 
Morphological examination of CMB-NB090 showed characteristic features of the genus 
Streptomyces, while CMB-NF041 showed characteristic features of the genus Fusarium (Figure 
7.2a). To further confirm the phylogeny, genomic DNA sequencing was performed. Genomic DNA 
was extracted from both strains using a blood and tissue kit (QIAGEN), following PCR amplification, 
the PCR products were purified using MiniElute PCR purification kit (QIAGEN) and then sequenced 
for ITS1 and ITS4 region for fungi and 16S rRNA for bacteria at Australian Genomic Research 
Facility (AGRF) of The University of Queensland. The sequences were analysed using Basic Local 
Alignment Search Tool (BLAST) of National Center for Biotechnology Information (NCBI). None 
of the reported nucleotide sequences showed 100% homology to neither CMB-NF041 nor CMB-
NF090; however, the result suggested that CMB-NF041 belong to the genus Fusarium, while 
confirming that CMB-NB090 belongs to the genus Streptomyces. A phylogenetic tree (Figure 7.2 and 
Figure 7.3) was constructed using 30 nucleotide sequences, which showed more than 95% homology. 
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Figure 7.2: Phylogenetic analysis of CMB-NF041. (a) Microscopic image of conidia and conidiophore. (b) Phylogenetic 
tree. The PhyML Maximum Likelihood analysis of ITS DNA sequences was performed using optimal nucleotide 
substitution model determined by jModeltest (JC69)1 using Unipro UGENE2 software. The phylogenetic relationship of 
CMB-NF041 to reference (nt/nr GenBank) strains (×30) that showed more than 95% homology shown with accession 
numbers indicated in brackets, highlighted in blue. 
  
Fusarium verticillioides A105 |KX607113.1|
Fusarium proliferatum  WS3MT12 |KT581404.1|
Fusarium proliferatum BY-A |KF924039.1|
Fusarium verticillioides JP44MY25 |KF031028.1|
Fusarium proliferatum WS1MT12 |KT581401.1|
Fusarium sp. Fs027TNPB-L |KF293325.1|
Fungal sp. TH03 |KY607735.1|
Fusarium sp. BRO-2013 |KF367547.1|
Fusarium circinatum SF1 |KX276593.1|
Fusarium sp. BRO-2013 |KF367548.1|
Fusarium begoniae |KM577645.1|
Fusarium sp. 3 HM-2018 |MH367065.1|
Fusarium sp. UFSMQ49 |KX496881.1|
Gibberella moniliformis UFMGCB 1229 |FJ605250.1|
Fusarium fujikuroi CT46 |KJ000439.1|
Fusarium proliferatum IPBCC 08.582 |KR610400.1|
CMB-NF041
Fusarium sp. Fs003TNW-R |KF293334.1|
Fusarium sp. CMB-MF017 |KU593647.1|
Fusarium sp. UFSMQ1 |KX496875.1|
Fusarium sp. |HQ631016.1|
Gibberella circinata 361-1 1 |FJ744110.1|
Fusarium proliferatum |FN868470.1|
Fusarium subglutinans |X94167.1|
Fusarium verticillioides SICAU SDT46 |KJ028004.1|
Fusarium proliferatum 6573 |MG437321.1|
Fusarium sacchari FsSiTNAU8W-T |KJ434046.1|
Fusarium verticillioides ZS108 |KJ598859.1|
Fusarium sp. CC2 |KJ190248.1|
Gibberella moniliformis P3AS2b |JN672602.1|
Fusarium sp. Fs002TNPB1-TR |KF293346.1|
(a) (b)
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Figure 7.3: Phylogenetic analysis of CMB-NB090. (a) Photograph of CMB-NB090 cultured on M1 agar medium and 
(b) Phylogenetic tree. The PhyML Maximum Likelihood analysis of ITS DNA sequences was performed using optimal 
nucleotide substitution model determined by jModeltest (JC69)1 using Unipro UGENE2 software. The phylogenetic 
relationship of CMB-NB090 to selected reference strains (nt/nr GenBank) that showed more than 95% homology shown 
with accession numbers indicated in brackets, highlighted in blue. 
  
Streptomyces castelarensis DSM 40830 |NR_117953.1|
Streptomyces sp. CH-7 16S |JX429997.1|
Streptomyces sp. MJM1684 |EU603331.1|
Streptomyces melanosporofaciens |KM361903.1|
Streptomyces sp. N98-1634 |DQ787153.1|
Streptomyces hygroscopicus Sh-43 |JQ027282.1|
Streptomyces antimycoticus CGMCC 4.1591 |HQ244448.1|
Streptomyces melanosporofaciens GC-8 |KY649385.1|
Streptomyces hygroscopicus subsp. hygroscopicus NRRL 3111 |DQ445789.1|
Streptomyces castelarensis  NBRC 15875 |NR_112479.1|
CMB-NB090
Streptomyces mordarskii NRRL B-1346 |NR_044200.1|
Streptomyces hygroscopicus subsp. hygroscopicus  NBRC 3192 |AB184740.1|
Streptomyces sp. AB2B |EF527809.1|
Streptomyces sp. E5N344 |KX279631.1|
Streptomyces sp. 3C-SSA1 |KX777627.1|
Streptomyces melanosporofaciens CGMCC 4.1742 |HQ244452.1|
Streptomyces castelarensis NRRL 3664 |DQ442510.1|
Streptomyces hygroscopicus subsp. enhygrus NBRC 13978 |AB184558.1|
Streptomyces sp. RJA2926 |JX535238.1|
Streptomyces castelarensis  NRRL 3111 |EF408732.1|
Streptomyces sp. MS1 |KT026467.1|
Streptomyces castelarensis NRRL 3664 |EF408734.1|
Streptomyces castelarensis BS30 |KR063210.1|
Streptomyces rutgersensis MJM4715 |FJ799177.1|
Streptomyces hygroscopicus subsp. enhygrus KP6107 |HQ441251.1|
Streptomyces sporoclivatus  DSM 41461 |NR_117954.1|
Streptomyces sp. W50 1 |KY402253.1|
Streptomyces sp. FXJ6.353 |JF346472.1|
Streptomyces geldanamycininus  NRRL 3602 |NR_043722.1|
Streptomyces sp. AB5A |EF527810.1|
(a) (b)
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7.1.2. Chemical profiling 
The fungus Fusarium sp. CMB-NF041 and the Streptomyces sp. CMB-NB090 were co-cultured on 
an agar plate loaded with M1 medium and incubated for 14 days at 26.5 oC.  After three days of 
incubation a prominent antifungal effect from Streptomyces sp. CMB-NB090 was observed with the 
interface colony colour of Fusarium sp. CMB-NF041 changing from pale white to dark red-brown. 
This colour change was indicative of the production of responsive (activated) metabolites, 
presumably due to the growth arrest (Figure 7.4). We hypothesized that an antifungal metabolite 
produced by Streptomyces sp. CMB-NB090 challenged Fusarium sp. CMB-NF041, and the fungus, 
in response, upregulated red-brown antibacterial defensive chemical to combat the Streptomyces sp. 
CMB-NB090.  
 
Figure 7.4: Photograph of the co-cultured Fusarium sp. CMB-NF041 and Streptomyces sp. CMB-NB090 
After the incubation period (14 days) agar cultures of both pure and co-cultured strains were 
sequentially sliced as shown in Figure 7.5, and each slice individually extracted with EtOAc (25 mL). 
The individual decanted organic phases were then evaporated in vacuo to yield crude extracts, which 
were resuspended in MeOH (500 µL) and analysed by UHPLC-DAD (Figure 7.5). These analyses 
showed that co-cultivation had noticeably enhanced the production of two fungal metabolites eluting 
at tR 1.88 (m/z 299 [M+H]+) and 2.72 (m/z 285 [M+H]+). Of note, these metabolites were only detected 
by single ion extraction (SIE) in the fungal monoculture. In contrast, no noticeable change was 
observed in the Streptomyces sp. CMB-NB090 chemical profile.  
To investigate the selectivity of this interaction, and activation of silent metabolites, CMB-NF041 
and CMB-NB090 were co-cultured with several other Streptomyces spp. and fungal spp., respectively 
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(Figure 7.6). The studies showed that the antifungal activity of the Streptomyces sp. CMB-NB090 
towards fungi was selective – such that CMB-NB090 did not inhibit all tested fungi. Even though 
CMB-NB090 showed antifungal activity against a few tested fungi, only CMB-NF041 (Figure 7.5) 
and CMB-F690 (data not included in this chapter) exhibited a noticeable response. Likewise, 
although CMB-NF041 was inhibited by a few other tested Streptomyces spp., none elicited a chemical 
response. This result suggested to us that the co-isolated strains CMB-NF041 and CMB-NB090 had 
co-adapted to be responsive to their respective chemical defence/cues. To identify the chemistry 
involved, scale-up cultivation was performed for CMB-NF041 and CMB-NB090 co-cultivation.  
 
Figure 7.5: UHPLC-DAD chromatogram (254 nm) of co-cultured CMB-NF041 and CMB-NB090 and the corresponding 
UV-Vis spectrum for enhanced peaks highlighted in red. (a) the fungus CMB-NF041, (b) interface between the two strains 
and (c) the Streptomyces sp. CMB-NB090. Peak in yellow is an internal calibrant.   
 
Figure 7.6: Investigation on the specificity of the CMB-NF041 and CMB-NB090.  Co-cultivation of Fusarium sp. CMB-
NF041 with (a) fungus CMB-F699 and (b) Streptomyces sp. ACM-2434, and of Streptomyces sp. CMB-NB090 with (c) 
fungus CMB-F690 and (d) fungus CMB-F697.  
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7.2. Preparative cultivation 
7.2.1. Co-cultivation of CMB-NF041, CMB-F690 and CMB-NB090 
A loop of spores from both 7 days old Fusarium sp. CMB-NF041 and Streptomyces sp. CMB-NB090 
was streaked on agar plates (×100) loaded with M1 medium so that there is a maximum interaction 
between two strains (Figure 7.7) and incubated for 14 days at 26.5 oC. After incubation, the co-culture 
was harvested and combined agar was extracted with EtOAc (4 × 500 mL). The decanted organic 
phase was evaporated to dryness in vacuo to yield a crude extract (250 mg). An aliquot of the crude 
extract was subjected to HPLC-DAD-MS (Zorbax SB-C8 column, 150 × 4.6 mm, 5 µm, 1 mL/min 
gradient elution over 15 min, from 10% MeCN/H2O to 100% MeCN inclusive of 0.05% formic acid 
modifier) to monitor the production of metabolites of interest (Figure 7.9). The crude extract was then 
sequentially triturated (8 mL aliquots) and concentrated in vacuo to yield n-hexane (89.6 mg), CH2Cl2 
(212.2 mg) and MeOH (30.5 mg) soluble fractions. The CH2Cl2 soluble fraction was subjected to 
semi-preparative HPLC to yield 7.1–7.3, 8-O-methylbostrycoidin (7.4) and bostrycoid (7.5). 
Subsequent purification of MeOH soluble fraction yielded amycin B (7.6). The structures of 7.1−7.6 
were determined by detailed spectroscopic analysis and comparisons to the reported literature. 
 
Figure 7.7: HPLC-DAD-MS chromatogram (210 nm) of the crude extract from co-cultivated CMB-NF041 and CMB-
NB090. Peaks coloured in blue are the new amides produced by CMB-NB090. Peaks coloured in red are the fungal 
metabolites enhanced during co-cultivation and the peak highlighted in magenta is amycn B produced by CMB-NB090. 
The extract was eluted with Zorbax SB-C8 column, 150 × 4.6 mm, 5 µm, 1 mL/min gradient over 15 min, from 10% 
MeCN/H2O to 100% MeCN inclusive of 0.05% formic acid modifier.    
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Scheme 7.1: Isolation scheme for the crude extract obtained from co-cultivated CMB-NF041 and CMB-NB090. (a) 
Trituration, (b) C8-SPE fractionation 10% MeCN/H2O to 100% MeCN stepwise gradient, (c) Semi-preparative HPLC Z-
SB-CN column, 250 × 9.4 mm, 5 µm, 3 mL/min elution over 20 min, isocratic 20% MeCN/ H2O inclusive of 0.01% TFA 
modifier, (d) Semi-preparative Z-SB-C18 column, 250 × 9.4 mm, 5 µm, 3 mL/min elution over 20 min, isocratic 25% 
MeCN/H2O inclusive of 0.01% TFA modifier and (e) preparative Phenomenex Luna-C18 column, 250 × 21 mm, 10 µm, 
20 mL/min elution over 20 min, 10% MeCN/H2O to 100% MeCN inclusive of 0.01% TFA modifier. 
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7.2.1.1. (2Z,4E)-6-methyl-2,4-heptadienamide (7.1) 
 
HRESI(+)MS analysis of 7.1 returned a pseudo-molecular ion [(2M+Na)+] consistent with a 
molecular formula (C8H13NO, Δmmu +2.5) requiring three double bond equivalent (DBE). Analysis 
of the 1H NMR (600 MHz, DMSO-d6) data for 7.1 (Figure 7.8, Table 7.1) revealed resonances for 
four olefinic protons, a methine and two methyls groups, while the 13C NMR (150 MHz, DMSO-d6) 
data for 7.1 (Figure 7.9, Table 7.1) confirmed the presence of four sp2 carbons (dC 119.8 C-2, 140.5 
C-3, 124.2 C-4 and 148.5 C-5) and a carbonyl (dC 167.5 C-1). Diagnostic 2D NMR analysis (Figure 
7.10) established the structure of 7.1 as above, with Z Δ2,3 and E Δ4,5 configurations assigned by 
comparison of experimental and calculated 13C NMR chemical shifts for C-2 (δC 119.8) [Ecalc δC 
129.68; Zcalc δC 119.10] and C-5 (δC 148.5) ([Ecalc δC 147.19; Zcalc δC 139.4]. This was further 
supported by coupling constants observed for Z Δ2,3 (3J2-3 = 11.2 Hz) and E Δ4,5 (3J4-5 = 15.5 Hz).  
 
Figure 7.8: 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN with formic acid at 210 nm) spectra 
for (2Z,4E)-6-methyl-2,4-heptadienamide (7.1). *Solvent peak. 
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Figure 7.9: 13C NMR (150 MHz, DMSO-d6) spectrum for (2Z,4E)-6-methyl-2,4-heptadienamide (7.1). 
 
Figure 7.10: Key 2D NMR correlations for (2Z,4E)-6-methyl-2,4-heptadienamide (7.1). 
Table 7.1: NMR data (DMSO-d6) for (2Z,4E)-6-methyl-2,4-heptadienamide (7.1) 
Position δH, multi, (J in Hz) δC COSY 1H–13C HMBC 
1  167.5   
2 5.60, d (11.2) 119.8 3 1, 4 
3 6.34, dd (11.2, 11.2) 140.5 2, 4 1, 5 
4 7.40, dd (15.5, 11.2) 124.2 3, 5 6  
5 5.90, dd (15.5, 6.6) 148.5 4, 6 7, 8 
6 2.37, m 30.80 5, 7, 6-Me  
7 0.99a 22.2b  6, 7, 8 
6-Me 0.98a 22.2b  6, 7, 8 
N-Ha 6.85, s    
N-Hb 7.36, s    
a, b Overlapping resonances 
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7.2.1.2. (2E,4E)-6-methyl-2,4-heptadienamide (7.2) 
 
HRESI(+)MS analysis of 7.2 returned a pseudo-molecular ion [(2M+Na)+] consistent with a 
molecular formula (C8H13NO, Δmmu +3.2) suggestive of an isomer of 7.1, with analysis of the NMR 
(DMSO-d6) data (Figure 7.11–7.13 and Table 7.2) disclosing the major changes as the chemical shift 
difference for H-3 (ΔdH +0.6) and H-4 (ΔdH –1.2). Comparison of coupling constants established 7.2 
as the E Δ2,3 geometric isomers of 7.1.  
 
Figure 7.11: 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN with formic acid at 210 nm) spectra 
for (2E,4E)-6-methyl-2,4-heptadienamide (7.2). *Solvent peak. 
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Figure 7.12: 13C NMR (150 MHz, DMSO-d6) spectrum for (2E,4E)-6-methyl-2,4-heptadienamide (7.2). 
 
Figure 7.13: Key 2D NMR correlations for (2E,4E)-6-methyl-2,4-heptadienamide (7.2).  
Table 7.2: NMR data (DMSO-d6) for (2E,4E)-6-methyl-2,4-heptadienamide (7.2).  
Position δH, multi, (J in Hz) δC COSY 1H–13C HMBC 
1  167.4   
2 5.89, d (15.3) 124.1 3 1 
3 6.96, dd (15.3, 10.8) 140.3 2, 4 1, 5, 4 
4 6.13, dd (15.3, 10.8) 126.0 3, 5 2, 3, 5, 6 
5 6.04, dd (15.3, 6.6) 148.7 6 3, 4, 6, 7/6-Me 
6 2.38, m 31.1 7/6-Me 4, 5, 7/6-Me 
7 0.99a 22.2b 6 5, 6  
6-Me 0.99a 22.2b 6 5, 6 
N-Ha 7.88, br s    
N-Hb 6.90, br s    
a, b overlapping resonances 
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7.2.1.3. (2E,4E)-2,4-octadienamide (7.3) 
 
HRESI(+)MS analysis of 7.3 revealed a pseudo-molecular ion [(2M+Na)+] consistent with a 
molecular formula (C8H13NO, Δmmu +1.9) indicative of 7.3 being an isomer of 7.2. Analysis of the 
NMR (DMSO-d6) data (Figure 7.14–7.16 and Table 7.3) for 7.3 revealed resonances for the E Δ2,3 
and E Δ4,5 as seen in 7.2., but with an unbranched (linear) hydrocarbon chain. 
 
 
Figure 7.14: 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN with formic acid at 210 nm) spectra 
for (2E,4E)-2,4-octadienamide (7.3). *Solvent peak.  
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Figure 7.15: 13C NMR (150 MHz, DMSO-d6) spectrum for (2E,4E)-2,4-octadienamide (7.3). 
 
Figure 7.16: Key 2D NMR correlations for (2E,4E)-2,4-octadienamide (7.3).  
Table 7.3: NMR data (DMSO-d6) for (2E,4E)-2,4-octadienamide (7.3).  
Position δH, multi, (J in Hz) δC COSY 1H–13C HMBC 
1  167.0   
2 5.89, d (15.2) 123.4 3 1 
3 6.97, dd (15.2, 10.9) 139.7 2, 4 1, 5,4 
4 6.17, dd (15.3, 10.9) 128.7 3, 5 2, 3, 5, 6 
5 6.07, m 141.5 6, 4 3, 4, 6, 7, 8 
6 2.10, dd (14.2, 7.0) 34.2 5, 7 4, 5, 7, 8 
7 1.40 21.5 8, 6 5, 6, 8 
8 0.88, t (7.3) 13.5 7 5, 6, 7 
N-Ha 7.39, br s    
N-Hb 6.90, br s    
 
  
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 ppm
O
H2N 1
3 5 7
5
1
3
4
3 6
7
8
O
H2N
753
1
COSY
HMBC
Chapter 7: Co-cultivation for activating silent fungal secondary metabolism  
 
 
245 
7.2.1.4. 8-O-methyl bostrycoidin (7.4) 
 
HRESI(+)MS analysis of 7.4 revealed a pseudo-molecular ion [(M+Na)+] consistent with a molecular 
formula (C16H13NO5, Δmmu +0.2) requiring 11 DBE. Analysis of 1H NMR (600 MHz, CDCl3) data 
(Figure 7.17 and Table 7.4) for 7.4 revealed resonances for three aromatic protons, two O-methyls 
and an aromatic methyl, while the 13C NMR (150 MHz, CDCl3) data (Figure 7.18 and Table 7.4) 
revealed the presence of two carbonyls and 11 sp2 carbons. A literature search of the molecular 
formula, supported by structure fragments, confirmed that 7.4 was the known fungal metabolite 8-O-
methyl bostrycoidin.3 A 1979 study by Steyn et al.3 first reported 8-O-methyl bostrycoidin (7.4) as 
the main pigment produced by F. moniliforme, and its structure was confirmed by spectroscopic data. 
 
Figure 7.17: 1H NMR (600 MHz, chloroform-d) and UV-vis (HPLC-DAD, H2O/MeCN with formic acid at 210 nm) 
spectra for 8-O-methyl bostrycoidin (7.4). *Solvent peak. 
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Figure 7.18: 13C NMR (150 MHz, chloroform-d) data for 8-O-methyl bostrycoidin (7.4).X Impurities.  
     
 
Figure 7.19: Key 2D NMR correlations for 8-O-methyl bostrycoidin (7.4).  
Table 7.4: NMR (CDCl3) data for 8-O-methyl bostrycoidin (7.4)  
Position δH, multi experimental δCa 1H–13C HMBC δH, multi, literature3 
1 9.43, s 149.0 3, 13, 14 9.44, s 
3  164.3   
4 7.84, s 117.2 3, 10, 13  7.85, s 
5  148.4   
5-OH 13.24, s   13.19, s 
6  156.4   
6-Me 4.03a 56.7b 6 4.05, s 
7 6.87, s 104.5 5, 6, 12 6.86, s 
8  155.6   
8-Me 4.03a 57.3b 8 4.05, s 
9  179.7   
10  189.3   
11  115.8   
12  111.3   
13  125.9   
14  137.9   
15 2.74, s 25.3 1  
a overlapping resonances. b resonances may be interchanged 
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7.2.1.5. Bostrycoidin (7.5) 
 
HRESI(+)MS analysis of 7.5 returned a pseudo-molecular ion [(M+Na)+] consistent with a molecular 
formula (C15H11NO5, Δmmu –0.8) indicative of a demethylated analogue of 8-O-methyl bostrycoidin 
(7.4). Comparison of 1H NMR (600 MHz, chloroform-d) and 13C NMR (150 MHz, chloroform-d) 
data (Figure 7.20, 7.21 and Table 7.5) of 7.5 with 7.4 revealed replacement of resonance attributed to 
the 8-OCH3 (dH 3.97 and dC 57.3) with an 8-OH (dH 13.46). Diagnostic HMBC correlations (Figure 
7.22), supported by a literature search, confirmed that 7.5 was the known fungal metabolite 
bostrycoidin.4 A 1953 study by Hamilton et al.5 first reported bostrycoidin as an antibiotic pigment 
of Fusarium bostrichidae, and later (1965) Arsenault established the complete structure of 
bostrycoidin (7.5) by analysing spectroscopic data.4   
 
Figure 7.20: 1H NMR (600 MHz, CDCl3) and UV-Vis (HPLC-DAD, H2O/MeCN with formic acid at 210 nm) spectra 
for bostrycoidin (7.5). *Solvent peak, ** residual H2O. 
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Figure 7.21: 13C NMR (150 MHz, CDCl3) spectrum for bostrycoidin (7.5). 
 
 
Figure 7.22: Key HMBC correlations for bostrycoidin (7.5).  
Table 7.5: NMR (CDCl3) data for bostrycoidin (7.5) 
Position δH, multi (experimental) δCa 1H–13C HMBC δH, multi (litreature3) 
1 9.46, s 149.4 3, 13, 14 9.47, s 
3  165.5   
4 7.93, s 118.3 3, 13, 15  7.91, s 
5  151.6   
5-OH 13.17, s  5, 6, 11 13.10, s 
6  157.5   
6-Me 4.00, s 57.0 6 4.00, s 
7 6.73, s 108.1 5, 6, 8, 12 6.70, s 
8  161.5   
8-OH 13.46, s  7, 8, 12 13.38, s 
9  186.5   
10  183.8   
11  112.8   
12  106.3   
13  124.7   
14  138.9   
15 2.76, s 25.2 1 2.78, s 
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7.2.1.6. Amycin B (7.6) 
 
HRESI(+)MS analysis of 7.6 returned a pseudo-molecular [(M+Na)+] ion consistent with a molecular 
formula (C56H101N3O15, Δmmu –2.5) requiring 8 DBE. A literature search for this unique formula 
suggested 7.6 was the known antifungal amycin B. First described in 19906 from a Greek soil-derived 
Streptomyces sp. DSM 3816, amycin B (7.6) is a member of guanidyl polyketide macrolide that is 
known for their remarkable antibiotic activity. The structure of amycin B (7.6) was confirmed by 
comparing spectroscopic data with a structurally related metabolite, niphimycin (7.7).7 In general, 
structure elucidation of this class of polyketide macrolide is challenging due to extensively 
overlapping NMR data. Therefore, no tabulated NMR data was found in the literature for amycin B 
(7.6). Having high-quality NMR data in hand, we elected to tabulate NMR data for 7.6.  
Analysis of 1H NMR (900 MHz, methanol-d4) data (Figure 7.23 and Table 7.6) for 7.6 revealed 
resonances for eight olefinic protons (dH 5.41–6.18), a series of oxymethines (dH 3.75–5.21), nine 
methyls (dH 0.86–1.08, C-47–C-56), including a deshielded singlet at dH 2.84 (C-56). The 13C NMR 
(225 MHz, methanol-d4) data (Figure 7.24 and Table 7.6) for 7.6, supported by 1H–13C HSQC data, 
confirmed the presence of a carbonyl (dc 176.8, C-1), a guanidyl carbon (dc 158.4, C-56), a hemiacetal 
carbon (dc 100.0, C-17), thirteen oxymethines and severely overlapped resonances for a series of 
methylene (dC 44.5–27.8). COSY and TOCSY correlations, supported by HMBC correlations, 
established a side chain (C-35–C-44, Figure 7.25) containing a N-methylated guanidine. Despite the 
highly overlapping resonances, strong HMBC correlations from reasonably separated methyl groups 
to nearby carbons permitted to establish several partial structure fragments (Figure 7.25, highlighted 
in green). These assignments were further confirmed with diagnostic COSY and TOCSY correlations. 
HMBC correlations from the methyl at dH 1.01 (H3-47) and oxymethine at dH 4.76 (H-35) to the 
carbonyl at dC 176.8 (C-1) confirmed the assignment of C-1 (Figure 7.24). Diagnostic HMBC 
correlation from a methyl group at dH 1.01 (H3-53) and a methylene at dH 1.01 (H2-37) to C-35 (dC 
79.8) established the connectivity of the guanidine containing side chain to C-35. The larger coupling 
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constant observed for 3J4-5 (15.3 Hz), 3J30-31 (15.1 Hz) and 3J32-33 (15.1 Hz) (Table 7.6) suggested E 
configuration. Collectively, these structure fragments established the planner structure of amycin B 
(7.6).   
 
Figure 7.23: 1H NMR (900 MHz, methanol-d4) and UV-vis (HPLC-DAD, H2O/MeCN with formic acid at 210 nm) 
spectra for amycin B (7.6). 
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Figure 7.24: 13C NMR (225 MHz, methanol-d4) spectrum for amycin B (7.5).  
 
Figure 7.25: Key 2D NMR (methanol-d4) correlations for amycin B (7.6). The unambiguously established structure 
fragments using COSY (in blue) and HMBC (in green) correlations are highlighted. 
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Table 7.6: NMR (methanol-d4) data for amycin B (7.6) 
Position δH, multi, (J in Hz) δC COSY 1H – 13C HMBC δC, literature19 
1  176.8   176.9 
2 2.43, m 48.1 3, 47 1, 3, 4, 47 47.9 
3 4.09a 76.0l 2, 4 1, 2 76.1 
4 5.43b 132.5 3, 5 2 132.6 
5 5.70, dd (15.3, 8.3) 136.6 4, 6 3, 6, 48 136.4 
6 2.31, m 43.5m 5, 7, 48 4, 5 43.4 
7 3.75c 76.0l 6, 8 5, 9, 48 75.8 
8 a 1.71d 39.3 7  39.5 
 b 1.51e  7 7  
9 3.75c 75.3 8, 10  75.0 
10 1.53e 44.5n 49 11 44.7 
11 3.89, m 72.5o   72.4 
12 a 1.61e 33.6 13  33.3 
 b 1.36f     
13 a 1.43f 30.4 14  30.1 
 b 1.29g     
14 1.60e 40.8 13, 50, 15 13, 15 40.5 
15 3.86h 72.4o  17 72.1 
16 1.85i 42.0p  17 42.0 
 1.79d     
17  100.0   99.9 
18 3.34, d (9.2) 77.5 19 16, 17, 19,  77.7 
19 3.86h 69.8q 19, 18 18, 20 69.7 
20 a 1.89i 41.3 19 18, 19 41.3 
 b 1.31g   18, 19  
21 5.21, m 71.4  23 66.3 
22 a 1.77d 44.4n  21, 23 44.4 
 b 1.70d     
23 3.84h 66.0   65.9 
24 a 1.60 43.3m  23/25 43.7 
 b 1.41     
25 4.09a 65.8   72.2 
26 a 1.60e 43.4   40.4 
 b 1.41f     
27 4.10a 69.6q   68.9 
28 1.54e 45.3 27, 29, 51  45.4 
29 4.07a 75.8 28, 30 28, 27, 31 75.2 
30 5.65, dd (15.1, 6.3) 135.3 29, 31 29, 32 134.9 
31 6.18, dd (15.1, 10.3) 132.0r 30, 32 29, 32, 33 132.1 
32 6.06, dd (15.1, 10.3) 132.0r 31, 33 30, 31, 34 131.9 
33 5.51, dd (15.1, 8.8) 137.0 32, 34 31/32 136.9 
34 2.53, m 40.8 33, 35, 52 32, 33, 35, 52 40.6 
35 4.76, m 79.8 34, 36 1, 33, 52, 53 80.1 
36 1.90i 32.7   32.6 
37 a 1.35f 42.5  35, 39, 53, 54 42.4 
 b 0.92j     
38 1.57e 30.8 37, 39  30.7 
39 a 1.29g 37.6 40  37.3 
 b 1.06, m     
40 a 1.38f 27.8 39, 41 42 27.6 
 b 1.31g     
41 1.98, m 34.0 40, 42 39, 42, 43 33.9 
42 5.49, m 133.2 41, 43 40, 43 132.9 
43 5.43b 129.9 44, 42 44 129.9 
44 2.07, q (6.8) 30.7 43, 45 42, 43, 45, 46 30.7 
45 1.65, m 30.0 44, 46 43, 44, 46 29.9 
46 3.16, t (6.8) 42.1p 45 55 42.0 
47 1.01, d (6.9) 15.2s 2 1, 2, 3 15.2 
48 1.08, d (6.9) 17.0 6 5, 6, 7 17.2 
49 0.89, d (6.9) 10.7 10 9, 10, 11 10.7 
50 0.91j 15.2s 14 13, 14, 15 15.4 
51 0.86k 11.4 28 27, 28, 29 11.1 
52 1.01, d (6.9) 17.9 34 33, 34, 35 18.1 
53 0.92j 15.0s 36 36 14.9 
54 0.87k 20.5 38 37, 38, 39 20.6 
55  158.4   158.2 
56 2.84, s 28.5  55 28.4 
1'*     171.4 
2'*     46.2 
3'*     174.1 
a-s Assignments with the same superscript are overlapping. l-s Assignments with the same superscript may be interchanged. * Not 
applicable for amycin B (7.6). 
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7.2.1.6.1 Amycin B (7.6) structure analysis  
The first member of this macrocyclic polyketide class, scopafungin/niphimycin (7.7), was described 
in 1971 from Streptomyces hygroscopicus var. enhygrus var. nova,7 and a 1982 study by Samain et 
al.8 established the planar structure. Following the isolation and characterization of 
scopafungin/niphimycin (7.7), a number of structurally close macrocyclic polyketides were reported 
from Streptomyces spp., that include copiamycin,9 azalomycins,10 guanidylfungins,11 neocopiamycin 
A,12 malolactomycin A,13 RP 63834,14 shurimycins,15 RS-22s,16 kanchanamycins17, primycins.18 and 
recently described niphymycin C-E.19 It is noteworthy that this class of macrolide received substantial 
attention during the 1990s due to its antifungal activity, which was comparable to that of amphotericin 
B, a drug of choice for the treatment of systemic fungal diseases. Unlike polyene antifungal such as 
amphotericin B, which are known for their high toxicity, guanidyl macrolide, such as amycin B (7.6), 
exhibit lesser toxicity while retaining broad-spectrum antifungal activity.8 Interestingly, demalonyl 
analogue of this class, such as amycin B (7.6), exhibit stronger fungicidal activity.6,20 
Notwithstanding peer literature, the structure elucidation of this class of metabolites has proved 
immensely challenging due to extensively overlapping NMR data and the presence of multiple 
stereocentres.  
 
Due to the amorphous nature of these metabolites, X-ray crystallography has not proved effective. 
Therefore, chemical degradation followed by NMR analysis of structure fragments was the 
mainstream approach for establishing the structures of the guanidyl polyketide macroloides.8 The 
planar structure of niphimycin (7.7), first in the class, was established by 1H and 13C NMR analysis 
of ozonolysis and periodate oxidation products, supported by mass spectroscopic analysis. Of note, 
this study established relative configurations from C-6 to C-9 and C-25 to C-28 by analysing coupling 
constants. Grabley et al. proposed the structure of amycin B (7.6) as a demalonyl product of 
niphimycin (7.7) by comparing the spectroscopic data, and this was proved by treating niphimycin 
(7.7) for 12 h with sodium methoxide, which resulted in amycin B (7.6).  
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Even though several other related metabolites have been reported, none of these reports established 
the absolute configurations. In most of the cases, only planar structures were reported, with occasional 
and partial relative configuration assignment of some stereocenters. A 2012 study by Laskowski et 
al.21 established absolute configurations of few stereocenters (34S, 35R, 36S, and 38S) for 
niphimycin A by analysing NMR data of degradation products.  
A 2015 study by Rho et al.22 demonstrated that J-based configuration analysis and universal NMR 
database23 are useful tools to determine the configurations of polyol macrolides. By comparing 
experimental NMR values with Kishi’s universal NMR database,23 Rho et al. partially established 
the configurations for 52 membered macrolatone.  Interestingly, a recent report by Hu et al.19 (2018) 
claimed to reveal the full absolute configuration of novel niphimycin analogues, niphimycin C–E, 
using biosynthetic gene cluster analysis.  
Comparison of specific rotation of 7.6, [α]20D +21 (c 0.70, MeOH), with literature,6 [α]20D +43.7 (c 1, 
MeOH) suggested that 7.6 might have configurations similar to that of reported amycin B. However, 
further studies warrant confirming the configuration of amycin B (7.6). To the best of our knowledge, 
here we report, for the first time, well assigned NMR (900 MHz) data for amycin B (7.6). 
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7.3. Bioactivity profiling of isolated metabolites  
To understand the underlying relationship of the fungistatic activity of Streptomyces sp. CMB-
NB090, and activation of silent metabolites 7.4 and 7.5, all the isolated metabolites were tested for 
antibacterial, antifungal and cytotoxic activities. In micro-broth dilution assay, bostrycoidin (7.5) 
showed substantial activity against S. pyogenes, B. subtilis (ATCC 6633) and C. albican 
(ATCC90028), while displaying a potent activity against tested tumour cells (Figure 7.27 and Table 
7.8). Methylation of bostrycoidin (7.5) [i.e. 8-O-methyl-bostrycoidin (7.4)] completely eliminated 
antimicrobial activity, while reducing the toxicity (Figure 7.26, Table 7.7 and 7.8). Amycin B (7.6) 
also showed antimicrobial activities against all above-mentioned strains, with comparatively a potent 
activity against C. albican. Based on these results, we hypothesised that co-cultivation of 
Streptomyces sp. CMB-NB090 with Fusarium sp. CMB-NF041 led to activation of the defensive 
antibacterial bostrycoidin (7.5) against antifungal amycin B (7.6). Relatively higher production of 
inactive 8-O-methyl-bostrycoidin (7.4) (Figure 7.8) could indicate Fusarium sp.’s self-protecting 
mechanism; with CMB-NF041 producing the inactive 8-O-methyl-bostrycoidin (7.4) and converting 
it into active antibacterial bostrycoidin (7.5) based on the level of threat. 
 Table 7.7: Antimicrobial activity of the major metabolites isolated from the co-cultivation 
 P. aeruginosa  
(ATCC 10145) 
S. pyogenes B. subtilis 
(ATCC 6633) 
C. albicans  
(ATCC 90028) 
MIC 
(µM) 
IC50  
(µM) 
MIC 
(µM) 
IC50  
(µM) 
MIC 
(µM) 
IC50 
(µM) 
MIC 
(µM) 
IC50 
(µM) 
7.1 >30 >30 >30 >30 >30 >30 >30 >30 
7.2 >30 >30 >30 >30 >30 >30 >30 >30 
7.3 >30 >30 >30 >30 >30 >30 >30 >30 
8-O-methylbostrycoidin (7.4) >30 >30 >30 >30 >30 >30 >30 >30 
bostrycoidin (7.5) >30 >30 1.1 0.28 3.3 1.35 10 3.94 
amycin B (7.6) >30 >30 1.1 0.05 3.3 2.75 1.1 0.37 
 
Table 7.8: Cytotoxic activity (IC50, µM) of the major metabolites isolated from the co-cultivation 
 Human colon 
cancer cells SW620  
Hepatocyte carcinoma 
HEP-G2 
7.1 >30 >30 
7.2 >30 >30 
7.3 >30 >30 
8-O-methylbostrycoidin (7.4) 0.37 1.53 
bostrycoidin (7.5) 0.13 1.31 
amycin B (7.6) 7.59 >30 
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Figure 7.26: Antimicrobial activity of the pure metabolites isolated from the co-cultivation.  
 
Figure 7.27: Cytotoxic activity of the pure metabolites isolated from the co-cultivation. 
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7.4. Investigation on the possible elicitor for the enhancement of the fungal metabolites 
In order to identify the possible chemical cues or mechanisms responsible for the cross talk between 
CMB-NF041 and CMB-NB090, a series of sequential experiments were designed and the following 
sections describe the experiments and the results observed.  
Experiment 1.  
Hypothesis: Amycin B (7.6) or other antifungal metabolites produced by Streptomyces sp. CMB-
NB090 could activate the production of antibacterial bostrycoidins.   
It has been reported that fungi produce defensive metabolites against antifungal producing bacteria. 
For example, a 2017 study by Chagas et al.24 reported that a polyol macrolide amphotericin B 
produced by Streptomyces lbospinus RLe7 induced a red colour phenotype in the fungus Coniochaeta 
sp. FLe4. To investigate the possibility that antifungal metabolites produced by CMB-NB90 activate 
defensive antibacterial metabolites of CMB-NF041, monocultures of CMB-NF041 were treated with 
(i) an EtOAc crude extract of monoculture of CMB-NB090 and (ii) pure amycin B (7.6). Neither 
amycin B (7.6) nor the EtOAc crude extract stimulated the production of bostrycoidins in CMB-
NF041 (Figure 7.28). To explore this interaction further, several commercially available polyol 
macrolide antifungals, as well as synthetic antifungals, were screened against Fusarium sp. CMB-
NF041. Intriguingly, only live Streptomyces sp. CMB-NB090 induced the production of 
bostrycoidins (Figure 7.29). The results proved that neither amycin B (7.6) nor commercially 
available antifungal metabolites can trigger activation of silent biosynthetic gene clusters that code 
for bostrycoidins.  
 
Figure 7.28: Disc diffusion assay used to investigate the chemical cues involved in the upregulation of bostrycoidins. (a) 
EtOAc crude extracts of a monoculture of CMB-NB090 (100, 57 and 50 µg/disc), (b) pure amycin B (7.6, 50 µg/disc) 
and (c) live CMB-NB090. The dark colour on interface indicates the enhancement of fungal metabolite 8-O-
methylbostrycoidin (7.4) and bostrycoidin (7.5). 1% DMSO was used as the control. 
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Figure 7.29: Screening commercially available antifungal agents (10 µ/well) against CMB-NF041 using well diffusion 
assay. 
Experiment 2. 
Hypothesis: Volatile metabolites produced by Streptomyces sp. CMB-NB090 might trigger 
activation of fungal secondary metabolites 8-O-methylbostrycoidin (7.4) and bostrycoidin (7.5). 
Streptomyces are known to produce volatile organic compounds (VOCs), which play a pivotal 
ecological role in interspecies communication.25,26 Studies have shown that Streptomyces’ VOCs 
clearly act as antifungal metabolites, and fungal growth is affected by these metabolites.27 To 
investigate whether Furasium sp. CMB-NF041 sensed the VOCs produced by the monoculture of 
Streptomyces sp. CMB-NB090, and produced the responsive metabolites, CMB-NF041 and CMB-
NB090 were co-cultured in the presence of a physical barrier that permits diffusion of VOCs. The 
result (Figure 7.30) clearly showed that VOCs from CMB-NB090 monoculture was not responsible 
for activation of fungal metabolites. Rather, only the co-culture without the physical barrier showed 
activation of fungal metabolites (i.e. bostrycoidins).  
 
Figure 7.30: Co-cultivation of Fusarium sp. CMB-NF041 and co-cultured Streptomyces sp. CMB-NB090 with or without 
a physical barrier. (a) Co-cultivation with a physical barrier and (b) without a physical barrier 
  
cycloheximide amphotericin B ketoconazole amycin B (7.6) nystatin 
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7.5. Conclusion and future directions 
The majority of microbial co-cultivation studies focus on the chemistry and biological activities of 
the activated metabolites. The underlying chemical communication between co-cultured organisms 
remains poorly addressed. However, knowledge on responsible chemical cues involved in microbial 
co-cultivation, and the means of activation of silent secondary metabolism, could facilitate the 
designing and application of elicitors to access silent BGCs.  
In this study we demonstrated that Furasium sp. CMB-NF041 and Streptomyces sp. CMB-NB090 
embrace a unique interaction. Other studies have also detected complex interactions between fungi 
and Streptomyces. For example, Schroeckh et al.28 revealed that a unique physical interaction of S. 
hygroscopicus with A. nidulans mycelia is required to trigger the silent archetypal polyketide 
biosynthesis in a co-cultivation of these strains. Intriguingly, a recent study by Ipcho et al.29 reported 
that fungi can detect and respond to Microbe-Associated Molecular Patterns (MAMPs) through the 
fungal innate immune system. A recent study in Capon group by Khalil et al.30 demonstrated that 
bacteriostatic Aspergillus metabolite cyclo-(L-Phe-trans-4-hydroxy-L-Pro) stimulated a co-isolated 
and co-adopted Streptomyces to produce nitric oxide (NO), and through NO-mediated transcriptional 
activation (NOMETA) the Streptomyces produced fungistatic heronapyrrole B.  
Taking experimental evidences and peer literature into account, we draw a possible underlaying 
mechanism for this co-cultivation (Scheme 7.2). Based on this, further investigation on the chemical 
communication between these two strains is warranted to better understand the molecular 
mechanisms behind this shared chemical ecology. Recently introduced advanced analytical tools, 
such as mass spectroscopic analysis of living microbial colonies31,32, could be useful to elaborate on 
the interaction between these two strains. 
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Scheme 7.2: Possible underlying mechanism in co-cultivation of Fusarium sp. CMB-NF041 and Streptomyces sp. CMB-
NB090. 
  
 
i. Streptomyces sp. CMB-NB090 monoculture produces antifungal amycin B (7.6). Despite the strong antifungal 
activity (Table 7.7), amycin B (7.6) was not the trigger for activating the fungus antibacterial defence (Figure 
7.30b). The result was the same even for the crude extract (Figure 7.30a).  
ii. We speculate that, in co-cultivation, unknown diffusible fungal metabolite/s activate Streptomyces silent BGCs. 
iii. Streptomyces sp. CMB-NB090 activate the production of silent chemical cue/s that the fungus can recognise.    
iv. Unknown diffusible Streptomyces metabolite/s activate fungal silent BGC 
v. Fusarium sp. CMB-NF041 active silent BGC to produce antibacterial bostrycoidins.  
vi. Fusarium sp. CMB-NF041 exerted a strong antibacterial defence against Streptomyces sp. CMB-NB090 
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7.6. Experimental 
7.6.1. General experiments 
See Appendix I General Experiments, page 263. 
7.6.2. Scaled-up cultivation and isolation of metabolites 
Scale-up cultivation was carried out as described in section 7.2.1., page 237. 
(2Z,4E)-6-methyl-2,4-heptadienamide (7.1): A amorphous solid; 1D and 2D NMR (600 MHz, 
DMSO-d6) see Tables 7.1 and Figures 7.8–7.10; HRESI(+)MS m/z 301.1872 [(2M+Na)+] (calcd for 
C16H26N2O2Na, 301.1897). 
(2E,4E)-6-methyl-2,4-heptadienamide (7.2): A amorphous solid; 1D and 2D NMR (600 MHz, 
DMSO-d6) see Tables 7.2 and Figures 7.11–7.13; HRESI(+)MS m/z 301.1848 [(2M+Na)+] (calcd for 
C16H26N2O2Na, 301.1897). 
(2E,4E)-2,4-octadienamide (7.3): A amorphous solid; 1D and 2D NMR (600 MHz, DMSO-d6) see 
Tables 7.3 and Figures 7.14–7.16; HRESI(+)MS m/z 301.1878 [(2M+Na)+] (calcd for 
C16H26N2O5Na, 301.1897). 
8-O-methyl-bostrycoidin (7.4): A red colour powder; 1D and 2D NMR (600 MHz, CDCL3) see 
Tables 7.3 and Figures 7.17–7.19; HRESI(+)MS m/z 322.0684 [(M+Na)+] (calcd for C16H13NO2Na, 
322.0686). 
Bostrycoidin (7.5): A red colour powder; 1D and 2D NMR (600 MHz, DMSO-d6) see Tables 7.3 
and Figures 7.20–7.22; HRESI(+)MS m/z 308.0537 [(M+Na)+] (calcd for C16H26N2O2Na, 308.0529). 
Amycin B (7.6): A amorphous solid; [α]20D +21 (c 0.70, MeOH); 1D and 2D NMR (900 MHz, 
methanol-d4) see Tables 7.3 and Figures 7.24–7.26; HRESI(+)MS m/z 1056.7525 [(M+H)+] (calcd 
for C56H102N3O15, 1056.7305). 
7.6.2.1. Disc/well diffusion assay 
A spore solution (1 mL) from 7 day old Fusarium sp. CMB-NF041 was prepared in sterile water, and 
an aliquot (150 µL) was spread evenly over M1 agar plates followed by drying excess liquid on the 
plates for 10 min. Sterile paper discs were gently placed on the agar using a sterile tweezers or made 
wells on agar using a sterile pasture pipette.  Test compounds dissolved in 1% DMSO (75 µL) were 
transferred onto paper discs or agar wells and incubated for 7 days with periodic examination.  
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8. Appendix I: Experimental  
8.1. General experimental details 
8.1.1. Materials 
All solvents used for experiments, particularly for extraction and solvent-solvent partition of crude 
extracts, were of analytical grade. For purification of metabolites in HPLC systems, HPLC grade 
solvents were used after filtering through 0.45 µm polytetrafluoroethylene (PTFE) filters. Water used 
was deionized water filtered through Elga PURELAB Ultra filtration system. Pre-prepared microbial 
culture media were purchased from BBL/Difco. Other chemicals were purchased from Sigma-
Aldrich, Merck and Fluka. For Marfey’s analysis, Nα-(2,4-dinitro- 5-fluorophenyl)-L-alaninamide 
(L-FDAA, synonym 1-fluoro- 2-4-dinitrophenyl-5-L-alanine amide) and Nα-(2,4-dinitro-5- 
fluorophenyl)-D-alanine amide (D-FDAA, synonym 1-fluoro- 2-4-dinitrophenyl-5-D-alanine amide) 
were purchased from NovaBiochem. Amino acids and standards were purchased from NovaBiochem, 
BAChem Biosciences, Sigma, Fluka, or Merck. 
8.1.2. General experiments 
Solvents used for extraction of metabolites were evaporated under reduced pressure by using Büchi 
Rotavapor R-114. Ultra-high-performance liquid chromatographic (UHPLC) data were obtained on 
an Agilent 1290 infinity UHPLC system composed of 1290 infinity quaternary pump, thermostat, 
autosampler and diode array detector (DAD). HPLC-DAD-ESIMS data were acquired on an Agilent 
1100 series separation module equipped with an Agilent 1100 series HPLC/MSD mass detector and 
Agilent diode array detector. Semi-preparative and preparative HPLCs were performed using Agilent 
1100 series HPLC instruments with corresponding detectors, fraction collectors, and software. 
HRESI(+)MS spectra were obtained on a Bruker micrOTOF mass spectrometer by direct injection in 
MeOH at 3 µL/min using sodium formate clusters as an internal calibrant. UHPLC- QTOF analysis 
was performed on UHPLC-QTOF instrument comprising an Agilent 1290 Infinity II UHPLC 
equipped with a Zorbax C8 column (2.1 mm × 50 mm, 1.8 µm particles), running with H2O/MeCN 
inclusive of 0.1% formic acid coupled to an Agilent 6545 Q-TOF. MS/MS analysis was performed 
on the same instrument for ions detected in the full scan at an intensity above 1,000 counts at 10 
scans/s, with an isolation width of 4 ∼m/z using a fixed collision energy and a maximum of 3 selected 
precursors per cycle. General instrument parameters were as follows; Gas temperature 325 oC, Drying 
gas 10 L/Min, nebulizer 20 psig, sheath gas temperature 400 oC, fragmenter voltage 180 eV, skimmer 
45 eV. Specific rotations ([α]D) were measured on a JASCO P-1010 polarimeter in a 100 × 2 mm 
cell at room temperature. NMR spectra were acquired on a Bruker Avance 600 MHz spectrometer 
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with either a 5 mm PASEL 1H/D–13C Z-Gradient probe or 5 mm CPTCI 1 H/19 F-13 C/15 N/DZ-
Gradient cryoprobe, controlled by TopSpin 2.1 software. In all cases, NMR spectra were acquired at 
25oC (unless otherwise specified) in hexadeuterated dimethylsulfoxide (DMSO-d6) and 
tetradeuterated methanol (methanol-d4) and deuterated chloroform (CDCL3) with referencing to 
residual [1H (δH 2.50, δH 3.31, and 7.24 respectively) or 13C (δC 39.51, δC 49.15 and 77.23, 
respectively)] NMR resonances.  
8.1.3. Antibacterial assay 
The bacterium to be tested was streaked onto a tryptic soy agar plate and was incubated at 37oC for 
24 h. One colony was then transferred to fresh tryptic soy broth (15 mL) and the cell density was 
adjusted to 104-105 CFU/mL. The compounds to be tested were dissolved in DMSO and diluted with 
H2O to give 600 µM stock solution (20% DMSO), which was serially diluted with 20% DMSO to 
give concentrations from 600µM to 0.2µM in 20% DMSO. An aliquot (10 µL) of each dilution was 
transferred to a 96-well microtiter plate, and freshly prepared microbial broth (190 µL) was added to 
each well to give final concentrations of 30−0.01µM in 1% DMSO. The plates were incubated at 
37oC for 24 h and the optical density of each well was measured spectrophotometrically at 600 nm 
using POLARstar Omega plate (BMG LABTECH, Offenburg, Germany). Each test compound was 
screened against the Gram-negative bacteria Escherichia coli ATCC 11775 and Pseudomonas 
aeruginosa ATCC 10145 and the Gram-positive bacteria Staphylococcus aureus ATCC 25923 and 
Bacillus subtilis ATCC 6051. Rifampicin was used as a positive control (40 µg/mL in 10% DMSO). 
The IC50 value was calculated as the concentration of the compound or antibiotic required for 50% 
inhibition of the bacterial cells using Prism 7.0 (GraphPad Software Inc., La Jolla, CA). 
8.1.4. Antifungal assay 
The fungus Candida albicans ATCC 10231 was streaked onto a Sabouraud agar plate and was 
incubated at 37oC for 48 h. One colony was then transferred to fresh Sabouraud broth (15 mL) and 
the cell density adjusted to 104–105 CFU/mL. Test compounds were dissolved in DMSO and diluted 
with H2O to give a 600µM stock solution (20% DMSO), which was serially diluted with 20% DMSO 
to give concentrations from 600 to 0.2µM in 20% DMSO. An aliquot (10 µL) of each dilution was 
transferred to a 96-well microtiter plate, and freshly prepared fungal broth (190 µL) was added to 
each well to give final concentrations of 30–0.01µM in 1% DMSO. The plates were incubated at 37oC 
for 24 h, and the optical density of each well was measured spectrophotometrically at 600 nm using 
POLARstar Omega plate (BMG LABTECH, Offenburg, Germany). Amphotericin B was used as a 
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positive control (30 µg/ml in 10% DMSO). Where relevant, IC50 value were calculated as the 
concentration of the compound or antifungal  
8.1.5. Cytotoxicity assay 
Adherent cell SW620 (human colorectal carcinoma) and NCI- H460 (human lung carcinoma) cells 
were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium. All cells were cultured as 
adherent mono-layers in flasks supplemented with 10% fetal bovine serum, L–glutamine (2mM), 
penicillin (100 unit/mL), and streptomycin (100µg/mL), in a humidified 37oC incubator supplied with 
5% CO2. Briefly, cells were harvested with trypsin, and dispensed into 96-well microtiter assay plates 
at 3,000 cells/well, after which they were incubated for 18 h at 37oC with 5% CO2 (to allow cells to 
attach as adherent mono- layers). Test compounds were dissolved in 20% DMSO in PBS (v/v), and 
aliquots (10 µL) applied to cells over a series of final concentrations ranging from 10 nM to 30 µM. 
After 48 h incubation at 37oC with 5% CO2 an aliquot (20 µL) of 3-(4,5- dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) in phosphate buffered saline (PBS, 5 mg/mL) was added to each 
well (final concentration 0.5 mg/mL), and microtiter plates were incubated for a further 4 h at 37oC 
with 5% CO2. After final incubation, the medium was aspirated, and precipitated formazan crystals 
dissolved in DMSO (100 µL/well). The absorbance of each well was measured at 580 nm with a 
PowerWave XS Microplate Reader from Bio-Tek Instruments Inc. Where relevant, IC50 values were 
calculated using Prism 7.0, as the concentration of analyte required for 50% inhibition of cancer cell 
growth (compared to negative controls). Negative control was 1% aqueous DMSO, while positive 
control was doxorubicin (30 µM). All experiments were performed in duplicate. 
 
